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Abstract
An increase in cellular inflammatory biomarkers directly increases the risk of
cardiovascular disease (CVD). Using the social ecological and biomedical theories, the
study examined quantitatively how specific inflammatory biomarkers are associated with
cardiorenal syndrome (CRS), a potential complication of hypertension and diabetes, and
how sociodemographic factors modify this association in the U.S. adult population. A
retrospective secondary data analysis of the data collected from National Health and
Nutrition Examination Survey (NHANES) 1999-2010 was utilized to evaluate these
hypotheses. High sensitivity C-reactive protein, homocysteine (hcy), and fibrinogen had
a modifying effect on Type 4 (chronic reno-cardiac etiology), Type 2 CRS (chronic
cardio-renal etiology), and a significant additive effect on CRS even after controlling for
known CVD and Chronic Kidney Disease (CKD) risk factors. For Type 4 CRS, the
adjusted Odds Ratio of CVD in individuals with CKD was elevated, 2.29 (Confidence
Interval [CI] 1.17-3.64, p < 0.05), among individuals with elevated hcy levels but close to
1.0 (0.65 CI 0.28-1.53, p > 0.05) among patients with normal hcy after the results were
controlled for medical and demographic risk factors. Finally, race modified the effect of
inflammatory markers on CRS. Out of all the biomarkers, income only modified the
effect of hcy on CRS. Education level modified the effect of every inflammatory marker
on CRS. While Ferritin-to-Transferrin ratio (F/T ratio) had a non-significant additive
effect, due to the lack of adequate subjects, the modifying effect of F/T ratio could not be
tested. This study can help initiate social change by urging healthcare professionals to
monitor these biomarkers as a part of preventing hypertension, diabetes, and CRS.
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Chapter 1: Introduction to the Study
Introduction
Cardiovascular disease (CVD) is the number one cause of mortality and a major
public health issue in the United States (Laslett et al., 2012; Roger et al., 2012).
Cardiorenal syndrome, a term researchers defined in 2008, refers to an association of
closely connected features of bidirectional renal and cardiac dysfunction (Ronco, House,
& Happio, 2008; Stucker & Saudan, 2013). Chronic inflammation along with the gradual
progression of development and hardening of plaques within the arterial supply leads to
CVD (Moore & Tabas, 2010). Chronic inflammatory markers like homocysteine (hcy),
Ferritin-to-Transferrin Ratio (F/T), albumin to creatinine ratio (ACR), fibrinogen, and hsCRP are well-known biomarkers of cardiovascular health (Maurer et al., 2010; Nguyen,
Lane, Smith, & Nguyen, 2009; Rosner, Ronco, & Okusa, 2012). Additionally, the high
incidence of suboptimal renal function in the elderly population, reaching epidemic
levels, is due to chronic inflammation and widespread oxidative stress (Elewa et al.,
2012; Vlassara et al., 2009). Due to the established connection between inflammation
and cardiovascular disease and chronic kidney disease individually, the link between
inflammation and cardiorenal syndrome is hypothesized. The main objective of this
dissertation is to evaluate the hypotheses that elevated levels of cellular markers of
inflammation, which are caused by diabetes, obesity, smoking, and elevated serum
cholesterol levels increase the risk of cardiorenal syndrome, 20 years of age and older.
Data from the National Health and Nutrition Examination Survey (NHANES), 19992010, was utilized for systematic analysis. The aforementioned NHANES dataset was
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analyzed to determine the effect of elevated levels of hcy, F/T, fibrinogen, and hs-CRP on
the risk of cardiorenal syndrome.
Statement of the Problem
Cardiorenal syndrome (CRS) is closely related to heart disease and is associated
with increased mortality, growing complications, and increased cost of care
(Lekawanvijit, Kompa, Wang, Kelly, & Krum, 2012). Cardiorenal syndrome can be
defined as a bidirectional pathological impairment of either the heart or the kidney as a
result of acute or chronic primary dysfunction in either organ (Stucker & Saudan, 2013).
Depending on the primary organ affected and the acuteness of the condition, this
syndrome constitutes five subtypes (Ronco, House, & Haapio, 2008). For instance, as
many as one-third of individuals who have acute decompensated heart failure have been
shown to have type 1 CRS (Ronco et al., 2010). However, little research has been done
in studying how to prevent CRS (Lekawanvijit et al., 2012). Understanding the
pathophysiology in specific cardiovascular disease like congestive heart failure can lead
to identifying critical biomarkers that could signal clinically aberrant manifestations
before they occur (Xue, Chan, Sakariya, & Maisel, 2010). Biomarkers are the important
solution in slowing or halting cascade and progression of disease development (Wang et
al., 2012). More specifically, by becoming aware of any increase in biomarkers (i.e. hsCRP and hcy) healthcare providers can shift their focus from tertiary prevention to
secondary prevention of CRS in populations at high risk (Veerana et al., 2011). Before
clinical manifestations of CRS occur, abnormalities at the molecular and the cellular level
take place (Ronco et al., 2008). By investigating and addressing the importance of
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inflammation as potential biomarkers, public health practitioners and healthcare
advocates and providers can effectively empower patients to improve their own health
and educate patients about how to control inflammation and slow or prevent disease
progression.
In summary, some of the major inflammatory markers have been shown to be
closely associated with CRS before the syndrome takes full clinical effect (Veerana et al.,
2011), but the problem is that these occurrences have not been demonstrated in a
nationally representative multiethnic population (El-Refai et al., 2011). Secondly, the
degree to which biomarkers interact has not been established. Hence, the purpose of the
study is to clearly delineate the role of inflammation in the development of CRS in a
nationally representative multiethnic population.
Nature of the Study
This quantitative study was performed using secondary data analysis with
NHANES data from 1999-2010. The analysis provided a quantitative analysis of
noninstitutionalized men and women within the general U.S. population and the
prevalence of diabetes, obesity, hypertension, smoking status, elevated serum cholesterol
levels, and elevated inflammatory markers and their association with CRS (Levitan et
al., 2009; Liu et al., 2012; Nguyen et al., 2009). The first two questions addressed the
bidirectional impact of inflammatory markers in the specific subtypes CRS. The next
question examined whether inflammatory markers have an independent, additive effect
on CRS. Finally, the last question addressed the differential impact of race and
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socioeconomic status on inflammation and CRS. These four questions were addressed
through multiple regressions controlled for confounding factors.
Research Questions and Hypothesis
Research Question 1:
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) modify
the effect of CKD on CVD controlling for CVD and CKD risk factors (obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho1: The elevated inflammatory biomarkers do not modify the effect of CKD on
CVD controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status).
Ha1: The elevated inflammatory biomarkers do modify the effect of CKD on CVD
controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia, gender,
diabetes status, and smoking status).
Research Question 2:
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) modify
the effect of CVD on CKD controlling for CVD and CKD risk factors (obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho2: The elevated inflammatory biomarkers do not modify the effect of CVD on
CKD controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status).
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Ha2: The elevated inflammatory biomarkers do modify the effect of CVD on
CKD controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status).
Research Question 3:
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) have an
additive effect on CRS along with CVD risk factors (e.g. obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho3: Elevated inflammatory biomarkers do not act as additive risk factors to CRS
along with known CVD risk factors.
Ha3: Elevated specific inflammatory biomarkers do act as additive risk factors to
CRS along with known CVD risk factors.
Research Question 4:
Do sociodemographic (race/ethnicity, family income, expressed relative to the
poverty threshold, or education level) indicators play a modifying role between the
relationship of inflammatory markers and CRS controlling for known CVD risk factors
(e.g. obesity, age, hypercholesterolemia, gender, diabetes status, and smoking status?
Ho4: Sociodemographic indicators do not play a modifying role between the
relationship of inflammatory markers and CRS.
Ha4: Sociodemographic indicators do play a modifying role between the
relationship of inflammatory markers and CRS.
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Purpose of the Study
While researchers have explored certain subsets of CRS in African American
demographic populations previously (Lea et al., 2009), inflammatory biomarkers in the
context of the development of cardiovascular disease and the subsequent development of
chronic kidney disease or vice versa among a multi-ethnic high risk population group
have not been explored, studied, or investigated adequately in the past. This study may
provide public health practitioners with early detection tools that can be specifically
geared towards certain populations that are in the highest risk for CRS. Insights gained
from this study will reduce long-term healthcare costs by aiding public health
practitioners, healthcare providers, and healthcare advocates to make a positive difference
in the health and quality of life in high-risk individuals who have early or preliminary
cardiovascular disease. Secondarily, because the link between inflammation and CRS
has been established, the next step is to empower patients through knowledge of
cardiorenal disease likelihood in order to achieve health equity in populations with
barriers to access. Mogford, Gould, and Devoght (2011) found that by motivating,
engaging, and empowering individuals on specific health topics like the importance of
inflammation in disease progression, improvements can be made in physical health in
high risk groups. Through this dissertation, the assertion may be made for a greater
awareness of the role of inflammation in disease progression which may help both health
practitioners and patients alike. In this medical paradigm shift, treatment changes from
focus on each individual organ to treating the body as a whole (Wallace & Wallace,
2004). In cardiovascular disease, health practitioners are beginning to recognize the need
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to track inflammatory markers. In a meta-analysis of 52 studies, Kaptoge et al. (2012)
found that if inflammatory biomarkers like fibrinogen and hs-CRP are measured in those
deemed to have intermediate risk of cardiovascular disease, then a considerable amount
of subsequent cardiovascular events can be decreased. Similarly, the importance of
inflammatory markers in the development of renal disease needs to be emphasized among
patients and become a public health priority (Stenvinkel, 2010). By investigating and
addressing the possible importance of inflammation as potential biomarkers, public
health practitioners may implement social change by empowering patients to improve
their health and teaching patients to control inflammation effectively and slow or prevent
disease progression.
Theoretical Framework
The primary theoretical framework for this study was the biomedical theory of
disease. This theoretical framework suggests CRS is a consequence of biological
aberrations in the body. More specifically, biomarkers can be used as an early marker for
identifying the eventual consequence of CRS (Mayeaux, 2004). Additionally, the
Bronfenbrenner’s social ecological model indicates that the nature of the community in
addition to individual demographic indicators like race, gender, and socioeconomic status
makes a difference in health status (Ceci, 2006; Henry, Donna, Jennifer, & Colleen,
2012). From this theory, it follows that the inflammatory markers might be different
according to the sociodemographic group and place of residence. Additionally, the social
ecological model purports that there are complex social determinants of health like the
interplay of community, interpersonal, societal, and personal interactions that impact
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cardiovascular risk factors (Chatterji, Joo, & Lahiri, 2013; Fleming & George, 2008).
Extrapolating from this theory, CRS would have a similar impact from social
determinants of health.
Conceptual and Operational Definitions
The following section is composed of different conceptual definitions of specific
terms that are used throughout the study. The conceptual and operational definitions are
both included in this section. The purpose of the conceptual definitions is to explain what
the connotation of each term is in the context of this study, and the purpose of the
operational definition is to demonstrate the empirical context of the term. While some of
the conceptual definitions were included in this section, the vast majority of definitions
have been further delineated in detail in Chapter 3. In contrast to conceptual definitions,
the operational definitions were empirically derived from definitions found in the
literature.
Body mass index (BMI): The BMI is calculated and operationalized through
weight (kg) divided by height (m2) (Eknoyan, 2008). BMI is a standardized unit that
takes into account body shape and used as an index of obesity.
C-reactive protein (CRP): An acute phase pentameric protein found on
chromosome 1 and produced primarily by the liver (Yeh, 2005). However, renal,
respiratory epithelial cells, and coronary artery smooth muscle cells have been shown to
produce this protein as well. Chronic inflammation and CVD have been associated with
elevated levels of CRP (Razavi et al., 2013). In this study CRP was quantified by hs-
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RP. The hs-CRP is a highly sensitive laser nephelometry test that is used to
measure the pertinent deviations.
Cardiorenal syndrome (CRS): Cardiorenal syndrome is a well-recognized recently
classified syndrome, in which healthcare professionals have understood that prognosis is
much worse when renal dysfunction occurs simultaneously with cardiac dysfunction
(McCullough & Ahmad, 2011). The symptoms that ensue are part of this syndrome.
Diabetes: A disorder that is characterized by insulin resistance or autoimmune
destruction of beta cells in the pancreas (McPhee, Papadakis, & Tierney, 2013).
Ferritin-to-transferrin receptor ratio: Ferritin is a nanocage structured acute phase protein,
which store 4,500 Fe (III), and increased amounts can have been associated with chronic
inflammatory conditions like Rheumatoid Arthritis (Vanarsa et al., 2012). The purpose
is to prevent the infective agent from attaining access to iron. A ferritin based
inflammatory marker controlling for status of iron is the purpose of the F/T ratio
(Skinner, Steiner, Henderson, & Perrin, 2010). Because there are no specific clinical
cutoffs that actually are present for this measure, in previous studies the defined F/T
saturation was considered high when the value was greater than the weighted 95th
percentile in the final analytic sample (Skinner et al., 2010).
Fibrinogen: Fibrinogen is a 340 kDa plasma glycoprotein that is converted to
fibrin and associated with systemic inflammation (Ford, 2003).
Homocysteine: This is an amino acid which increases with inflammation, associated with
increased oxidative stress, and has been shown to increase the risk of CVD (Oudi et al.,
2010).
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Obesity: A condition that is characterized by an increased number of adipose
tissue and operationalized by a BMI ≥30 kg/m2 (McPhee, Pappadakis, & Tierney, 2013).
Obesity is associated with increase inflammatory markers and metabolic syndrome
(McPhee et al., 2013).
Assumptions, Advantages, Limitations, and Delimitations
Assumptions
Multiple assumptions were made based on previously published research for the
purposes of this study. The different inflammatory markers hcy, F/T, fibrinogen, and hsCRP have individually been demonstrated to be associated with higher frequency of
cardiovascular disease. The two inflammatory markers hs-CRP and hcy have received so
much attention, that some researchers have either recommended or integrated these
markers into risk scoring systems for predicting 10-year CVD risk (Maurer et al., 2010;
Rosner, Ronco, & Okusa, 2012). Another assumption is that by integrating different
frameworks, a unique model can be ascertained to find the association between
inflammation and CRS. Next, the assumption can be made that that ferritin-to-transferrin
ratio can be used as an inflammatory marker because inflammatory outcome which
controls for status of iron (Skinner, Steiner, Henderson, & Perrin, 2010). Additionally,
the assumption was made that the responses reported by subjects through the
questionnaire were made accurately. Finally, the cardiovascular risk factors tested with
CRS are also risk factors for each of the inflammatory markers.
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Advantages
There were multiple advantages of this study. The main advantage of these data
was that the dataset used included some of the most recent data. Additionally, the sample
selected is systematic and nationally representative data. Because the NHANES data
have been collected for forty-four years, its reliability is enhanced (CDC, 2013b). Many
public decisions are made based on conclusions from these data. Additionally, the
laboratory methods used are standardized for each specimen, contributing to the
objectivity and the validity of the study.
Limitations
Multiple limitations in this study needed to be adequately addressed. There was
insufficient preexisting information concerning the association of inflammatory markers
and CRS. Due to this lack of information, a methodical approach was employed where
theoretical frameworks and conceptual models were utilized to better understand the
association. By applying existing models to better understand the relationship, the
etiology of CRS was better elucidated, making prevention a possible option.
The second limitation is that when using previously collected survey data, there
are limitations as to what types of questions and how they are asked. When using
previously collected data, the problem of the increased statistical error may occur because
of the lack of ability to check for complete accuracy of the data presented. Because the
NHANES survey has gone through numerous iterations in the past four decades,
researchers have included more up to date questions which were adequately designed
to accommodate changes to meet stakeholders’ needs (CDC, 2013b). Additionally,
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due to the inability to check accuracy of data, there may be an increase in statistical
error. As mentioned previously, because of the reputation for validity in collection
and recording of the data, this potential error is minimal. Any possible errors can also
be mitigated by using overlapping information so that data can be cross-checked.
Another potential source for error was the reliance on self-reported information, which
may lead to bias. Again, in order to address this limitation, objective, examination
information was used. While the NHANES dataset is compatible with specific
programs, all functions are not available without the knowledge or access to specific
programs. Consequently, another limitation is that rudimentary knowledge in
weighting methods and analysis in specific statistical software is necessary for the
proper use of the data. Finally, a limitation that is an aspect of many cross-sectional
studies is that the biomarker levels are a reflection of one moment in time and could be
as a result of a spurious factor like infection. To control for these factors a large, a
representative population was utilized for this study.
Scope and Delimitations
In this study, only adults aged 20 years or older were included the participant
population. This criterion was necessary because the inclusion of minor participants
would have added confounding factors that would have influenced the outcome.
Additionally, complete information on individual cellular biomarkers for inflammation
was necessary. Only subjects who were tested for specific biomarkers were included,
when testing the effect of that biomarker on CRS. Furthermore, those subjects who have
complete information on BMI, diabetes, serum cholesterol level, and smoking status were
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included. Details on the method of statistical analysis were identified prior to the actual
data analysis in Chapter 3. This was to make certain that the scope of the study is not
crossed (Frankfort-Nachmias & Nachmias, 2008).
Study Significance and Social Change
In the context of inflammation, the conclusions from this study can be used for
advancements in the field and social change. This study provides both professionallevel data collection and unanalyzed data for future research and social change. The
conclusions of this study have overarching implications to implement primary
prevention for CRS. Monitoring C-reactive protein and other inflammatory markers,
as a method of primary prevention, is another change in clinical practice that can save
money and lives in the future for not only CVD, but also in the context of CRS
(Yousuf et al., 2013). Despite clinical evidence and creators of certain risk scores, like
the Reynolds risk score, having demonstrated the need to integrate the regular use of
hs-CRP, this inflammatory marker is still not being standardly recommended by the
American Heart Association or the American College of Cardiologists according to the
revised guidelines released in November 2013 (Goff et al., 2013; Windgassen,
Funtowicz, Lunsford, Harris, & Mulvagh, 2011). Other inflammatory markers are not
recommended as frequently for cardiovascular disease. Extrapolating the same
associations to CRS, demonstrates the expanded need to universally screen
inflammatory markers so that terminal illnesses like acute coronary syndrome and
Stage 4 CKD can be prevented. The conclusions from this research have the potential
to address the gaps and give proponents additional evidence to make inflammatory
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markers a national priority among all organizations. Additionally, making this a
national goal like through Healthy People 2020 can let patients and healthcare
providers realize the importance of inflammation. Obesity has been associated with
inflammation and is an additional reason for a renewed campaign against obesity in the
context of CRS (McManus et al., 2013). While Healthy People 2020 has
cardiovascular-related goals, there are no goals specifically related to inflammation
(Henderson, 2013). A strong argument must be developed in order to convince public
policy makers to invest in related research and public health initiatives.
Creating other sources of positive social change within groups at risk of CRS is a
very important aspect of this study as well. Analysis of the NHANES survey data
provided evidence related to the association between metabolic syndrome, inflammatory
markers, and CRS in the context of differential sociodemographic factors within the
noninstitutionalized, civilian U.S. population ages 20 years and older. In order to control
chronic diseases, the results can be useful for developing and implementing new policies
and procedures in target populations. These new policies and procedures can influence
additional federal and state funding for interventional programs geared toward combating
obesity in specific racial and socioeconomic groups (Henderson, 2013).
Summary
Cardiorenal syndrome is a significant public health concern in the United States
and worldwide. While the association between obesity, smoking status, hyperlipidemia,
hypertension, and diabetes and CRS has been established, the potential modifying
effect of inflammatory markers between the aforementioned variables and CRS has not
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been previously established. The intention of the present study was to examine and
analyze the representative sample from the general U.S. population for inflammation as
independent and additive risk factors for CRS. I was able to identify specific risk
factors for CRS and to increase awareness of how inflammation plays a role in the
pathophysiology of disease. Chapter 2 of the dissertation will provide a general
overview of CVD, CKD, the association of inflammation with CRS, and the possible
mechanism and etiology of CRS. Publicly available data were utilized from the
National Health and Nutritional Examination Survey (NHANES) that was collected
between the years of 1999-2010. Chapter 3 will detail the quantitative research method,
the study population, the process of how the data were collected and analyzed. In
Chapter 4, the outcomes from univariate, bivariate, and multivariate analyses will be
discussed through charts and graphs. Chapter 5 will provide a discussion of the
outcomes and the recommendations pertaining to the association between elevated
inflammatory markers and CRS.
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Chapter 2: Literature Review
Introduction
The primary purpose of this literature review is to assemble systematically all of
the current literature regarding the pathophysiological understanding of the development
of cardiovascular disease (CVD) and chronic kidney disease (CKD), risk factors, how
inflammation plays a role in each condition individually, and the scientific connection
between inflammatory biomarkers and cardiorenal syndrome (CRS). In the literature
review I explain the pathophysiology of atherosclerosis, the public health burden of
CVD, and the connection of inflammation with CVD. In the review I then focus on the
public health burden of chronic kidney disease and the connection with inflammation.
Finally, I discuss the epidemiology and connection of inflammatory biomarkers to CRS.
Literature Review
An exhaustive literature review was performed in order to compile and analyze
previous research. The literature was searched using the following databases: PubMed,
ProQuest Central, Science Direct, and the Johns Hopkins intranet. Keywords,
individually and in combination, were used to search the literature and included: “CRS”;
“cardiorenal syndrome”; "hs-CRP”; “C-reactive protein”; “homocysteine”; “ferritin”;
“metabolic syndrome”; “cardiovascular disease”; “serum”; “biomarkers”; “obesity”;
“overweight”; “physical inactivity”; “GFR”; “chronic kidney disease”; “cholesterol”;
“inflammation”; “gender”; “race”; and “NHANES”. The first authors of many of the
articles were contacted about the articles that they wrote. The years were from 19702014. The earlier dates were included for historical development of the databases.
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Theoretical Foundation
Control of modifiable risk factors like diet, high blood pressure,
hypercholesterolemia, tobacco use, weight management, and diabetes has been
traditionally targeted to make changes in cardiovascular disease. However, controlling
inflammation can have equally beneficial effects (Dzau et al., 2006). The theory outlined
below is the biomedical theory of disease used in CVD in which scholars utilize a
continuum approach.

Figure 1. Cardiovascular disease model in the context of atherosclerotic continuum.
Adapted from “The Cardiovascular Continuum extended: aging effects on the aorta and
microvasculature,” by M. Rourke, M. Safar, and V. Dzau, 2010, Vascular Medicine,
15(6), 461-468.
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Understanding cardiovascular disease sequelae in the context of a continuum is
imperative (O’Rourke, Safar, & Dzau, 2010). In the process of understanding the
atherosclerotic continuum, the first stage takes place due to the risk factors of
hypertension, dyslipidemia, diabetes, smoking, and obesity as outlined in Figure 1. In
each of these stages, inflammatory markers play a critical role in exacerbating the
symptoms of the disease. These risk factors along with chronic inflammation like hsCRP released from the endothelial cells can additionally cause atherosclerosis and in turn
left ventricular hypertrophy. The next stage is coronary artery disease, which is also
interrelated to hs-CRP released from the coronary vessels (Yeh, 2005). Due to coronary
artery disease, there is myocardial ischemia and angina (Dzau, 2005). When myocardial
ischemia becomes more severe, this becomes coronary thrombosis. Thrombosis can lead
to myocardial infarction and acute coronary syndrome. This can lead to arrhythmias and
remodeling of the heart. Remodeling leads to ventricular dilatation and congestive heart
failure (CHF). CHF leads to end stage heart disease and death. Additionally, CHF is
directly connected with CKD.
Additionally, the social ecological model from Bronfenbrenner’s ecological
systems theory indicates that not only the individual demographic indicators like race,
gender, and socioeconomic status, but other demographic factors like the nature of the
community makes a difference in health status (Ceci, 2006; Henry, Donna, Jennifer, &
Colleen, 2012). From this theory, it follows that the inflammatory markers might be
different according to the sociodemographic group and place of residence. Additionally,
the social ecological model purports that there are complex social determinants of health

19
like the interplay of community, interpersonal, societal, and personal interactions that
impact cardiovascular risk factors (Chatterji, Joo, & Lahiri, 2013; Fleming & George,
2008). Extrapolating from this theory, CRS would have a similar impact from social
determinants of health. Different social determinants in the may play a varying role in
the context of CRS.
Cardiovascular Disease
Cardiovascular Disease Definition and Epidemiology
Cardiovascular disease is the primary cause of death of adults in the United States
and worldwide (Laslett et al., 2012). Because cardiac dysfunction is closely connected
with the renal system, dysfunction in one organ is closely connected with dysfunction in
another organ. Early identification of underlying sources of pathology like
atherosclerosis and inflammation is imperative. These public health issues are
tantamount in importance to the issue of CVD itself. More specifically the category of
CVD includes coronary heart disease (i.e. angina, acute myocardial infarction), heart
failure, cardiomyopathy, atrial fibrillation, cerebrovascular disease (i.e. stroke),
hypertensive disease, peripheral arterial disease, and congenital malformations. Chronic
inflammation along with the gradual progression of development and hardening of
plaques within the arterial supply leads to CVD.
Cardiovascular disease is an enormous public health burden and a large source
morbidity and mortality. In 2008, over 82 million people were estimated to have CVD
which led to $180 billion in direct health care expenditures (NIH, 2012). The American
Heart Association estimated that between 2010 and 2030 healthcare costs related to CVD
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will triple from $272.5 billion to $818.1 billion (Heidenrich et al., 2011). Even though
CVD related death rates had dropped by 2-5% each year, in 2008 there were still over
700,000 CVD related deaths, primarily from heart attacks and strokes. The gradual
development of atherosclerosis has been established as a source of CVD. Atherosclerosis
develops from the combination of benign fatty streaks and intimal thickening during
childhood (Spagnoli, Bonanno, Sangiorgi, & Mauriello, 2007). Next there is everything
from accumulation of fibrous plaques to accumulation of cholesterol and fat. Finally, the
multiplication and migration of smooth muscle cells play a role to solidify the plaques
and narrow the lumen of arteries. As an individual ages, stenosis and loss of arterial
elasticity leads to lower blood flow and increased chance of plaque rupture creating an
embolus. At an average heart rate of 70 beats per minute, the expansion repeatedly
stretches the aorta and the connected elastic arteries 30 million times per year (O’Rourke,
Safar, & Dzau, 2010). The elastic lamellae frays and fractures, consequently causing
distension, remodeling, and stiffening of the aorta and arteries. Because the elastic artery
stiffens, the microvasculature experiences shear force and endothelial damage. If this
occurs in the kidneys, then the microinfarcts can cause pulse wave nephropathy (Dzau,
2005).
Congestive Heart Failure
Congestive heart failure is difficult to quantify and has many levels to the clinical
definition and is therefore subjective. The New York Heart Association utilized Class IIV in the functional definition (Christensen et al., 2013; Lee et al., 2002). Class I states
that the individuals has no limitations to physical activity and does not experience any
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angina, fatigue, palpitations, or dyspnea. In Class II, while there is slight limitation of
physical activity, the person is comfortable during rest (Christensen et al., 2013).
However, the angina, fatigue, palpitations, or dyspnea is present with just ordinary
activity. In class III, there significant limitation of physical activity, but still the person is
comfortable at rest. In this class patients experience angina, fatigue, palpitations, or
dyspnea in less than ordinary activity. Class III is divided into a and b, where IIIa is no
dyspnea at rest while IIIb happens when there is recent dyspnea at rest (Lee et al., 2002).
Finally, class IV is comprised of patients who are unable to perform physical activity
because of excessive discomfort (Williams, Weiss, Patel, Nwakanma, & Patel, 2007).
The symptoms are present with activity as well as rest.
Inflammatory Hypothesis of Atherosclerosis
Although atherosclerosis plays a role in CVD progression, certain individuals do
not develop active CVD even in the presence of plaques (Moore & Tabas, 2010).
Researchers have found that plaques can be either stable or unstable. While stable
plaques are slow growing and benign, unstable plaques are necrotic and have many signs
of inflammation leading to serious clinical manifestations (Lichtman, Binder, Tsimikas,
& Witztum, 2013). More specifically, the atheromatous fibrous cap has a large necrotic
core with large inflammatory cells (i.e. macrophages and T-lymphocytes) which lead to
an excessively calcified lesion or a complicated hemorrhagic lesion. From this fact
follows the need to regularly monitor inflammatory biomarkers. Certain health
practitioners have called for the monitoring of inflammatory biomarkers in every patient
(Ben-Yehuda, 2007).
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One of the first markers, that was an acute phase biomarker known since to
rheumatologists since the 1930’s was hs-CRP (Deron, 2004). More recently, this
pentameric biomarker, produced in the liver, was connected to unstable angina and
became a part of guidelines to diagnose and treat acute coronary syndrome (Berk,
Weintraub, & Alexander, 1990; Liuzzo et al., 1994; Rapezzi, Biagini, & Branzi, 2008).
Researchers that added more evidence to provide overwhelming credibility to the
inflammatory hypothesis of CVD and published in The New England Journal of
Medicine, studied the effect of lipid-lowering drugs on hs-CRP (Nissen et al., 2005;
Ridker et al., 2005). Nissen et al. (2005) performed intravascular ultrasound in 502 in
order to study the effect of atorvastatin on atherogenesis, LDL, and hs-CRP. They found
that after 1.5 years, not only was there slower rate of atherogenesis, but also a reversal of
LDL and hs-CRP. Similarly, Ridker et al. (2005) found that individuals who had a lower
hs-CRP had more improved clinical outcomes compared to individuals with high hsCRP.
Numerous clinical trials provided support to the inflammatory hypothesis of
CVD, and the importance of screening for hs-CRP in high risk individuals for primary
prevention (Kjekshus et al., 2007; McMurray et al., 2009; Mora, Musunuru, &
Blumenthal, 2009; Ridker et al., 2008). The Justification for the Use of Statins in
Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and
Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trials were the
classic trials that demonstrated the power of assessing hs-CRP as a primary prevention
tool (Ridker et al., 2008). Rosuvastatin is a potent 3-hydroxy-3-methylgluytaryl-CoA
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(HMG-CoA) reductase inhibitor which decreases levels of LDL. Researchers from the
JUPITER trial found that in a cohort of 17,802 subjects with low-to-normal levels of
LDL and elevated levels of hs-CRP > 2 there was a higher reduction in both of these
values than in placebo. Furthermore, there was a decrease in one-year the absolute risk
stroke, myocardial infarction, and mortality. In another Danish study, Correale et al.
(2011) found that the use of statins blunted the inflammatory markers and ameliorated
left ventricular function by Doppler studies. Additionally, when a retrospective analysis
was performed on the CORONA trial, researchers found that patients on rosuvastatin
therapy and those with ≥ 2 mg/L hs-CRP had significantly better cardiovascular
outcomes than those with elevated hs-CRP and not on therapy (McMurray et al., 2009).
While the JUPITER trial prospectively demonstrated that reduction in one inflammatory
marker along with lipid levels lead to a decrease in cardiovascular disease incidence,
other randomized control trials are needed to demonstrate that anti-inflammatory drugs
alone has an effect to decrease CVD. Consequently, researchers from the Canakinumab
Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) are researching the effect of
a monoclonal antibody that exclusively targets inflammation (Ridker, Thuren, Zalewski,
& Libby, 2011).
Canakinumab is a potent inhibitor of an inflammatory cytokine interleukin-1β. In
a double-blinded control trial, Ridker et al. (2011) allocated randomly 17,200 stable
subjects that had elevated hs-CRP and suffered a previous myocardial infarction (MI) to
the treatment group who were administered canakinumab versus a control group who
were administered placebo. The treatment group was administered 50, 150, or 300 mg of
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medication every 3 months. Additionally, researchers from the Cardiovascular
Inflammation Reduction Trial (CIRT) trial are studying if methotrexate reduces death,
stroke, or MI in those people who have suffered a previous MI and have metabolic
syndrome and type 2 diabetes. The results to both of these aforementioned studies are
still pending (Ridker, 2009).
Connection of Autoimmune Diseases and Cardiovascular Disease
Another aspect that can serve to support the inflammatory hypothesis of CVD is
the connection of autoimmune disease and higher incidence of CVD. Systemic Lupus
Erythematosus (SLE) and Rheumatoid Arthritis are the two primary autoimmune
conditions which afflict people and coexist simultaneously to the point that this is known
as rhupus syndrome (Tani et al., 2013). In fact individuals who have autoimmune
diseases with elevated hs-CRP like in SLE invariably suffer from premature mortality
due to cardiovascular disease (Gustaffson et al., 2009). This association is important to
focus on because it supports the theory that inflammation leads to cardiovascular disease.
Additionally researchers found that there was an increased risk of cardiovascular disease
due to the inflammation associated with rheumatoid arthritis and that more research needs
to focus on risk factors rather than treat these variables as covariates (Liao and Solomon,
2013).
Renal Dysfunction
Description and Epidemiology of Kidney Dysfunction
Renal dysfunction is a major component of the CRS sequelae. Out of individuals
who are on dialysis, 33% suffer from heart failure (Stucker & Saudan, 2013). Renal
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dysfunction can be divided into two categories—acute and chronic. Acute kidney injury
(AKI) is a constellation of signs which are collectively placed together to connote the
deterioration of renal function. The AKI is a specific syndrome which includes acute
tubular necrosis, acute vasculitic and glomerular renal diseases, acute interstitial
nephritis, prerenal azotemia, acute postrenal obstructive nephropathy. According to
Marrenzi et al. (2013), not only can Acute Coronary Syndrome (ACS) cause AKI, but the
former can be considered as serious as the latter. As noted, the etiology for AKI
syndrome can be either from direct renal injury or functional impairment (Van Biesen,
Vanholder, & Lameire, 2006). Worsening Renal Failure (WRF) is a traditional way to
determine if there is AKI by assessing the change in creatinine from baseline (Di Tano,
Misuraca, Ronco, Zocali, & Frigerio, 2006). If the change is greater than or equal to
change in 0.3, then this is defined as WRF (Raichlin et al., 2013).
Unlike AKI, chronic kidney disease takes place over an extended period of time
and is measured by GFR (Parmar, 2012). Stage 1 CKD is considered to be a GFR ≥ 90
mL/min/1.73m2. Next, stage 2 CKD is considered between 60-89 mL/min/1.73m2.
During this stage there is initial glomerular damage. In stage 3 (30-59 mL/min/1.73m2)
CKD and stage 4 (15-29 mL/min/1.73m2) CKD, there is fibrosis and sclerosis of the
kidneys (Levey et al., 2011). Finally in stage 5 (<15 mL/min/1.73m2), the patient needs
dialysis. There has been considerable controversy as to how to quantify GFR using either
creatinine or Cystatin C (Lopes et al., 2013). Additionally, there are different equations
to calculate GFR. The two ways that have been compared recently are the Modification
of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology
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Collaboration (CKD-EPI) method of calculation (Masson et al., 2013). According to
Shafi et al. (2012), CKD-EPI had better risk stratification than the MDRD method as
applied to NHANES III data. CKD has significant detrimental effects on the heart due to
the excess sodium and water retention, uremic solute retention, calcium and phosphorus
abnormalities, and anemia. In recent years, due to these observed connections the
therapeutic effects of endothelin antagonists, adenosine antagonists, B-type natriuretic
peptide (BNP) derivative, and vasopressin antagonists have been tested through
randomized controlled trials (Ahmed, Wong & Pai, 2010) .
Chronic Kidney Disease and Inflammation
In individuals with CKD, one of the largest causes of mortality is CVD (Go,
Chertow, Fan, McCulloch, & Hsu, 2004; McCullough et al., 2007). According to
Vlassara et al. (2009), suboptimal renal function in the elderly population is reaching
epidemic levels because of chronic inflammation and widespread oxidative stress. In an
aging Bavarian population, increased hs-CRP levels and CKD at baseline were associated
with a greater prevalence and vascular related diseases (Jalal, Chonchol, Etgen, &
Sander, 2011). In a multicenter study in Taiwan, researchers evaluated 22,043 adults for
the relationship between hcy and hs-CRP and CKD (Chuang et al., 2013). According to
this study, females had plasma hcy that was associated with CKD. However, in males
only plasma hs-CRP was associated with CKD.
Inflammation and CRS
Inflammation plays not only a critical role in the progression of CRS, but also in
the severity and poor clinical outcome in both CKD and CRS. Inflammatory biomarkers
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are helpful in testing and following in assessing the progression of CRS. Researchers
have found that hcy, F/T, fibrinogen, and hs-CRP are critical biomarkers that are helpful
in (Maurer et al., 2010; Rosner, Ronco, & Okusa, 2012). According to Maurer et al.
(2010), from analysis of 161 patients, individuals with high hcy with ≥20 micromol had a
higher likelihood of decompensated CHF and death than normal hcy. In this same study,
patients with CRS were 3.7 times more likely to have an adverse clinical outcome than
those that do not have the syndrome. Additionally, researchers have studied ferritin not
only in the context of iron status, but also in the context of inflammation and autoimmune
conditions (Claes, Ellis, Rettie, Butcher, & Bradley, 2013; Pan & Jackson, 2008; Vanarsa
et al., 2012). In order to control for inflammation, researchers performed a
Ferritin/Transferrin (F/T) saturation ratio and F/T was considered elevated if it was >4.81
(Skinner, Steiner, Henderson, & Perrin, 2010). The ratio was better because it controlled
for iron status.
Another key inflammatory marker that researchers have traditionally associated
with cardiovascular disease is hcy (Davalos & Akassoglou, 2012; Ridker, Hennekens,
Buring, & Rifai, 2000). Homocysteine has been demonstrated to increase free radical
activity and oxidative stress (Jonasson, Ohlin, Gottsäter, Hultberg, & Ohlin, 2005). This
action aids in the oxidizing of low-density lipoprotein (LDL) inducing atherosclerosis.
Furthermore, hcy promotes the synthesis of other inflammatory cytokines in smooth
muscle and endothelial cells.
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CRS Definition
In order to investigate CRS, the first step researchers had to take was to define
and elucidate what CRS entailed. In 1951, the term CRS was first coined in France to
mean the simultaneous failure of the heart and kidney (McCullough et al., 2013).
However, until recently, the definition and the classification were unclear. In 2004, The
National Heart, Lung, and Blood Institute took a stance in a report by loosely defining
CRS as a hindrance to treatment of CHF. The decline in the function of the kidneys
reflected by decreasing GFR was seen as a contributory factor for why therapy against
congestive symptoms failed against CHF. In September 2008, Ronco and colleagues
(2008) participated in a consensus conference composed of nephrologists and intensivists
known as the Acute Dialysis Quality Initiative (ADQI), and defined CRS and concretely
identified five subtypes. They defined CRS as an inclusive term identifying a disorder,
“whereby acute or chronic dysfunction in one organ may induce acute or chronic
dysfunction in the other organ” (Ronco et al., 2008). Different authors have different
perspectives on the proper definition, but much of the confusion was clarified through a
subsequent ADQI which was held in November 2012 (Hasse et al., 2013).
At the eleventh ADQI conference, in Venice, Italy, the pathophysiology was
updated and more researchers defined CRS, resolving to spread more awareness in this
relatively novel model (McCullough et al., 2013). However there is still debate about the
exact mechanism and pathophysiology of CRS and more is being done to find how to
effectively treat this syndrome at an early stage. Different organizations are placing
efforts to make a more collaborative effort to create an interdisciplinary to explore this
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difficult topic. In 2011, the Cardiorenal Society of America (CSRA) was created to
increase awareness about this syndrome (CSRA, 2011). They meet annually to discuss
about research and clinical progress that scientists have made in the previous year. More
effort and non-profit organizations need to place more effort in trying to prevent CRS in
those individuals with underlying CKD or CVD. With the collaboration of physicians
and health care workers in both disciplines, more important and awareness trickle down
to patients as well. The different subtypes are clearly illustrated in Figure 2
(McCullough, 2010). Type 1 CRS entails patients who had kidney dysfunction or injury
due to a primary acute deterioration of heart function (Hasse et al., 2013; Ronco, Cicoira,
& McCullough, 2012). As McCullough (2010) demonstrates in the figure, acute
coronary syndrome, acute decompensated heart failure, and even contrast procedures can
cause a domino effect from the heart to the kidneys. Increased central venous pressure
and renal congestion along with oxidative stress causes irreversible necrosis and
apoptosis of nephrons in the kidneys. More importantly, cytokines are involved in this
process as well, which are closely interrelated with hs-CRP (Papadakis et al., 2013).
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Figure 2. Definition and pathophysiology of different subtypes of CRS. From
“Cardiorenal syndromes: pathophysiology to prevention,” by P. McCullough, 2010,
Journal of Nephrology, 2011, 2. Reprinted with permission.
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The underlying etiology and pathophysiology of each type of CRS are similar to
each other. While in Type 1 CRS acute injury to the heart was the primary source of
pathophysiology, as demonstrated in Figure 2, Type 2 CRS entails patients who had
kidney dysfunction or injury due to chronic repeated deterioration of heart function (Cruz
et al., 2013). Type 3 CRS describes patients with primary acute kidney injury which
leads to cardiac dysfunction (Bagshaw et al., 2013). In type 4 CRS, patients with initial
chronic kidney disease eventually have cardiac injury and dysfunction (Tumlin et al.,
2013). Finally, in type 5 CRS, different conditions in the body lead to renal and cardiac
dysfunction (Mehta et al., 2013).
In most studies CRS 2 and 4 subtypes were challenging to discern due to the
difficulty in determining if heart or kidneys was the primary source of dysfunction.
Consequently, another proposal was to make a more general subtype known as CRS 2/4
(Bagshaw et al., 2008). There were also different researchers that grouped various
cardiovascular diseases in different subtypes differently. In McCullough and Ahmad
(2011), researchers chose to describe CRS type 2 and 3 as including acute coronary
syndrome, stroke, and arrhythmias, instead of just CHF.
CRS epidemiology
According to multiple studies, researchers have determined that patients that have
CHF, one of the most common comorbidities are renal dysfunction (Cruz, Gheorghiade,
Palazuolli, Ronco, & Bagshaw, 2011). Additionally, McCullough (2002) indicated that
six million Americans had a combination of chronic CVD and CKD, making the
prevalence rate 2.1%. In individuals over the age of 65 years, an estimated 22% suffer
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from the threat of CKD, diabetes, and CHF (Byham-Gray, Burrowes, & Chertow, 2010).
According to the Acute Decompensated Heart Failure National Registry (ADHERE), as
many as 21% with CHF have a serum creatinine > 2.0 mg/dl (Heywood, 2004).
Additionally, 30% of the patients had renal failure. According to the Atherosclerosis
Risk in Communities (ARIC) data studying 14,875 middle-aged subjects, those with
estimated GFR at <60ml/min/1.73m2 had a crude CHF incidence of 17.7 per 1000
person-years compared to 5.7 per 1000 person-years in those with a GFR of
≥90ml/min/1.73m2 (Kottgen et al., 2007). Additionally, in those that developed heart
failure or death experienced greater renal dysfunction than those that did not develop
heart failure. According to the Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness (ESCAPE), 31.4% of the subjects who
had CHF had a GFR of <60ml/min/1.73m2. When researchers later analyzed the
subpopulation of 401 subjects who had a creatinine level recorded, they found that
patients with a dynamic renal function, whether improving or worsening, had worse
prognosis than those with stable renal function (Testani, McCauley, Kimmel, & Shannon,
2010). In another clinical trial known as the Candesartan in Heart Failure Assessment of
Reduction in Mortality and Morbidity (CHARM) trial, in 2,680 Class II-IV NYHA Heart
Failure subjects, 36% had moderate to severe renal dysfunction (Hillege et al., 2006;
Stojiljkovic & Behnia, 2007). After a follow-up of approximately 3 years, researchers
found that in those with eGFR < 45 are 1.86 times more likely to suffer a heart failure
hospitalization and cardiovascular death than those with CHF exclusively. The research
suggests that adverse outcomes in different cohorts are exacerbated by CKD.
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Researchers from another major clinical trial demonstrated the need to pay
attention the renal component of CRS. The researchers from the Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) clinical
trial focused on how 2,737 patients who were given the aldosterone antagonist fared
compared to placebo when they have an ejection fraction of 35% and Class 2 New York
Heart Association Heart Failure (Cleland et al., 2011; Collier et al., 2013; Zannad et al.,
2011). Patients were >55 years of age, 78% men, and followed for an average of 2 years.
The results demonstrated a reduction of 37% in CVD hospitalization and death.
Additionally out of patients with class 2 NYHA CHF, 33.4% had moderate to severe
renal dysfunction. In another study, researchers from the Cardiac Registry of Heart
Failure in Cardiology (JCARE-CARD) studied 2,013 Japanese CHF subjects and found
that those with estimated GFR at <30 ml/min/1.73m2 were 2.5 times more likely to suffer
all-cause mortality than those without CKD (Hamaguchi et al., 2009). Among
individuals in the Digitalis Investigation Group (DIG) study, researchers found that 45%
with CHF had concomitant kidney dysfunction. These studies demonstrate another study
in which the cardiorenal component is critical to study as a syndrome (Hamaguchi et al.,
2009).
Cardiovascular mortality and morbidity rates were as high as 45% in patients with
advanced kidneys disease, creating more challenges to reducing mortality in this high risk
population (Sharma, 2012, p. 6). When compared to an age matched non-CKD control,
individuals with CHF have mortality rates which are 10- to 20-fold higher (Cruz&
Bagshaw, 2010). Additionally, in 2010, 43.6% of individuals with CKD had CHF;
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whereas, only 19.1% of individuals without CKD had CHF (United States Renal Data
System, 2013). In several studies, the frequency of CKD has been as high as 63% in
those individuals with CHF. However, while these conditions coexist, the challenge in
these studies has been to determine which disease took place first (Cruz & Bagshaw,
2010). Together these conditions are known as CRS, which is defined as a syndrome that
has the presence of renal dysfunction or the development of renal dysfunction in people
with heart failure (Liu et al., 2012, p. 692). According to the National Kidney
Foundation (2013), the direct cost of coexisting CKD and CHF was $19.4 billion in 2010.
This accounted for 37% of all Medicare related CHF expenditures.
While morbidity, mortality rates, and expenditures are especially high in CRS,
one of the main problems noted is that CRS is not fully understood in its entirety, and
there are biochemical, hormonal, hemodynamics, and pathophysiological factors that can
cause negative effects to the organs (Carubelli Metra et al., 2012, p. 272). The traditional
pharmacological interventions that are available to treat CVD or CKD individually tend
to cause serious negative interactions to the other organs when treatment is started and
have detrimental effects on the other body systems as well (Carubelli et al., 2012). Public
health professionals, researchers, and physicians look for ways to reduce the morbidity
and mortality in these individuals; however there are no gold standard tests to evaluate
sudden death in the population CRS (Sharma, 2012). Additionally, the direct
associations between heart and kidney disease is not clear and not enough research is
available to define proper treatment options and to reduce the morbidity and mortality in
individuals with CRS (Asinger et al., 2011, p. 581; Herzog et al., 2011).
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Pathophysiology of CRS
While researchers have clearly delineated the epidemiology of CKD and CVD,
literature is sparse about the bidirectional relationship between the two conditions.
Researchers have long established that the kidney plays a critical role in cardiovascular
and that hypertension originating from dysfunction related to sodium epithelial channels
can be resolved by renal transplantation (Weir, 2009). Furthermore, large clinical trials
have demonstrated the link between renal and cardiac dysfunction. Weir et al. (2008)
performed the Candesartan in Heart failure - Assessment of Mortality and Morbidity
(CHARM)-added trial, which was a randomized control trial to demonstrate efficacy of
reno-protective drugs like aldosterone receptor blockers in patients with congestive heart
failure. However, since CRS has unclear etiology, some researchers look for common
clues to the pathological response of the organs that are associated with CRS. Among
these clues that have been observed include sympathetic nervous system upregulation,
oxidative stress enhancement, increased activity of the renin-angiotensin system, and
immune-mediated inflammation. These aforementioned pathological changes of
oxidative stress and calcium overload many times causes observed abnormalities like left
ventricular regional wall motion abnormalities as a result of hemodialysis (Zuidema &
Dellsperger, 2012). Additionally, inflammatory markers are frequently studied because it
is the body’s response to protect the organs from infection; however, longstanding
inflammation can cause problems with any organ in the body and eventually result in
detrimental effects of the cardiovascular and renal systems in individuals with CRS
(Colombo et al., 2012). According to a pilot study by Colombo et al. (2012), serum
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samples from those individuals with Type 1 CRS demonstrated that pro-inflammatory
cytokines like TNF-, IL-6 and IL-18 were significantly higher than those individuals
with acute heart failure and control. As is demonstrated in Figure 3, TNF-α, IL-1β, IL-6,
and HS-CRP are all byproducts of CKD and CHF (Colombo et al., 2012). Additionally,
researchers have found nitric oxide and COX-2 are other proinflammatory molecules
released due to endothelial damage. These findings demonstrate that these individuals
not only have immune dysregulation, but also more specifically dysregulation of
apoptosis (cell death) (Virzi' et al., 2012).
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Figure 3. Potential Inflammatory Etiology of CRS. Adapted from “Inflammatory
activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal
syndrome,” by P. C. Colombo, A. Ganda, J. Lin, D. Onat, A. Harxhi, J. E. Iyasere, and G.
Atalay, 2012, Heart Failure Reviews, 17(2), 177-180.
Cardiorenal Anemia
Any discussion of cardiorenal syndrome is not complete without a discussion of
anemia. This syndrome causes anemia by the fact that renal failure causes decrease in the
release of erythropoietin. This hormone is responsible for erythropoiesis in the bone
marrow. Additionally, anemia of chronic disease, which is induced by hepcidin
production due to CRS, causes further deterioration of anemia (Nitta, 2011). The latter
condition is primarily caused by macrophage retention of iron, decreased retention of iron
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through the duodenum, and anemia from chronic inflammation. Chronic inflammation
also causes a lack of responsiveness of erythropoietin. Due to the need to control anemia,
according to the Anemia Working Group from the European Renal Best Practice (ERBP),
hemoglobin levels should be maintained above 11-12 g/dL (Attansio, Ronco, Anker,
Ponikowski, & Ander, 2010). However, in order to prevent overproliferation, they are of
the opinion that hemoglobin levels should not exceed 13 g/dL in the population with
CKD.
Prevention of CRS
Screening and prevention is a large component of CRS public health campaigns
(McCullough et al., 2008). If the biomarkers are identified ahead of time, then the
complications can be prevented in advance. Because CKD leads to accelerated
atherosclerotic disease in the cerebral, coronary, and peripheral circulatory systems,
management is more complex. According to the analysis from the Prevention of Renal
and Vascular End-stage Disease (PREVEND) cohort, researchers assessed the effect of
screening the population of CRS biomarkers from a population size of 500,000 in
northern Netherlands (Brouwers et al., 2013; Smink et al., 2012). After following a
cohort for an average of 6.5 years, they found that in a targeted and specific population,
like those subjects with albuminuria, screening is more effective than in performing it in
a general population.
Because CRS is such a complex syndrome, the task of prevention can be quite
challenging. As the pathophysiology becomes clearer, prevention strategies can be
further elucidated. Authors in England, utilizing logistic regression, found that in order
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to determine the likelihood of acute kidney injury, their CHF status is necessary (Forni et
al., 2013). In contrast, when researchers utilized the traditional definition of WRF,
subjects that demonstrated the aforementioned criteria showed only an additive effect in
predicting unfavorable outcomes in the context of heart failure (Metra et al., 2012).
However, in the retrospective analysis 949 patients in the Outcomes of a Prospective
Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIMECHF) study, individuals with >10 mg/dL change in BUN had a worse 60 day prognosis.
According to McCullough and colleagues (2010), an important area to consider
for prevention is assessing the level of acute kidney disease the patient has using newer
criteria. Based on the available data about what is acute renal failure, in 2002, a
consensus conference formulated the Risk, Injury, and Failure; and Loss, and End-stage
kidney disease (RIFLE) criteria. In terms of public health prevention programs, the
period before the risk phase (R) when GFR has not decreased more than 25% and serum
creatinine has not increased 150% to 200% is the time period to take prevention measures
(Endre, 2008). Other researchers use different criteria known as Kidney Disease:
Improving Global Outcomes (KDIGO) criteria and Acute Kidney Injury Network
(AKIN) criteria in order to determine when the patient is experiencing AKI. In the
context of CRS, researchers found that when the traditional WRF definition was used as
compared to the newer definitions, the newer definitions had a benefit in determining
unfavorable outcomes like death, dialysis, and readmission in those with Acute
Decompensated Heart Failure (ADHF) (Roy et al., 2013). This research demonstrates the
fact that new criteria need to be used to stratify those with cardiovascular disease.
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Similarly another potential area of intervention and prevention is to identify
individuals at high risk for cardiovascular disease and heart failure. While the original
authors for the major risk scores like Framingham Risk Score and Reynolds Risk did not
include diminished renal function as a major risk factor for cardiovascular disease, the
authors of QRISK-2 included CKD as a risk factor of 10-year CVD (Chen et al., 2013;
Collins and Altman, 2012; Ridker, Paynter, Rifai, Gaziano, & Cook, 2008; Santos,
Vinagre, Silva, Gil, & Fonseca, 2010). In both of these risk-scoring systems
inflammatory markers and kidney failure status is necessary.
Critique of Methods
Researchers have performed multiple studies which have assessed the connection
of CVD and CKD in different ways. For instance Go et al. (2004) published findings in
The New England Journal of Medicine assessing differential effective GFR outcomes
among 1,120,295 adults who were part of the Kaiser Permanente Renal Registry, which
according to modern classifications would be considered Type 4 CRS (Go et al., 2004).
They were longitudinally studied, and using Multivariate Cox Proportional Hazards,
researchers found that between 1996 to 2000, as the range of effective GFR worsened,
the number of cardiovascular events increased (Go et al., 2004). While at a range of 45
to 59 ml/minute/1.73 m2 the Hazard Ratio (HR) of 1.4 (95% CI, 1.4-1.5), when GFR was
less than 15 ml/minute/1.73 m2, the HR for CV events was 3.4 (95% CI, 3.1-3.8). The
limitations of this study were that it only included insured people in northern California
and did not take into account diabetes and hypertension as confounders (Go et al., 2004).
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While the study is reliable due to sample size, the lack of generalizability jeopardizes the
external validity.
While Go et al. (2004) assessed Type 4 CRS in a large population in northern
California, Sato et al. (2013) studied if there was a difference in cardiovascular outcomes
in CHF patients with CKD versus without CKD. A total of 505 patients with a mean age
of 60 at Fukushima University in Japan with CHF were followed between the years of
2007 to 2010. Out of individuals with CHF who had concomitant CKD 34% had adverse
cardiovascular events, whereas patients with CHF who did not have CKD only 14% had
adverse cardiovascular events (p < 0.001). Additionally, through Multivariate Cox
Methods, researchers found that pro-BNP was a significant biomarker in predicting
adverse cardiovascular events in the group with both CKD and CHF. Similar to the study
conducted by Go et al., this study also lacked generalizability due to its applicability to
one community in Japan with good exercise tolerance.
Similar to Sato et al. (2013), another group of researchers studied cardiovascular
outcomes in those CHF patients from Brazil who also had CKD (Galil, Pinheiro,
Chaoubah, Costa, & Bastos, 2009). In this prospective cohort study, conducted between
January to December of 2006, researchers found that among 83 CHF patients, the
presence of CKD increased the chance cardiovascular outcomes by 3.6 times (CI 95%
1.04-12.67, p = 0.04) (Galil et al., 2009). While this study took many potential
confounding variables like physical inactivity and cholesterol level into account, the
small sample size might have compromised the power of the study. Additionally, due to
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differences in diet and cultural differences, the results may not be generalizable to the
United States.
Researchers from another major study assessed the relationship between renal
function and cardiac function in a slightly different manner. Gutiérrez et al. (2013)
published findings in the Journal of American Medical Association, from a prospective
cohort study assessing differential associations of ACR (marker of renal vascular
function) and coronary heart disease CHD stratified by race (blacks vs. whites) (Gutiérrez
et al., 2013). The analysis was done on 28,207 individuals, 45 years and older, from the
Reasons for Geographic and Racial Differences in Stroke (REGARDS) study between
2003 and 2007 and were followed up for 4.4 years (Gutiérrez et al., 2013). The most
significant finding in this study was that in blacks, when medications and traditional
CVD risk factors are controlled, the rate of incident CHD was depending ACR rate. The
HR was 3.21 (95% CI, 2.02-5.09) when comparing ACR >300 mg/g vs <10 mg/g, while
in whites the HR was not as significant (Gutiérrez et al., 2013). One weakness of this
study was that due to many categories of ACR, the sample size was low in some
categories, potentially affecting power. Additionally, because other races were excluded,
the generalizability of the study could be called into question.
The continuous NHANES dataset was used previously in many analyses to assess
different variables associated with cardiovascular disease (Bansal, Vittinghoff, Plantinga,
& Hsu, 2012). In this study, Bansal et al. (2012) used a cross-sectional analysis on
34,326 subjects between the years of 1999-2006, in order to study if CKD modified the
association between BMI and CVD risk factors. Out of the CVD risk factors tested as
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outcome variables, one of the outcome variables tested was C-reactive protein (Bansal et
al., 2012). The conclusion was that there was no association between BMI and risk
factors, when race, sex, and age were used as covariates. Regardless of the presence or
absence of CKD, an increase in BMI was associated with an increase in CRP in the same
way and had no statistically significant difference (p=0.095). This study had robust
power due to the large sample size (Bansal et al., 2012). Due to the use of the NHANES
dataset, the weaknesses were the lack of knowledge of other comorbid conditions and use
of self-reported data. Additionally, the absence of stroke and arrhythmia as
cardiovascular disease led to possible inaccurate results.
Knowledge Gap
As reflected in the previous section, many researchers have studied the impact of
CKD of CVD (Bansal et al., 2012; Go et al., 2004; Gutiérrez et al., 2013; Sato et al.,
2013). These studies were only representative of small communities and did not reflect a
larger population (Go et al., 2004; Sato et al., 2013). In other studies, the definition of
CVD was too narrow, making the results inaccurate (Bansal et al., 2012). In recent years,
researchers have increased their interest in the role of inflammatory biomarkers (Bansal
et al., 2012; Lekawanvijit et al., 2012). In the context of obesity, diabetes, and metabolic
syndrome, out of all the biomarker, hs-CRP has been studied repeatedly. Researchers
have demonstrated the need to screen hs-CRP in especially high risk individuals with
CRS in smaller populations in different countries like Bavaria, Korea, Brazil, and Spain
(Jalal, Chonchol, Etgen, & Sander, 2012; Park & Kim, 2003; Soriano, González, MartínMalo, Rodríguez, & Aljama, 2007; Xue et al., 2010).
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Due to the recent establishment of the definition of CRS, there has been very little
research done on the relationship of biomarkers in this syndrome in particular in a
nationally representative population (Xue et al., 2010). While Soriano et al. (2007) found
in CKD patients with high hs-CRP increased cardiovascular events in a small community
in Spain, no researcher has studied how different biomarkers interact with known CKD
and CVD risk factors in a nationally representative population (Ronco, Cicoira, &
McCullough, 2012; Tumlin et al., 2013). Very little research has been done in studying
how to prevent CRS, due to the complexity of the syndrome (Lekawanvijit et al., 2012).
Understanding the epidemiological association in specific cardiovascular diseases and
CKD can lead to identifying critical biomarkers that could signal clinically aberrant
manifestations before they occur (Xue et al., 2010). Additionally, literature is scant on
how upstream demographic factors potentially differentially interact with inflammatory
markers in associations with CRS in a nationally representative population (Gutiérrez et
al., 2013). By investigating and addressing the importance of inflammation as potential
biomarkers, public health practitioners and healthcare advocates and providers can
effectively empower patients to improve their own health and educate patients about how
to control inflammation and slow or prevent disease progression.
National Health and Nutritional Examination Survey
The National Health and Nutritional Examination Survey (NHANES) was started
in 1971 with the intent to quantitatively and qualitatively measuring the nutritional and
health status of children and adults (McDowell, Engel, Massey, & Maurer, 1981).
Additionally, the intent was to assess the prevalence of major diseases and understand
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risk factors. This annual survey is conducted in the United States and includes
socioeconomic, demographic, exposure-related, and dietary information. Researchers
and health practitioners ask subjects to provide blood and urine samples with the intent of
measuring exposure and nutritional exposures.
Summary and Conclusion
This chapter entailed a thorough literature review on the inflammatory etiology of
CVD. Additionally, there was discussion on the risk factors of CVD and the definition of
CKD. Furthermore, CRS was specifically defined, and the epidemiology was delineated.
Finally, there was a thorough discussion on the potential etiology and different subtypes
of CRS. While multiple etiologies have been proposed on the role of inflammation on
CRS, how the specific inflammatory markers are connected to CRS is not well known.
Additionally, the current research will not only fill the gap on the impact of inflammatory
markers on CRS, but also delineate how demographic factors play a role in this
relationship between inflammatory markers and CRS. Chapter 3 will include the
research method that was utilized for this study. The design and approach of the
research, population sample, data collection, and data analysis method was included.
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Chapter 3: Research Method
Introduction
CRS, a growing public health burden, is associated with increased mortality,
growing complications, and increased cost of care (Lekawanvijit, Kompa, Wang, Kelly,
& Krum, 2012). Chronic inflammation is a multifactorial effect that has become
epidemic throughout the world as a result of chronic diseases like diabetes, hypertension,
hyperlipidemia, and chronic kidney disease. A significant increase in chronic disease
prevalence among all populations has become a primary public health issue mainly
because risk factors like diabetes and obesity are on the rise.
The purpose of this study was to evaluate whether specific inflammatory markers
make CRS more likely in the general population. According to literature reviews, several
factors such as gender, race/ethnicity, age, education, socioeconomic status, obesity,
hyperlipidemia, and diagnosis of diabetes mellitus have been previously associated with
CVD and CKD individually (Graves, 2012; Hui et al., 2013; Wong et al., 2012). The risk
factors that were utilized in the data analyses were used because of the potential
confounding effect and have been delineated in greater detail in the data analysis section.
The current chapter entails critical information about the methodical approach to
selecting the proper research question, selection criteria of the research design and
approach that was utilized, setting of the study and the specific sample method, data
collection method, and various statistical methods that was employed to test hypotheses
of the association between inflammatory markers and CRS. Additionally, power
considerations for the appropriate sample size selection, ethical and legal considerations,
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and the specific biases which threaten empirical, content, and construct validity are
delineated in detail.
Research Design
Research Approach
In a nationally representative population, the goal of the present study is to
conclusively determine whether inflammation is a risk factor for CRS. In this study, the
quantitative approach was selected to study this association because this method is the
most appropriate to understand the relationship between numerous variables. According
to Creswell (2009), this approach is better for understanding new theories, determining
specific proportions, and testing multiple hypotheses. Researchers who employ
quantitative methodology for analysis utilize a methodical deductive approach.
Alternatively, the study is driven by measurement represented by numbers in order to
quantify the outcome (Trochim & Donelly, 2008). From the general population in the
United States, NHANES is one such survey where health and nutritional data have been
collected for over four decades and the survey and examination techniques have evolved and
made to increase the public policymakers. This study will explore the association between
elevated serum inflammatory levels and CRS both independently and additively with
known CVD risk variables like obesity, age, gender, diabetes status, hyperlipidemia, and
smoking status.
Research Rationale
The nature of this study will have a quantitative focus. This secondary data
analysis on cross-sectional data is consistent with developing a thorough understanding in
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a multi-ethnic population (non-Hispanic whites, non-Hispanic blacks, and Mexicans) on
how inflammatory biomarkers can signal the subsequent development of renal failure,
with the development of cardiovascular disease. Inflammatory markers and their
association with cardiovascular and renal disease was taken into account, while
controlling for known cardiovascular risk factors like obesity, age, gender, diabetes
status, and smoking status (Levitan et al., 2009). The inflammatory markers and
demographic data were included in the respective datasets. Survival analysis was
employed to assess the differential development of cardiovascular disease between
demographic groups and different inflammatory status in individuals with chronic kidney
disease.
The main goal of this study is to determine whether inflammatory markers play a
significant role in CRS. In order to study this relationship, quantitative methodology was
utilized due to the robustness in examining numerous variables, determining proportions,
formulating new theories (Creswell, 2009). In order to test the hypothesis of this
association, quantitative methodology can be used through deductive reasoning. This
distinct methodology is utilized when determining the theory is the main goal and is
derived from quantitative measurements that made from outcome measurements
(Frankfort-Nachmias & Nachmias, 2008; Trochim & Donelly, 2008).
Out of other alternatives, the NHANES survey was selected due to multiple
reasons. First of all, all of the different information like detailed demographic
information, inflammatory markers, and past medical history information has been
systematically collected on a nationally representative population. Additionally, between
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the years of 1999-2010, researchers have collected enough data in order to study CRS,
providing a large sample size in a population who were 20 years or older. Because CRS is
an uncommon syndrome, a large range of years are necessary to capture an adequate
number to have adequate power for a study.
The main theory that is at the crux of the study is the biomedical model in which
researchers purport that CRS is a consequence of biological aberrations in the body.
More specifically, biomarkers can be used as an early marker for identifying the eventual
consequence of CRS (Mayeaux, 2004). Similar to diabetes, increased inflammatory
markers have been linked to cardiovascular disease and renal disease individually.
Consequently, it is highly likely that increased inflammatory markers will play a role in
both of these diseases simultaneously. Exploring the association of inflammatory
markers and CRS was tested using the presence of biomarkers like C-reactive protein,
hcy, ferritin-transferrin ratio, and fibrinogen.
The cross-sectional design was appropriate for this study because the specific
prevalence of the disease of interest and outcomes of health can be ascertained from
surveys and clinical records in the NHANES. Since CRS is a newer classification, this
dataset allows for a unique perspective into the syndrome which is not studied routinely.
Additionally, the same design can be replicated or the study can further extended to a
longitudinal study in order gather and obtain more information on this specific problem
(Creswell, 2009). Rather than incidence, these findings will provide information on
prevalence (Levin, 2006). A causal relationship is difficult to ascertain because it is
conducted in a single moment in time, making this a major limitation (Singleton & Straits,
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2005). Even though there are limitations, this study design is the most appropriate
because it is the first study to fill a gap on the role of inflammatory markers as a risk factor
for CRS in a multiethnic nationally representative population.
Alternative study designs were inappropriate due to different reasons. A casecontrol study was not practical in studying CRS in the context of inflammation because
the time to develop the constellation of symptoms in the syndrome may be longer than
others. Additionally creating a prospective control, retrospective control, or experimental
study would have been time consuming, expensive and unusually complex (Singleton &
Straight, 2005). Only when specific associations are established are these designs
applied. Therefore, because this study is the first study to explore whether inflammatory
markers are a risk factor for CRS, cross-sectional design and the quantitative
methodology were utilized to analyze relationships derived from the most recently
acquired data (1999-2010) collected by NHANES.
While C-reactive protein, hcy, ferritin, and fibrinogen have been studied in the
past, there is a gap in the literature in understanding how they interact in the context of
CRS. Furthermore, how sociodemographic indicators modify the relationship between
inflammatory markers and CRS remains unknown. The joint effect of cardiovascular risk
factors and inflammation on CRS in a multiethnic population has not been assessed in
any other study.
Study Sample and Population Setting
The NHANES dataset that was previously collected by the NCHS and is
available for public use was utilized for this study. Data from individuals who reside
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with the general United States population was utilized in this retrospective secondary data
analysis for the quantitative research study. Civilian, non-institutionalized adults who
reside within the continental United States was included as part of this study. There were
62,160 individuals who participated in the questionnaire component only and 59,367
NHANES who participated in the questionnaire and examination component in the
survey years 1999-2010. Of the adult men and women, a net total of 51,130 individuals
who took part in the NHANES survey years 1999-2010 aged 20 years and older, were
incorporated into the analysis. The six 2-year cycles of the continuous was used for the
purposes of this analysis. Age was used as a primary variable for inclusion in the
secondary analysis because this study is only pertaining to inflammatory markers
associated with chronic diseases affecting adults. According to previous research, at least
2.1% has CRS out of the general population (Cruz et al., 2011; McCullough, 2002).
Questions specifically asked by the researchers of the NHANES survey, in addition to
data collected from laboratory analysis and medical examination were used to study the
identified population. The aspects of the NHANES datasets that was included are:
questions related to height and weight; history of diabetes; history of chronic kidney
disease and heart disease; history of smoking; and serum collected for analysis of hsCRP, hcy, ferritin-transferrin ratio, and fibrinogen (CDC, 2011).
Power Analysis
The NHANES data sets include 51,130 responders who are aged 20 years or older
from the aforementioned dataset. Results from previous analyses demonstrate that 2% of
the US population has CHF with 60% who have concomitant CKD (Adams et al., 2005;

52
Ezekowitz et al., 2004; Heywood et al., 2007; Hillege et al., 2007; Smith et al., 2006). As
determined by McCullough (2002), using the 2.1% as an estimate for the prevalence of
cardiorenal syndrome, the calculated total number with CRS out of the NHANES
datasets (51,130 subjects) was determined to be 1074 subjects. In order to determine
whether the total sample of 614 participants was adequate for this analysis, calculations
were made using he G*power utility (Buchner, Erdfelder, Faul, & Lang, 2013).
The main analysis for this study was a logistic regression. For a logistic regression
analysis, sample sizes of 568 will yield a power of 80% with α = 0.05 and a minimum
detectable odds ratio of 1.3 with inflammatory markers as the predictor variable and
CKD, CVD or CRS as the outcome variables when testing the different hypotheses
(Buchner, Erdfelder, Faul, & Lang, 2013; Muncer, Taylor, & Craigie, 2002). The
minimum detectable odds ratio of 1.3 was used because based on the odds ratio in
previous research (Skinner, Steiner, Henderson, & Perrin, 2010). Additionally, according
to Vittinghoff and McCullough (2006), each predictor variable conservatively must have
ten outcome events per predictive variable in order to prevent overfitting, under special
circumstances less than ten is permissible. In light of these calculations in support of the
power analyses, there was confidence that the sample size of 51,130 participants with
anticipated 614 participants with CRS was adequate to perform the analyses in the
present study.
Instrumentation and Materials
The secondary analysis was performed retrospectively using archival data in the
NHANES database, which is readily accessible from the internet (CDC, 2011). The
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NHANES survey is derived from a cluster sample design with a complex, stratified, and
multistage survey. In the process of collecting data for NHANES, the first part is sample
selection. The sample selection is performed methodically in stages by first selecting
Primary Sampling Units (PSUs) (CDC, 2011). These are either sets of counties that are
continuous with each other or larger counties. Next, a cluster of households or segments
which are a component of a group of blocks or PSUs are selected. After this, households
that compose the segments are selected. Finally, specific participants within households
are selected. Those identified as fitting the appropriate inclusion criteria were included in
the NHANES sample by sending them a letter in advance, informing them that an
interviewer from NHANES was going to visit their home. Once the home visit took
place, the interviewer proceeded to recruit who are eligible to participate in NHANES.
They assured the individuals confidentiality of the data collected from the survey,
informed the respondents of their rights, and requested them to sign the form for
Informed Consent. A computer-assisted personal interview (CAPI) system using the
Blaise computer program was used (CDC, 2011). After completion of the household
interview, persons that were interviewed were requested to complete a component about
health information. This was only performed on individuals who signed an additional
consent form agreeing to participate in the health examination part.
Validity and Reliability of the Instrument
Validity
In order to ensure validity of each measurement and instrument used throughout
the study, special precautions needed to be taken during the collection and analysis
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component of the study. Because the NHANES has a long history and has been collected
since the 1960s (earlier version was known as the National Health Examination Survey),
the validity of the survey has been repeatedly tested throughout the years on over 130,000
study participants (Birkner, 1965; Khrisanopulo, 1964; McDowell, Engel, Massey, &
Maurer, 1981). Specific errors that had emerged have been controlled for by making
changes in the creation, development, implementation, and administration of the survey.
In the NHANES data, the types of validity that was explicated are as follows: empirical
validity, content validity, and construct validity (Frankfort-Nachmias & Nachmias, 2008).
Empirical validity. Researchers from National Center for Health Statistics
(NCHS) go through different measures to ensure that the NHANES is empirically valid
(CDC, 2011). In terms of the NHANES survey, researchers had to ensure that the
questions measured the outcomes needed to be measured. For instance, in measuring hsCRP, they had to make sure that the labs that were using had a consistent protocol in
place in order to measure this critical biomarker. This is closely interrelated with
predictive validity where the measures can be helped to ascertain associations expected to
be obtained. In numerous secondary analysis studies, SAS and SPSS have been utilized
in order to analyze NHANES data. In this study, these two statistical packages was
utilized to follow suit with what packages was used in order to confirm and ensure
empirical validity to the study proposed here (CDC, 2011; Frankfort-Nachmias &
Nachmias, 2008; Petrou, Morrell, & Spiby, 2009).
Content validity. In this study, the content validity of the NHANES survey is
ensured by various means, and also specific measures are necessary in order to minimize
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bias. Through stratification and cluster design of the survey, content validity can be
ensured. Additionally, the NHANES survey uses objective measurements like
examination and laboratory data along with questionnaire results. In summary, the
NHANES survey ensures not only face validity, which is a subjective evaluation of
appropriateness, but also sampling validity. The following descriptions of selection bias
and information bias demonstrate how these are minimized in order to ensure content
validity (CDC, 2011; Frankfort-Nachmias & Nachmias, 2008).
Selection bias. When selecting individuals that are adequate for a specific
research question, there is potential bias in determining and selecting individuals who are
with or without disease. Researchers from the Centers for Disease Control and
Prevention used a complex and systematic approach in order to ensure randomness and
minimize selection bias. The steps they took were as follows: 1) they selected Primary
sampling units (PSUs); 2) they divided the PSUs into neighborhoods; 3) they selected
random households from the neighborhoods; and 4) Depending on the gender and
ethnicity of each household, 1.6 individuals per household were selected (CDC, 2011).
This systematic approach ensured the representativeness of the sample throughout the
general population and ensures the presence of external validity. Historically, in previous
versions of NHANES, high nonresponse rates have led to the potential for bias. For
instance, according to Forthofer (1983), NHANES II had a nonresponse rate of 27%
during the examination phase, in the first years. In order to address these issues, some
techniques that were used included better follow-up methods than previously used. They
started to market and advertise the success stories, in especially those communities that
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the survey took place in. Additionally, they incorporated an introductory letter, and the
interviewer began by verbally expressing the significance of NHANES during each
household visit. Other techniques that were used were providing incentives to encourage
participation. For instance, participants were provided with a free medical education,
free transportation, and guaranteeing confidentiality. In order to further adjust for
nonresponse and adjust for unequal probability of selection, NHANES investigators
provide a separate sample weight variable. Consequently current non-response rates have
gone down to 20% and are much lower than the 55% nonresponse rates seen in
Behavioral Risk Factor Surveillance System (BRFSS), another national self-reported
questionnaire (Hu, 2008, p. 17).
Information bias. Information bias is an error that is systematically made during
the process of making measurements of the participant study. There are two primary
types of misclassification—differential or non-differential misclassification. In this
study, the primary source of information bias is the recall bias, which is part of a
differential misclassification. In this type of bias, respondents may not be able to
accurately recall information accurately because they are based on certain previous
experiences or diagnoses that were given to them in the past. Some of the data from the
NHANES data may contain self-reporting bias because the interview component depends
on accurately recalled information by the participants of events from the past. In general,
subjects that felt their information would be negatively perceived underreported the
frequency of the incident (Klesges et al., 2004). This type of information bias is a
combination recall bias and social desirability bias. In another recent study, Canadian
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researchers reported that out of 4,615 subjects, men and women overestimated their
height and underestimated their weight, resulting in 15% decreased rate of obesity (Elgar
& Stewart, 2008). Other researchers found that among NHANES respondents between
different years, with similar discrepancies in height and weight measurements resulted in
an underestimation of the corresponding BMI (Connor, Gorber, & Tremblay, 2009). In
order to minimize this information bias, the variables that was primarily studied was
taken from anthropometric measurements and laboratory results rather than self-reported
data. C-reactive protein and obesity data are all collected from direct measurements. In
order to control for self-report bias, Hunt et al. (2003) proposed that direct and
systematically objective measurements which are unbiased need to be utilized whenever
available.
Construct validity. Researchers at the NHANES ensure the construct validity by
employing different strategies. With construct validity it is important to ensure that the
measurement technique being used yields the same result as other measurement
techniques. For instance if there are two health care taking blood pressures of different
people, the measurement technique employed by both health care worker must be
consistent in order to yield meaningful findings. Because the NHANES survey has been
collected for many years on the U.S. population, the measurement techniques are time
tested methods. Inferentially, construct validity can be demonstrated by yielding similar
from previous studies in regards to HS-CRP level, cardiovascular disease, and CKD
(Frankfort-Nachmias & Nachmias, 2008).
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Reliability
By controlling for errors in measurement, reliability must be preserved in a given
study. In this study, multiple steps were taken to make sure that there is reliability in the
instrument. On the data collection level, this took place by, first, checking the data transcripts
and matching them with the respective windows on the CDC website. Once the data had been
checked, the ordinal, nominal, and ratio data variables were accurately coded and they must be
given numbers, ranked accurately, and dummy coded properly with the fixed values.
Next, data collection, data analysis, and assignment were discussed in regular meetings
with staff members to ensure uniformity and reliability. Finally, the data was crosschecked with other colleagues to compare and cross-reference the accuracy of the
analysis of the data. As mentioned previously, a time tested instrument added to the
reliability and credibility of the NHANES survey (Frankfort-Nachmias & Nachmias,
2008).
Study Variables
The research study variables were selected based on current research interest,
literature review, and the availability if the collected data in the NHANES survey.
Weight, height, blood pressure, and blood tests for inflammatory markers were performed
on the study population at the mobile examination center by NCHS. Other variables,
such as diabetes, age, gender, education level, socioeconomic status, smoking status were
obtained from interviews with the study population. The specific details about each
individual survey procedure are thoroughly described in detail in the accompanying
documentations which were provided by the NCHS (CDC, 2011).
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Dependent Variables
Chronic Kidney Disease. A trichotomous CKD variable was created using the
KDOQI (Kidney Disease Outcomes Quality Initiative) study classification for stages of
CKD (Tan et al., 2011). Before CKD can be categorized, a urine albumin-to-creatinine
ratio (ACR) was calculated. Urine creatinine and albumin concentration were ascertained
from random spot urine samples using sterile containers and a clean-catch technique. As
previous researchers have indicated, the categories for the ACR >30 can be defined as
albuminuria and a reflection of early CKD (Inker, Coresh, Levey, Tonelli, & Muntner,
2011).
For demographic purposes, individuals in stages 3–5 (eGFR of 0–59 mL/min/1.73
m2) was classified as having late CKD (coded 2); individuals in the stages 1 and 2 (eGFR
of 60–89 mL/min/1.73 m2) or eGFR of greater than 90 mL/min/1.73 m2 with ACR>30)
was classified as having early CKD (coded 1) (CDC, 2011; Whaley et al., 2008). All
other individuals were classified as having normal kidney function (coded 0).
Cardiovascular Disease. In this evaluation, cardiovascular disease can be
defined as coronary heart disease, congestive heart failure, angina, cerebrovascular
accident, and heart attack (coded as 1). The presence or absence of all of these diseases
was based on self-reported data (CDC, 2011). All reports were based on if the study
participant was or was not informed by a physician if s/he has had one or more of any of
the aforementioned conditions. The rest was coded as 0.
Cardiorenal Syndrome. Cardiovascular syndrome can be defined as all
individuals with eGFR less than 60 mL/min/1.73 m2 (1.0 mL/s/1.73 m2) or ACR of 30
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mg/g or greater and having self-reported CVD. More specifically, any individual with
coronary heart disease, congestive heart failure, angina, cerebrovascular accident, and
heart attack and 60 mL/min/1.73 m2 or ACR of 30 mg/g (CDC, 2011).
Independent Variables
In studying CRS, because the variables are bidirectional, cardiovascular disease
and CKD will used as dependent or independent variables depending on the question
being answered. The main independent variable for this study was inflammatory markers
hcy, ferritin-to- transferrin ratio, fibrinogen, and hs-CRP.
Homocysteine. Total plasma hcy levels were determined using the fully
automated fluorescence polarization immunoassay (Abbott Laboratories). As previous
researchers have indicated, the categories for the hcy are 2.0-6.9 μmol/L, 7.0-8.7 μmol/L,
8.8-11.0 μmol/L and > 11.0 μmol/L. According to researchers, ≥ 8.5 μmol/L (≥50th
percentile coded 1) is considered a cardiovascular risk factor, while the rest (coded 0) is
not (Foley, Wang, & Collins, 2005; Mangoni & Woodman, 2011; Veeranna et al., 2011).
Hcy data collection was cycled out in 2007 (CDC, 2011).
Ferritin-to-transferrin saturation-ratio (F/T). A ferritin based inflammatory
marker controlling for status of iron is the purpose of the F/T ratio. Because there are no
specific clinical cutoffs that actually are present for this measure, in previous studies the
defined F/T saturation was considered high when the value was greater than the weighted
95th percentile in the final analytic sample (Skinner, Steiner, Henderson, & Perrin, 2010).
Following suit from a previous study, for categorical analysis, F/T was considered
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elevated if it is ≥ 11.67 (≥50th percentile coded 1), the rest (coded 0) of the study
population was considered not (Skinner et al., 2010).
C-Reactive Protein. Hs-CRP was quantified by using latex-enhanced
nephelometry, and a high-sensitivity assay was performed on a Behring (Deerfield, IL)
nephelometer. The lower limit of detection for this test was 0.2 mg/L. For continuous
analyses, all values of 0.2 mg/L were coded as equal to 0.1. Research in adults has
indicated increased risk of cardiovascular disease beginning at values of 1.0 mg/L, so this
value was used as a cut point for analysis (Ridker, 2003; Ridker et al., 2005). Values of
hs-CRP >0.51 (greater than 75th percentile coded as 1) was considered as cardiovascular
risk, and hs-CRP < 0.09 (less than 25th percentile coded as 0) was not.
Fibrinogen. Fibrinogen concentration in plasma was determined using the Clauss
clotting method. This test method involves measuring the rate of fibrinogen to fibrin
conversion in a diluted sample under the influence of excess thrombin. Since under these
conditions the fibrinogen content is rate limiting, the clotting time can be used as a
measure of the concentration of the fibrinogen and in fact, the clotting time is inversely
proportional to the level of fibrinogen in the plasma. A fibrinogen level of greater than or
equal to 378 is considered increased risk of CVD, CKD, or CRS because this was greater
than the 50th percentile (Dhangana, Murphy, Pencina, & Zafar, 2011).
Covariates
Age. The age of each subject was ascertained according to the provided age or
date of birth provided by the respective subject. In this study, age categories was dummy
coded as follows; 20-34 (coded 1), 35-49 (coded 2), 50-64 (coded 3), and 65 and older
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(coded 4). These categories were used for the descriptive statistics section providing the
age distribution for the study. In all other statistical analyses, age was used as a
continuous variable to the study.
Gender. The respondents of the NHANES study were asked whether their gender
was either male or female. In the study, gender categories were dummy coded as either
“Male” (coded 1) or “Female” (coded 2).
Diabetes. Diabetes was ascertained from the NHANES questionnaire about
diabetes. All respondents over the age of 20 were asked “Other than during pregnancy,
have you ever been told by a doctor or other health professional that you have diabetes or
sugar diabetes?”. For the purposes of this study, the participants who answered
“borderline” or “yes” was considered as diabetic (dummy coded as 1). However, those
participants who answered “no” were considered as non-diabetic (dummy coded as 2).
Respondent answers such as “don’t know” “refuse” or “not sure” was marked
accordingly as missing data and will not be included in data analyses.
Hyperlipidemia. Each respondent was asked about their cholesterol status.
Previous researchers found that there was more data available on total cholesterol than
LDL, so as per Adult Treatment Panel III guidelines, total cholesterol was used as the
marker for hyperlipidemia (Chatterji, Joo, & Lahiri, 2011). Dyslipidemia or
hyperlipidemia (coded as 1) was ascertained and determined to be present with use of
cholesterol lowering medications, self-reported diagnosis, or a total serum cholesterol of
> than 240 mg/dl. In subjects with diabetes, this number was > than 200 mg/dl and also
coded as 1. The rest of the subjects were coded as 0.
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Obesity. A well-recognized unit of measurement of obesity in the scientific
community is the BMI. The unit is categorized according to the varying grades of health
risk (WHO, 2006). In this study, BMI was arranged into four different categories. The
first category is participants with BMI < 25, which is considered normal weight (dummy
coded as 1); participants with a BMI = 25-29 was considered overweight (dummy coded
as 2); participants with a BMI 30-39.9 was considered as obese (dummy coded as 3); and
participants with a BMI >40 was considered severely obese (dummy coded as 4). BMI
categorization is controversial because distinguishing between weight from fat versus
weight from muscle (Faeh, Marques-Vida, Chiolero, & Bopp, 2008; WHO, 2006).
Hypertension. Hypertension (coded as 1) was defined as average
systolic/diastolic blood pressure ≥140/90 mm Hg or self-reported antihypertensive
medication use. The rest was considered as non-hypertensive (coded 0).
Smoking Status. A two-variable indicator of current smoking status was created
with “nonsmoker” (coded 0) and “smoker” (coded 1). The subject was considered a
“smoker” if s/he reports “yes” to the question, “Have you smoked at least 100 cigarettes
in your entire life?” and did not answer “not at all” to the question, “Do you now smoke
cigarettes…” in the NHANES 1988-1994 and 1999–2010 (CDC, 2011). Any answers by
the participants such as “don’t know”, “refuse”, or “not sure” was recorded as missing
data and will not be included in the data analyses
Education level. The question “What is the highest grade or level of school you
have completed or the highest degree you have received?” was the basis by which
education level of the respondents was determined. In order to be consistent with
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associated literature, eight categories were narrowed down to three categories for
education level. The three categories that were dummy coded are as follows: “Less than
high school” (coded 1), “High school graduate or GED” (coded 2) and “Higher” (coded
3). Other answers like “refused” or “don’t know” was marked as missing data (CDC,
2011).
Race/ethnicity. In order to ascertain the race/ethnicity of the subject, the
interviewer asked “What race do you consider yourself to be?” Within the NHANES
questionnaire, respondents were allowed to select one out of five categories. The different
categories were dummy coded as; Non-Hispanic White (coded 1), Mexican American
(coded 2), Non-Hispanic Black (coded 3) and Other (coded 4) (CDC, 2011). Any other
answers by the participant such as “refused” or “don’t know” was marked as missing data
(CDC, 2011).
Socioeconomic status. The socioeconomic status was based on poverty income
ratio (PIR) included in the questionnaire. PIR, established according to the US Census
Bureau (2012), was established based on the estimate of the per annum income of a
family income per year and the size of each family. Groups of individuals were classified
as families if they were related through marriage, adoption, or by birth. Other scenarios
that were considered as family were parents or siblings or unmarried partners who had a
biological or adopted child that was in common were considered as a family unit as well
(CDC, 2011). In this study, the socioeconomic status of the family was categorized as
follows; PIR <2 (< 200% federal poverty rate) was labeled as poor (coded 1) and PIR ≥ 2
was considered as not poor (coded 2). Answers by the participants such as “don’t know”,
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“refuse”, or “not sure” were labeled as missing data and were not used in the data
analyses.
Data Categorization and Analysis
Table 1 demonstrates the nature of all the variables that were utilized in this
study. The reason the inflammatory markers was continuous and categorical is because
in the context of multivariate analysis, they was categorized into levels that have been
previously shown to be associated with CVD. This was discussed more thoroughly in
the study variables section.
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Table 1.
Different Variables and the Corresponding Types of Variables
Section/Data Set Title
Demographics (Demo)

Variables
Gender
Race/Ethnicity
Age Group
Poverty Income Ratio
Education Level

Variable Type
Categorical
Categorical
Categorical
Categorical
Categorical

Medical Conditions

Cardiovascular Disease
(ACS, stroke, arrhythmias,
congestive heart failure, and
coronary heart disease
(CHD))
Chronic Kidney Disease
CRS (ACS, stroke,
arrhythmias, CHD, and
CKD)
Diabetes
Hyperlipidemia
Obesity
Hypertension

Categorical

Body Measures
C-Reactive Protein (hsCRP)
Hcy

Body Mass Index (kg/m2)
C-reactive protein (mg/dL)

Continuous
Continuous and Categorical

Hcy (μmol/L)

Continuous and Categorical

Ferritin/Transferrin Ratio

Ratio controlling for other
sources of iron increase
Fibrinogen (mg/dL)

Continuous and Categorical

Medical Conditions
Medical Conditions

Medical Conditions
Medical Conditions
Medical Conditions
Medical Conditions

Fibrinogen

Categorical
Categorical

Categorical
Categorical
Categorical
Categorical

Continuous and Categorical

.
All statistical analyses were performed using SAS 9.3 and SPSS 21.0 software
(SAS, 2010). The main goal in this particular study was to answer the research question
whether inflammatory markers are risk factors of CRS, and if sociodemographic factors
modify this effect. Because the direction of the relationship is unknown, being that this
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is the first study addressing this relationship, the two-tailed t-test if the distribution is
normal, or Mann-Whitney U statistical analysis was utilized if the distribution was
nonparametric (Zhao, Rhardja, & Qu, 2008). Therefore, based on what is available in
the literature, the type of data available in the dataset, and NHANES recommendations,
the alpha was set to 0.05 (CDC, 2011; Sun, Pan, & Wang, 2011). In other words, the
probability of the association to happen by chance is 5%. Univariate analysis was
performed to assess the gender, age, and racial distribution of the selected sample.
Bivariate analyses was performed to evaluate the association between independent
variables (age, race/ethnicity, PIR, etc.) of the study participants and to evaluate the
relationship to dependent variables (CRS). More specifically body mass index (normal,
overweight, obese and severely obese), diabetes (yes, no), age (continuous), gender
(male or female), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Mexican
American, and Others), education level (less than high school, high school/GED, higher
than high school), and socioeconomic status (poor, not poor) was assessed for a
relationship with CRS. After this, multivariate analysis through logistic regression was
used to study the relationship of the different inflammatory markers with CRS. The
first two questions addressed the bidirectional impact of inflammatory markers in the
specific subtypes CRS through logistic regression, studying the interaction effect of
each inflammatory marker with the respective independent variable of interest (CKD or
CVD). The next question addressed if inflammatory markers have an independent,
additive effect on CRS. Finally, the last question addressed the differential impact of
race and socioeconomic status on inflammation and CRS. These four questions was
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addressed through multiple regression, controlling for confounding factors like obesity,
age, hypercholesterolemia, gender, diabetes status, and smoking status.
Data Collection and Analysis
The purpose of this study was to evaluate the relationship between inflammatory
markers and CRS. More specifically, the research questions that guided this study were:
Research Question 1
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) modify
the effect of CKD on CVD controlling for CVD and CKD risk factors (obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho1. The elevated inflammatory biomarkers do not modify the effect of CKD on
CVD controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status).
Ha1. The elevated inflammatory biomarkers do modify the effect of CKD on CVD
controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia, gender,
diabetes status, and smoking status).
In order to address this research question simulating Type 4 CRS, a stepwise
logistic regression model was utilized to assess the association between the dependent
variable cardiovascular disease (Y) and CKD (Xi) while controlling for selected covariates
(Xic) such as obesity, age, hypercholesterolemia, gender, diabetes status, and smoking
status. Preliminarily, the model significance levels was set at levels that are greater than
0.05. For inclusion in the model, as Menard (1997) recommends, p=0.10 was utilized and
for exclusion from the model p=0.15 was utilized in order to ensure that variables are not
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prematurely eliminated stepwise regression model. For the final test of statistical
significance, a two-tailed p-value <0.05 or 95% Cl of the odds ratio that excludes 1.0 was
considered significant. In the final model, first order interactions were assessed in order to
test for effect modification between the different inflammatory markers and CKD.
Equations 1-4, written below, reflect the regression models being studied. Using the
Hosmer and Lemeshow test, a model would pass the goodness-of-fit if p>0.05.
Additionally, multicollinearity was assessed by testing the final model in logistic regression
with >0.20 tolerance level (Tabachnick & Fidell, 2014). The equations would be as
follows:
1. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hcy + β8*CKD + β78*hcyhigh
Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hcy + β8*CKD + β78*hcyLow
2. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7* F/T + β8*CKD + β78*F/Thigh
3. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7* F/T + β8*CKD + β78*F/TLow
4. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*CKD +
β78*fibrinogenhigh
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5. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*CKD +
β78*fibrinogenLow
6. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*CKD + β78*hsCRPhigh
7. Logit (CVD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*CKD + β78*hsCRPLow
Research Question 2
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) modify
the effect of CVD on CKD controlling for CVD and CKD risk factors (obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho2. The elevated inflammatory biomarkers do not modify the effect of CVD on
CKD controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status).
Ha2. The elevated inflammatory biomarkers do modify the effect of CVD on CKD
controlling for CVD and CKD risk factors (obesity, age, hypercholesterolemia, gender,
diabetes status, and smoking status).
In a cross sectional analysis, to model the effect of CVD on CKD as is seen in Type
2 CRS, the following method was used. A backward stepwise logistic regression model
was utilized to assess the association between the dependent variable CKD (Y) and CVD
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(Xi) while controlling for selected covariates (Xic) such as obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Preliminarily, the
model significance levels was set at levels that are greater than 0.05. For inclusion in the
model, as Menard (1997) recommends, p=0.10 was utilized and for exclusion from the
model p=0.15 was utilized in order to ensure that variables are not prematurely eliminated
stepwise regression model. For the final test of statistical significance, a two-tailed p-value
<0.05 or 95% Cl of the odds ratio that excludes 1.0 was considered significant. In the final
model first order interactions was assessed in order to test for effect modification between
the different inflammatory markers and CVD. Equations 5-8, written below, reflect the
regression models being studied. Using the Hosmer and Lemeshow test a model would
pass the goodness-of-fit if p>0.05. Additionally, multicollinearity was assessed by testing
the final model in logistic regression with >0.20 tolerance level (Tabachnick & Fidell,
2014). The equations would be as follows:
8. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hcy + β8*CVD + β78*hcyhigh
9. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hcy + β8*CVD + β78*hcyLow
10. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7* F/T + β8*CVD + β78*F/Thigh
11. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7* F/T + β8*CVD + β78*F/TLow
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12. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*CVD +
β78*fibrinogenhigh
13. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*CVD +
β78*fibrinogenLow
14. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*CVD + β78*hsCRPhigh
15. Logit (CKD) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender
+ β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*CVD + β78*hsCRPLow
Research Question 3
Do elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP) have an
additive effect on CRS along with CVD risk factors (e.g. obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho3. Elevated inflammatory biomarkers do not act as additive risk factors and
increase the susceptibility of CRS along with known CVD risk factors.
Ha3. Elevated specific inflammatory biomarkers do act as additive risk factors of
CRS along with known CVD risk factors.
In order to test for the direct effect of inflammatory marker on CRS, a backward
stepwise logistic regression model was utilized to assess the association between the
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dependent variable CRS (Y) and inflammatory markers (i.e. hcy, F/T, fibrinogen, and hsCRP) (Xi) while controlling for selected covariates (Xic) such as obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Equations 9-12,
written below, reflect the regression models being studied. Preliminarily, the model
significance levels was set at levels that are greater than 0.05. For inclusion in the model,
as Menard (1997) recommends, p=0.10 was utilized and for exclusion from the model
p=0.15 was utilized in order to ensure that variables are not prematurely eliminated
stepwise regression model. For the final test of statistical significance, a two-tailed pvalue <0.05 or 95% Cl of the odds ratio that excludes 1.0 was considered significant.
Using the Hosmer and Lemeshow test a model would pass the goodness-of-fit if p>0.05.
Additionally, multicollinearity was assessed by testing the final model in logistic
regression with >0.20 tolerance level (Tabachnick & Fidell, 2014). The equations would
be as follows:

16. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy
17. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* F/T
18. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen
19. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hs-CRP
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Research Question 4
Do sociodemographic (race/ethnicity, family income, expressed relative to the
poverty threshold, or education level) indicators play a modifying role between the
relationship of inflammatory markers and CRS controlling for known CVD risk factors
(e.g. obesity, age, hypercholesterolemia, gender, diabetes status, and smoking status)?
Ho4. Sociodemographic indicators do not play a modifying role between the
relationship of inflammatory markers and CRS.
Ha4. Sociodemographic indicators do play a modifying role between the
relationship of inflammatory markers and CRS.
In a cross sectional analysis, to model the effect of demographic factors on the
relationship between inflammatory markers and CRS, the following method was used. A
backward stepwise logistic regression model was utilized to assess the association
between the dependent variable CRS (Y) and demographic factors (race/ethnicity, family
income, or education level) (Xi) while controlling for selected covariates (Xic) such as
obesity, age, hypercholesterolemia, gender, diabetes status, and smoking status.
Preliminarily, the model significance levels was set at levels that are greater than 0.05.
For inclusion in the model, as Menard (1997) recommends, p=0.10 was utilized and for
exclusion from the model p=0.15 was utilized in order to ensure that variables are not
prematurely eliminated stepwise regression model. For the final test of statistical
significance, a two-tailed p-value <0.05 or 95% Cl of the odds ratio that excludes 1.0 was
considered significant. In the final model first order interactions was assessed in order to
test for effect modification between the individual inflammatory markers and individual
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demographic factors. Equations 13-24, written below, reflect the regression models
being studied. Using the Hosmer and Lemeshow test a model would pass the goodnessof-fit if p>0.05. Additionally, multicollinearity was assessed by testing the final model in
logistic regression with >0.20 tolerance level (Tabachnick & Fidell, 2014). The
equations would be as follows:
20. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy + β8*raceNon-Hispanic White
21. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy + β8*raceNon-Hispanic Black
22. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy + β8*raceHispanic
23. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*F/T + β8*raceNon-Hispanic White
24. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*F/T + β8*raceNon-Hispanic Black
25. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*F/T + β8*raceHispanic
26. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*raceNon-Hispanic White
27. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*raceNon-Hispanic Black
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28. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*raceHispanic
29. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*raceNon-Hispanic White
30. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hs-CRP + β8*raceNon-Hispanic Black
31. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*raceHispanic
32. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy + β8*family incomeHigh
33. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hcy + β8*family incomeLow
34. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*F/T + β8*family incomeHigh
35. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*F/T + β8*family incomeLow
36. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*family incomeHigh
37. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*fibrinogen + β8*family incomeLow
38. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*family incomeHigh
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39. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7*hs-CRP + β8*family incomeLow
40. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hcy + β8*education levelsome high school
41. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hcy + β8*education levelhigh school
graduate

42. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hcy + β8*education levelsome college
43. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* F/T + β8*education levelsome high school
44. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* F/T + β8*education levelhigh school
graduate

45. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* F/T + β8*education levelsome college
46. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* fibrinogen + β8*education levelsome
high school

47. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* fibrinogen + β8*education levelhigh
school graduate
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48. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* fibrinogen + β8*education levelsome
college

49. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hs-CRP + β8*education levelsome high
school

50. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hs-CRP + β8*education levelhigh school
graduate

51. Logit (CRS) = β0 + β1*obesity + β2*age + β3*hypercholesterolemia + β4*gender +
β5*diabetes status + β6*smoking status + β7* hs-CRP + β8*education levelsome
college

Sample Weights and Other Considerations
Due to a multistage, complex, probability cluster design, there has to be special
techniques utilized to decrease the correlation amount that is found within a specific
cluster (CDC, 2011). This specific design requires for the use of differential weighting,
stratification, and clustering. Logistically, in order to achieve this, fewer individuals with
a cluster and multiple clusters are sampled. A total of 30 population sampling units
(PSUs) are sampled within a 2-year period (CDC, 2011). Consequently, one PSU
represents 5,000 individuals. Individual sample weights are placed on individual subjects
who are part of an oversampled (downweighted) or undersampled group (Park & Lee,
2004). Due to this specialized sampling technique, if simple random sampling is used,
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then the significance levels would be overstated and variance estimates would be too low
due to the lack of consideration of differential weighting (CDC, 2011).
In order to derive the weighing amounts certain calculations were made first.
Three steps of calculations are made for sample weights (CDC, 2013). First of all, the
final probability by calculating the product of the probability of an individual being
selected, the probability of the household being selected, the probability of the section of
the PSU being selected, and the probability of the PSU being selected (CDC, 2013). This
then had to be adjusted for nonresponse. The final adjustment that is made is the poststratification adjustment for the purpose of matching the control totals derived from the
year 2000 United States Census population. In order to understand the use of sample
weights, the design effect (DEFF) is calculated. The DEFF is derived by finding the ratio
of the variance of the complex sample design by the simple random sample (CDC, 2011).
Usually, in NHANES the DEFF is greater than 1, or the variance estimate of the cluster is
greater than that of a simple random sample. The DEFF varies for different variables,
and the minimum sample size for analysis should yield a relative standard error of 30%
or less (CDC, 2011). In order to take into account the complex sample design, the Taylor
Series Linearization was used. Because of ethical issues, actual PSUs cannot be used,
and Masked Variance Units (MVUs) are used. While the PSU variable is known as
sdmvpsu in the dataset, the stratum variable is known as sdmvstra (CDC, 2009).
Additionally, the individual weighting previously mentioned has the prefix “wt” (CDC,
2009).
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The NHANES study is a study which is representative of the national population.
Researchers in the Centers for Disease Control and Prevention estimated that each
participant corresponds to approximately 50,000 residents in the United States (CDC,
2013b). In order to simplify the process, the U.S. was divided into different counties,
which was further divided into local areas, which was divided into housing communities,
and then divided into households. In order to maintain randomness, each year 15
different counties are sampled randomly. Each individual household is also selected
randomly. Random sampling serves two purposes: it ensures generalizability of the
findings from research and it ensures that equal probabilities of subjects participate in the
survey.
Sampling Method
There are numerous measures the National Center for Health Statistics (NCHS)
takes in order to ensure a high rate of participation and optimal quality of results (CDC,
2013b). Through local media personnel, the NCHS informs the individuals of the local
communities about the details of the upcoming study and notifies the leadership in the
specific community. An introductory letter is sent to each participant in order to explain
the details of what the survey entails and the benefits. In order to ensure that each
participant is eligible, the interviewers from NCHS visit each individual household. The
participants are guaranteed confidentiality, informed of their rights to stop participation
when they choose, instructed about the goals and purpose of the survey, and the different
components of the NHANES survey. Along with the household interview, NCHS
workers about conduct medical examination in mobile examination centers (CDC,
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2013b). Consequently, participants are given a written consent for the household
interview and one for the medical examination. If the participant chooses to, they can
participate in one without participating in the other component.
Ethical Protection of Human Participants
Different ethical guidelines must be considered in order to perform research
studies with human subjects. Before data collection for NHANES, the NCHS received
approval from the NCHS Research Ethics Review Board (changed from the Institute
Review Board), continuance of the protocol #2011-17. The NCHS complies strictly
with the different laws and regulations which are written with the intent of protecting
the specific participant’s confidentiality and safety (McQuillan & Porter, 2011). Other
protective laws that are in place are the Public Health Service Act of 1956 (42 USC
242k) which allows for the collection of data and the Privacy Act of 1974 (5 USC
552A) (Pappas & Hyder, 2005). Finally, the Confidential Information Protection and
Statistical Efficiency Act (PL 107-347) prohibits the illegal information distribution
which could lead to subject identification without the participant’s expressed consent or
permission. The NCHS ensures that the collected data is stored securely with all
personally identifying information replaced with codes, making it impossible to retrace
the subjects back. Because there is high variability of literacy and health literacy, the
NCHS takes extra measures in order to ensure that the consent is written at a literacy
level that the majority of the population can understand.
This study used publicly available secondary data provided by the NCHS.
Before collection of data, informed consent was obtained for the home interview and
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medical examination components. During the examination component, the subjects
wear bar code bracelets so that the examiners are even blinded to the personal identifier.
After collection of data, specific personal identifiers like social security number, name,
email address, and birthdate are removed before publication of data. Because this study
cannot be traced or linked in any way back to the individual participant, the study poses
no violation of confidentiality to the subject. An approval by the Institute Review
Board from Walden University was pursued prior to any data being gathered from the
NHANES database and prior to data analysis in order to meet additional ethical
requirements. The IRB approval number is 05-27-14-0303779. Additionally, the sole
intent of this study was to fill knowledge gaps without seeking any financial benefits,
and there is no financial interest that was involved in this study.
Summary
The NHANES data, collected between the years 1999-2010, was analyzed for this
study using quantitative data analysis to evaluate the theory that elevated inflammatory
markers, which are caused by several different factors, independently increase the risk of
cardiovascular disease among in the United States, aged 20 years and older. By analyzing
the same NHANES data sets, elevated levels of inflammatory markers was studied as to
how they can independently and additively predict CRS. Chapter 4 will present the
descriptive and multivariate data analyzed from NHANES, between 1999-2010. The
hypotheses were evaluated to show how elevated inflammatory markers can
independently and additively predict CRS in a cross-sectional manner. Chapter 5 will
discuss the results presented in Chapter 4. Chapter 5 will explain how these results
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promote positive social change, including the limitations of the data analysis and the
recommendations for further study.
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Chapter 4: Results
Introduction
The primary aim of this study was to determine whether inflammatory markers
could be a potential risk factor for CRS. Additionally, by analyzing NHANES data this
study evaluated the theory that elevated inflammatory markers, which are caused by
smoking, obesity, high serum cholesterol levels, and hypertension independently increase
the risk of CVD, CKD, and CRS in the United States, in those individuals ages 20 years
and older. The distribution of each inflammatory marker is further delineated.
A representative sample of the adult U.S. population between 1999 and 2010
was examined to determine whether inflammatory markers were associated with the
susceptibility to CRS. The associations between CRS and other variables, age, gender,
poverty level, education, marital status, and diabetes were also explored during
bivariate analyses. Age was divided into seven categories representing each decade of
life: 20-29; 30-39; 40-49; 50-59; 60-69; 70-79; and ≥80. Socioeconomic factors and
variables that were determined to be statistically significant during bivariate analyses
were further tested by logistic multivariate regression analysis. Weights adjusting for
the complex NHANES design were used in all analyses to represent the U.S.
population as recommended by NHANES. This chapter provides the results of these
analyses.
A total of 32,464 participants were included in the NHANES 1999-2010.
Among those participants, 1,872 individuals did not participate in the questionnaire.
Consequently, 30,592 responded to the CVD questions, 28,278 were included in the
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analysis for CKD, and 24,625 were included in the analysis for CRS. Because this
study was interested in the adult population and inflammatory markers vary between
children and adults, only participants between 20 and 85 years of age were included in
the analyses. In addition, this study only included participants who had complete
records for all tested variables. The final sample size used for analyses was 3,512 for
self-reported CVD, 3,028 for CKD, and 1,548 for CRS.
Cardiovascular Disease
Demographic Characteristics
Table 2 provides data on the distribution of demographic characteristics of
the participants by status of CRS using bivariate analysis. The prevalence of CVD in
the US population in the age group between 20-85 years was 8.7% (n = 3,512) which
is representative of 17,967,979 individuals of the United States population. The
average age of participants with CVD was 64.9 ± 0.39. There was statistically
significant (p<0.001) association between gender, age, race/ethnicity, and CVD.
There were with slightly more males (52.6%) with CVD as seen in Figure 4, more
Non-Hispanic Whites (77.6%), and the highest percentage over 80 years of age as
seen in Figure 5.
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Table 2
Risk of CVD by Demographic Characteristics
% of Sample

CVD
3512 (8.7)

Total population n
(%)
Age Mean (SE)*
64.9 (0.39)
Age groups
20-39 (%)
4.7
1.1
40-59 (%)
28.6
6.5
60-69 (%)
23.8
18.6
70-79 (%)
24.2
27.4
≥80 (%)
18.7
38.3
Gender (%)*
Male
52.6
9.5
Female
47.4
7.9
Race/Ethnicity (%)*
NH White
77.6
9.6
NH Black
11.4
8.9
Hispanic
6.6
4.5
Other
4.3
6.9
Note. *Tests for difference were statistically significant

p values
0.0000

0.000
0.0000
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Figure 4. Gender distribution of CVD.

Figure 5. Percentage of individuals in each age group with CVD (N=3512).
CVD and Covariates
In addition to the basic demographic descriptive statistics, the following variables
that may confound the effect and modifying effect of inflammatory biomarkers on
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CVD are presented in Table 3. Based on bivariate analyses, individuals with less than a
high school education had the highest percentage rates (13.3%) of CVD. Individuals in
lower socioeconomic status had CVD (10.7%) than those individuals in higher economic
status (8.3%). Finally, more individuals with diabetes (26.1% vs 6.7%) and obesity
(11.4% severely obese vs. 5.9% normal weight) were likely to have CVD than those
without diabetes and obesity. When the Framingham Risk Score was calculated, the
group with CVD had a significantly higher mean risk score than those without CVD
(14.7 vs 12.8, p < 0.001).
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Table 3
Risk of CVD Across Covariates
Variable
Education (%)*
Less than HS
HS
Higher than HS
PIR (%)*
Poor
Not poor
Diabetes (%)*
Yes
No
BMI Mean (SE)
BMI Groups*
Normal (<25)
Overwt. (2529.9) (30-39.9)
Obese
ObeseS.(30)
Obese (>40)
High Cholesterol
(%) Yes
No
Smoking Status (%)
=
Current Smoker
Former Smoker
Nonsmoker
Hypertension (%)
Yes
No
Framingham Risk
Score Mean (SE)*

% of sample

CVD

30.3
28.9
40.8

13.3
10.1
6.5

16.8
83.2

10.7
8.3

27.9
72.1

26.1
6.7
29.8 (.14)

p values
0.0000

0.0000
0.0000

23.0
34.7
34.9
7.4

5.9
8.7
10.7
11.4

64.3
35.7

17.9
6.9

20.0
41.2
38.8

7.4
14.5
6.5

62.5
37.5

23.3
4.3
14.8 (.14)

0.001
0.0000

0.001

0.0000

Note. * Tests for difference among the groups were statistically significant
(p≤0.001).

<.001

90
Chronic Kidney Disease
Demographic Characteristics
Table 4 provides data on the distribution of demographic characteristics of
the participants by status of CKD using bivariate analysis. The prevalence of CKD
in US population in the age group between 20-85 was 7.1% (n = 3,028) which is
representative of 13,797,140 individuals of the United States population. The average
age of participants with CKD was 74.4 ± 0.28. There was statistically significant
(p<0.001) association between gender, age, race/ethnicity, and CKD. There were
with significantly more females (68.0%) with CKD than males as seen in Figure 6.
According to Figure 7, most (73.6%) of the individuals who were age 80 and above
had CKD. Among Non-Hispanic Whites, the percentage (8.1%) with CKD was the
highest.
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Table 4
Risk of CKD by Demographic Characteristics
% of Sample
Total population n
(%)
Age Mean (SE)*
Age groups
20-39 (%)
40-59 (%)
60-69 (%)
70-79 (%)
≥80 (%)
Gender (%)
Male
Female
Race/Ethnicity (%)*
NH White
NH Black
Hispanic
Other

CKD
3028 (7.1)

p values

74.4 (0.28)

0.0000

0.9
8.1
13.
6
36.
4
41.
0
32.
0
68.
0
80.
57
9.3
5.2
5.0

* Tests for difference were statistically significant

0.2
1.5
8.6
34.
0
73.
4
4.7
9.4

0.0000
0.0000

8.1
6.3
2.9
6.6
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Figure 6. Gender distribution of CKD.

Figure 7. Percentage of individuals in each age group with CKD (N=3028)
CKD and Covariates
In addition to the basic demographic descriptive statistics, the following variables
that may confound the effect and modifying effect of inflammatory biomarkers on
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CKD are presented in Table 5. Based on bivariate analyses, individuals with less than a
high school education had the highest percentage rates (10.4%) of CKD. Individuals in
lower socioeconomic status had CKD (9.6%) than those individuals in higher economic
status (5.7%). Finally, more individuals with diabetes (14.7% vs 6.3%) and
hypertension (23.3% vs. 4.3%) were likely to have CKD than those without diabetes
and hypertension.
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Table 5
Risk of CKD Across Covariates
Variable

Education (%)*
Less than HS
HS
Higher than HS
PIR (%)*
Poor
Not poor
Diabetes (%)*
Yes
No
BMI Mean (SE)
BMI Groups*
Normal (<25)
Overwt. (2529.9)
Obese (30-39.9)
ObeseS.(30)
Obese (>40)
High Cholesterol (%)
Yes
No
Smoking Status (%)
=
Current Smoker
Former Smoker
Nonsmoker
Hypertension (%)
Yes
No

% of sample

CKD

p values

0.0000
28.
3
27.
5
44.
1
46.
0
54.
0
18.
52
81.
5

10.
4
7.9
5.7

14.
7
6.3
25.2 (.12)

52.
30
33.
27
13.
4
1.1

11.
2
6.9
3.4
1.4

0.0000
9.6
5.7
0.0000

0.0000
0.0000

0.0000
64.
12.
3
0
35.
6.5
7
0.000
11.
3.5
5
36.
10.
3
4
52.
7.2
1
62.
23.
0.0000
5
3
37.
4.3
5
* Tests for difference among the groups were statistically significant (p≤0.001).
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Cardiorenal Syndrome
Demographic Characteristics
Table 5 provides data on the distribution of demographic characteristics of
the participants by status of CRS using bivariate analysis. The prevalence of CRS in
US population in the age group between 20-85 was 3.9% (n=1,548) which is
representative of 6,770,775 of the United States population. The average age of
participants with CRS was 72.8 ± 0.41. There was no statistically significant
difference association between gender and CRS, with slightly more females
(according to Figure 8) with CRS and more Caucasians (78.7%). According to
Figure 9, most (63.8%) of the individuals who were age 80 and above had CRS.
Age and race/ethnicity tested statistically significant (p<0.05).
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Table 6
Risk of CRS by Demographic Characteristics
% of Sample
Total population n
(%)
Age Mean (SE)*
Age groups
20-39 (%)
40-59 (%)
60-69 (%)
70-79 (%)
≥80 (%)
Gender (%)
Male
Female
Race/Ethnicity (%)*
NH White
NH Black
Hispanic
American
Other

CRS
1548 (3.9)

p values

72.8 (0.41)

0.0000

0.7
11.
6
18.
4
32.
2
37.
1
48.
1
51.
96
78.
7
11.
7
5.8

0.1
1.1
7.0
23.
0
63.
8
3.8
4.0

3.8

2.8

* Tests for difference were statistically significant

0.652
0.0000

4.4
4.3
1.7
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Figure 8. Gender distribution of CRS.

Figure 9. Percentage of individuals in each age group with CRS (N=1548)
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CRS and Covariates
In addition to the basic demographic descriptive statistics, the following variables
that may confound the effect and modifying effect of inflammatory biomarkers on CRS
are presented in Table 7. Based on bivariate analyses, individuals with less than a high
school education had the highest percentage rates (7.0%) of CRS. Individuals in lower
socioeconomic status had CRS (4.3%) than those individuals in higher economic status
(3.7%). Finally, more individuals with diabetes (24.2% vs 6.6%) and hypertension
(27.1% vs. 4.7%) were likely to have CRS than those without diabetes and
hypertension.
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Table 7
Risk of CRS Across Covariates
Variable

Education (%)*
Less than HS
HS
Higher than HS
PIR (%)
Poor
Not poor
Diabetes (%)*
Yes
No
BMI Mean (SE)
BMI Groups*
Normal (<25)
Overwt. (2529.9)
Obese (30-39.9)
ObeseS.(30)
Obese (>40)
High Cholesterol (%)
Yes
No
Smoking Status (%)
=
Current Smoker
Former Smoker
Nonsmoker
Hypertension (%)
Yes
No

% of sample

CRS

33.
5
26.
7
39.
8
14.
7
85.
3
59.
0
41.
0

7.0
4.2
2.7

p values

0.0000

34.
5
38.
4
23.
5
3.6

0.08
4.3
3.7
0.0000
24.
2
6.6
28.4 (.19)
12.
9
9.3
7.5
11.
1
16.
2
11.
5
8.0
16.
4
8.6

0.0000
< 0.05

60.
3
39.
7
0.001
18.
3
36.
7
45.
0
66.
27.
0.0000
7
1
33.
4.7
3
* Tests for difference among the groups were statistically significant (p≤0.001).
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Figure 10. Percentage of individuals in each ethnicity with CVD, CKD, or CRS

Figure 11. Prevalence of cardiorenal syndrome between 1999-2010
The percentage distribution of CVD, CKD, and CRS is shown in Figure 10. This
demonstrates that the percentage of CRS in Non-Hispanic Whites and Non-Hispanic
Blacks is almost equal. Additionally, the prevalence of CRS in each biannual period
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was tracked in the NHANES years 1999-2010 in Figure 11. Cardiovascular health
among non-institutionalized individuals aged 20 years and older for NHANES years
1999-2010 is shown in Table 8. Cardiovascular health for this evaluation includes
congestive heart failure, coronary heart disease, angina, stroke and heart attack. All
reports were based on whether or not the study participant was informed by a physician if
she has had one or more of these conditions. Out of all individuals, 8.7% of the study
population reported being told by a physician that they have had either congestive heart
failure (2.3%), coronary heart disease (3.4%), angina (2.6%), stroke (2.7%), and heart
attack (3.4%). The remaining approximately 91.3% of the study population either have
not been told by a physician that she had either one or more of these heart conditions or
data was missing from these individuals.
Table 8
Cardiovascular Health of Individuals Aged 20 Years and Older, NHANES, 1999-2010

Congestive Heart Failure
Coronary Heart Disease
Angina
Stroke
Heart Attack

N

%

1003
1307
984
1154
1387

2.3
3.4
2.6
2.7
3.4

Inflammatory Biomarkers
Table 9 demonstrates the mean and standard error of the original continuous
variables and the years the measurements were made. As demonstrated in the table the
mean hs-CRP was 0.42 mg/dl. Because there were not as many subjects with a
fibrinogen measurement, the standard error was higher among these subjects.
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Table 9
Mean and Standard Error of each inflammatory marker.
Inflammatory
Biomarkers
hs-CRP
Homocysteine
Fibrinogen
F/T Ratio

N

Mean ± SE

Years Collected

28,924
9,453
3,010
5,943

0.42 ± 0.006
8.76 ± 0.086
372.97 ± 4.768
20.51 ± 0.364

1999-2010
2001-2006
2001-2002
1999-2010 (females
age 20-49)

More univariate analyses were performed to examine if there was a relationship
between inflammatory biomarkers and CVD. First of all, the relationship between
inflammatory biomarkers and CVD was examined individually by stratifying the study
sample into “elevated” and “normal” and comparing the two groups as seen in Table 10.
Elevated hs-CRP was significantly associated (12.5% vs 5.4%, p<.001) with higher rates
of CVD. Additionally, elevated homocysteine was significantly associated (14.3% vs
4.2%, p<.001) with CVD. Next, elevated fibrinogen was significantly associated (16.9%
vs 9.1%, p<.001) with higher rates of CVD. Finally elevated ferritin/transferrin ratio was
not significantly associated (2.6% vs.2.2%, p=0.38) with higher rates of CVD.
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Table 10
Elevated Serum Biomarkers and CVD in individuals Age 20 years and older NHANES,
1999-2010
Inflammatory
Biomarkers
hs-CRP
Elevated (>0.51 mg/dl)
Normal (<0.09 mg/dl)
Homocysteine
Elevated (≥8.15
µmol/L)
Normal (<8.15 µmol/L)
Fibrinogen
Elevated (≥ 378 mg/dL)
Normal (< 378 mg/dL)
F/T Ratio
Elevated ( 11.67)
Normal (<11.67)

N

% (SE%)

1054
535

12.5 (0.5)
5.4 (0.3)

892

14.3 (0.9)

239

4.2 (0.3)

303
179

16.9 (1.2)
9.1 (1.2)

82
54

2.6 (0.4)
2.2 (0.4)

p-value
<0.001
--<0.001
--<0.001
--0.38
---

Univariate analysis was performed to examine if there was a relationship between
inflammatory biomarkers and CKD. First of all, in the relationship between
inflammatory biomarkers and CKD was examined individually by stratifying the study
sample into “elevated” and “normal” and comparing the two groups as seen in Table 11.
Elevated hs-CRP was significantly associated (7.6% vs 6.2%, p=0.001) with higher rates
of CKD. Additionally, elevated homocysteine was significantly associated (14.2% vs
2.0%, p<.001) with CKD. Next, elevated fibrinogen was significantly associated (17.8%
vs 7.6%, p<.001) with higher rates of CKD. Finally elevated ferritin/transferrin ratio was
not significantly associated (0.6% vs.0.3%, p=0.15) with higher rates of CKD.
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Table 11
Elevated Serum Biomarkers and CKD in individuals Age 20 years and older NHANES,
1999-2010
Inflammatory
Biomarkers
hs-CRP
Elevated (>0.51 mg/dl)
Normal (<0.09 mg/dl)
Homocysteine
Elevated (≥8.15
µmol/L)
Normal (<8.15 µmol/L)
Fibrinogen
Elevated (≥ 378 mg/dL)
Normal (< 378 mg/dL)
F/T Ratio
Elevated ( 11.67)
Normal (<11.67)

N

% (SE%)

721
654

7.6 (0.3)
6.2 (0.3)

996

14.2 (0.7)
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2.0 (0.3)

355
179

17.8 (1.0)
7.6 (0.6)

18
9

0.6 (0.1)
0.3 (0.1)

p-value
0.001
--<0.001
--<0.001
--0.15
---

Univariate analyses were performed to examine if there was a relationship
between inflammatory biomarkers and CRS. First of all, the relationship between
inflammatory biomarkers and CRS was examined individually by stratifying the study
sample into “elevated” and “normal” and comparing the two groups as seen in Table 12.
Elevated hs-CRP was significantly associated (5.6% vs 2.3%, p<.001) with higher rates
of CRS. Additionally, elevated homocysteine was significantly associated (8.2% vs
1.0%, p<.001) with CRS. Next, elevated fibrinogen was significantly associated (10.8%
vs 3.2%, p<.001) with higher rates of CRS. Finally elevated ferritin/transferrin ratio was
not significantly associated (0.2% vs. 0.2%, p=0.65) with higher rates of CRS.
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Table 12
Elevated Serum Biomarkers and CRS in individuals Age 20 years and older NHANES,
1999-2010
Inflammatory
Biomarkers
hs-CRP
Elevated (>0.51 mg/dl)
Normal (<0.09 mg/dl)
Homocysteine
Elevated (≥8.15
µmol/L)
Normal (<8.15
µmol/L)
Fibrinogen
Elevated (≥ 378
mg/dL)
Normal (< 378 mg/dL)
F/T Ratio
Elevated ( 11.67)
Normal (<11.67)

N

% (SE%)

p-value

462
251

5.6 (0.3)
2.3 (0.2)

494

8.2 (0.6)

<0.001
--<0.001
--

56

1.0 (0.2)

--

166

10.8 (0.9)

<0.001
--

71

3.2 (0.6)

8
7

0.2 (0.1)
0.2 (0.1)

-0.65
---

Hypothesis 1
Hypothesis 1 predicted that elevated inflammatory biomarkers modify the effect
of CKD on CVD after controlling for known CVD risk factors like obesity,
hypercholesterolemia, diabetes status, and smoking status. The demographic variables of
age and gender were also controlled for so that confounding factors would not influence
the study results. Initially, a multiple regression analysis was performed to determine if
elevated serum CKD stages predict cardiovascular health in individuals 20 years and
older within the U.S. population after controlling for obesity, hypercholesterolemia,
diabetes status, smoking status, as well as for demographic variables including age and
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gender. Then, separate multiple regression analyses were run for normal versus elevated
hs-CRP levels in order to look for effect modification as demonstrated in Table 13 and
Figure 12. This process was repeated for homocysteine, fibrinogen, and F/T ratio.
Table 13
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
Total OR (95% CI)
(N=14,602)

CRP- OR (95% CI)
(N=3,338)

CRP+ OR (95%
CI) (N=3,732)

Model 1 (CKD)

1.28 (1.10, 1.50)*

1.08 (0.80, 1.46)**

1.51 (1.15, 2.00)

Model 2 (CKD, obesity)

1.66 (1.41, 1.96)**

1.32 (0.97, 1.79)

Model 3 (CKD, obesity,
diabetes status)

1.67 (1.41, 1.99)**

1.34 (0.96, 1.87)

1.76 (1.30,
2.38)**
1.67
(1.23,2.28)**

Model 4 (CKD, obesity,
diabetes status, smoking
status)

1.73 (1.46, 2.07)**

1.67 (0.98, 1.93)

1.78 (1.31,
2.43)**

Model 5 (CKD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

1.82 (1.48, 2.24)**

1.49 (1.00, 2.21)

1.92 (1.37,
2.68)**

Model 6 (CKD,
Framingham Risk Score)

1.75 (1.39, 2.20)**

1.42 (0.88, 2.28)

2.40 (1.59,
3.62)**

Note. *p < .05 **p < .001
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Figure 12. Crude and Adjusted Odds of CVD in individuals with CKD modified by hsCRP level.
The overall regression model was tested at hs-CRP levels. A significant
regression was found (F(10,67) = 180.855, p < .001), with the model explaining 27%
(Nagelkerke R2) of the variance and correctly classifying 89% of the cases for all variables
in the model. Individuals with stage 3 CKD and higher were 1.82 times more likely to
exhibit CVD than those without CKD. Chronic Kidney Disease, β = 0.60, t (76) = 5.82,
p < .001, was seen to be a significant coefficient in the regression model. A significant
regression was found for obesity, hypercholesterolemia, diabetes status, smoking status,
as well as for demographic variables including age and gender.
The overall regression model was tested at hs-CRP levels less than 0.09 (first
quartile), representing baseline or low levels of hs-CRP. A significant regression was
found (F(10,66) = 42.750, p < .001), with the model explaining 31% (Nagelkerke R2) of
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the variance and correctly classifying 93% of the cases for all variables in the model
except CKD. Individuals with stage 3 CKD and higher were 1.49 times more likely to
exhibit CVD than those without CKD. Chronic Kidney Disease, β = 0.40, t (75) = 2.02,
p = .05, was seen to be a statistically non-significant coefficient in the regression model.
A significant regression was found for obesity, hypercholesterolemia, diabetes status,
smoking status, as well as for demographic variables including age and gender.
The overall regression model was tested at hs-CRP levels greater than 0.51 (third
quartile), representing elevated levels of hs-CRP. A significant regression was found
(F(10,67) = 30.506, p < .001), with the model explaining 26% (Nagelkerke R2) of the
variance and correctly classifying 85% of the cases for all variables in the model.
Individuals with stage 3 CKD and higher were 1.92 times more likely to exhibit CVD
than those without CKD. Chronic Kidney Disease, β = 0.65, t (76) = 3.88, p < .001, was
seen to be a significant coefficient in the regression model. A significant regression was
found for obesity, diabetes status, smoking status, serum cholesterol level, as well as for
demographic variables including age and gender.
Comparison of the aforementioned models demonstrates that hs-CRP plays an
effect modifying role on how CKD affects CVD as hypothesized. While in the elevated
hs-CRP group the odds ratio was (1.92) much higher than 1 and statistically significant,
the regular hs-CRP group had a non-significant low odds ratio at 1.49 as demonstrated in
Table 13 and Figure 12. The stark contrast in the odds ratio demonstrated the effect
modifying role of hs-CRP. Additionally, different cofactors were significant in each hsCRP level.
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Table 14
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
Total OR (95% CI)
(N=3409)

Hcy- OR (95% CI)
(N=1653)

Hcy+ OR
(95%CI)
(N=1756)

Model 1 (CKD)

1.19 (0.87, 1.62)

0.37 (0.19, 0.72)*

1.35 (0.96, 1.91)

Model 2 (CKD, obesity)

1.59 (1.16, 2.17)*

0.54 (0.28, 1.06)

1.76 (1.25, 2.49)*

Model 3 (CKD, obesity,
diabetes status)

1.70 (1.18, 2.43)*

0.64 (0.29, 1.43)

1.71 (1.11, 2.62)*

Model 4 (CKD, obesity,
diabetes status, smoking
status)

1.80 (1.24, 2.61)*

0.64 (0.27, 1.49)

1.88 (1.21, 2.90)*

Model 5 (CKD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

2.00 (1.32, 3.00)*

0.66 (0.27, 1.61)

2.21 (1.43-3.42)*

Model 6 (CKD, obesity,
diabetes status, smoking
status,
hypercholesterolemia,
hypertension)

1.98 (1.32, 2.97)*

0.65 (0.28, 1.53)

2.29 (1.44, 3.64)*

Note. *p < .05 **p < .001
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Figure 13. Crude and Adjusted Odds of CVD in individuals with CKD modified by hcy
level.

The overall regression model was tested at all hcy levels as demonstrated in Table
14 and Figure 13. A significant regression was found (F(10,21) = 47.637, p < .001),
with the model explaining 28% (Nagelkerke R2) of the variance and correctly classifying
90% of the cases for all variables in the model. Individuals with stage 3 CKD and
higher were 2.00 times more likely to exhibit CVD than those without CKD. Chronic
Kidney Disease, β = 0.69, t (30) = 3.44, p =.002, was seen to be a significant coefficient
in the regression model. A significant regression was found for obesity,
hypercholesterolemia, diabetes status, smoking status, as well as for demographic
variables including age and gender.
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The regression model was tested at hcy levels less than 8.15µmol/L (50 th
percentile), representing baseline or low levels of hcy. A significant regression was
found (F(10,20) = 11.620, p < .001), with the model explaining 20% (Nagelkerke R2) of
the variance and correctly classifying 95% of the cases for all variables in the model
except CKD. Individuals with stage 3 CKD and higher were 0.66 times more likely to
exhibit CVD than those without CKD. Chronic Kidney Disease, β = 0.42, t (29) =
0.96, p = .34, was seen to be a statistically non-significant coefficient in the regression
model. A significant regression was found for obesity, hypercholesterolemia, and
diabetes status as well as for the demographic variable including age. Gender and
smoking status were non-significant factors in the model.
The regression model was tested at hcy levels ≥ 8.15 µmol/L (50th percentile),
representing elevated levels of hcy. A significant regression was found (F(10,21) =
28.359, p < .001), with the model explaining 28% (Nagelkerke R2) of the variance and
correctly classifying 85% of the cases for all variables in the model. Individuals with
stage 3 CKD and higher were 2.21times more likely to exhibit CVD than those without
CKD. Chronic Kidney Disease, β = 0.80, t (30) = 3.73, p = .001, was seen to be a
significant coefficient in the regression model. A significant regression was found for
obesity, diabetes status, serum cholesterol level, smoking status as well as for
demographic variables including age and gender.
Comparison of the aforementioned models demonstrates that homocysteine plays
an effect modifying role on how CKD affects CVD as hypothesized and demonstrated in
Table 14 and Figure 13. While in the elevated hcy group the odds ratio was (2.21) much
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higher than 1 and statistically significant, the regular hcy group had a non-significant low
odds ratio at 0.66. The stark contrast in the odds ratio demonstrated the effect modifying
role of hcy. Additionally, different cofactors were significant in each hcy level.
Table 15
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
(N=2827) OR
(95% CI)

Fibrinogen- OR
(95% CI)
(N=1424)

Fibrinogen+
(95% CI)
(N=1403)

Model 1 (CKD)

1.53 (1.05-2.24)*

1.39 (0.79, 2.44)

1.64 (1.09-2.48)*

Model 2 (CKD, obesity)

2.24 (1.48-3.40)*

1.98 (1.21, 3.25)*

2.17 (1.47, 4.26)*

Model 3 (CKD, obesity,
diabetes status)

2.21 (1.46-3.33)*

1.98 (1.22, 3.23)*

2.42 (1.41, 4.14)*

Model 4 (CKD, obesity,
diabetes status, smoking
status)

2.33 (1.46-3.71)*

2.11 (1.27-3.51)*

2.56 (1.45, 4.54)*

Model 5 (CKD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

2.55 (1.40-4.66)*

2.06 (0.60-7.01)

3.16 (1.45-6.85)*

Model 6 (CKD, obesity,
diabetes status, smoking
status,
hypercholesterolemia,
hypertension)

2.43 (1.29-4.57)*

1.95 (0.56-6.81)

3.00 (1.34-6.69)*

Note. *p < .05 **p < .001
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Figure 14. Crude and Adjusted Odds of CVD in individuals with CKD modified by
fibrinogen level
The regression models were tested at all fibrinogen levels, normal fibrinogen
levels, and elevated fibrinogen levels respectively to assess for effect modification. At all
fibrinogen levels, a significant regression was found (F(10,6) = 52.088, p < .001), with
the model explaining 23% (Nagelkerke R2) of the variance and correctly classifying 78%
of the cases for all variables in the model as demonstrated in Table 15 and Figure 14.
Individuals with stage 3 CKD and higher were 2.55 times more likely to exhibit CVD
than those without CKD. Chronic Kidney Disease, β = 0.94, t (15) = 3.32, p = .002, was
seen to be a significant coefficient in the regression model. A significant regression was
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found for obesity, hypercholesterolemia, diabetes status, smoking status, as well as for
demographic variables including age and gender.
The regression model was tested at fibrinogen levels less than 378 mg/dL (50th
percentile), representing baseline or low levels of fibrinogen. A significant regression
was found (F(10,6) = 11.287, p = .004), with the model explaining 26% (Nagelkerke R2)
of the variance and correctly classifying 82% of the cases for all variables in the model
except CKD. Individuals with stage 3 CKD and higher were 0.49 times more likely to
exhibit CVD than those without CKD. CKD, β = 0.72, t (15) = 1.25, p = 0.23, was seen
to be a statistically non-significant coefficient in the regression model. A significant
regression was found for obesity, hypercholesterolemia, diabetes status, smoking status,
as well as for demographic variables including age. Gender, diabetes, and obesity were
not significant coefficients in the regression model.
The regression model was tested at fibrinogen levels ≥ 378 mg/dL (50th
percentile), representing elevated levels of fibrinogen. A significant regression was
found (F(10,6) = 7.290, p = .012), with the model explaining 24% (Nagelkerke R2) of the
variance and correctly classifying 76% of the cases for all variables in the model.
Individuals with stage 3 CKD and higher were 3.16 times more likely to exhibit CVD
than those without CKD. Chronic Kidney Disease, β = 1.15, t (15) = 3.16, p = .006, was
seen to be a significant coefficient in the regression model. A significant regression was
found for serum cholesterol level, as well as for demographic variables including age and
gender. Diabetes status and obesity were not significant coefficients in the regression
model.
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Comparison of the aforementioned models demonstrates that fibrinogen plays an
effect modifying role on how CKD affects CVD as hypothesized and demonstrated in
Table 15 and Figure 14. While in the elevated fibrinogen group the odds ratio was (3.16)
much higher than 1 and statistically significant, the regular fibrinogen group had a nonsignificant low odds ratio at 1.95. The stark contrast in the odds ratio demonstrated the
effect modifying role of fibrinogen. Additionally, different cofactors were significant in
each fibrinogen level.
When the F/T ratio was tested for effect modification, the analysis was
unsuccessful due to inadequate number of subjects. At the elevated level of F/T Ratio >
11.67, there were no subjects at every level of CKD. Therefore, comparison of odds ratio
with the normal F/T ratio was impossible. Consequently the answer to this hypothesis
was not determined by the data.
Hypothesis 2
Hypothesis 2 predicted that elevated inflammatory biomarkers modify the effect
of CVD on CKD after controlling for known CKD risk factors like obesity,
hypercholesterolemia, diabetes status, smoking status, and hypertension. The
demographic variables of age and gender were also controlled for so that confounding
factors would not influence the study results. Initially, a multiple regression analysis was
performed to determine if elevated serum CKD stages predict cardiovascular health in
individuals 20 years and older within the U.S. population after controlling for obesity,
hypercholesterolemia, diabetes status, smoking status, as well as for demographic
variables including age and gender. Then, separate multiple regression analyses were run
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for normal levels versus the elevated levels of hs-CRP in order to look for effect
modification as demonstrated in Table 16 and Figure 15.
Table 16
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
Total OR (95%
CI) (N=23,320)

CRP- OR (95%
CI)
(N=6992)

CRP+ OR (95%
CI) (N=6838)

Model 1 (CVD)

1.64 (1.40, 1.93)*

1.39 (1.05, 1.85)*

Model 2 (CVD, obesity)

2.09 (1.75-2.49)**

1.67 (1.21, 2.30)*

Model 3 (CVD, obesity,
diabetes status)

1.95 (1.62-2.35)**

1.57 (1.09, 2.27)*

1.94 (1.472.58)**
2.17 (1.60,
2.95)**
1.94
(1.41,2.66)**

Model 4 (CVD, obesity,
diabetes status, smoking
status)

1.95 (1.61-2.35)**

1.60 (1.10-2.34)*

1.95 (1.42,
2.67)**

Model 5 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

1.96 (1.55-2.47)**

1.66 (1.08-2.54)*

2.07 (1.602.68)**

Model 6 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia,
hypertension)

1.77 (1.41, 2.23)**

1.58 (1.04-2.41)*

1.81 (1.272.57)**

Note. *p < .05 **p < .001
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Figure 15. Crude and Adjusted Odds of CKD in individuals with CVD modified by hsCRP level
The overall regression model was tested at hs-CRP levels. A significant
regression was found (F(10,67) = 161.730, p < .001), with the model explaining 57%
(Nagelkerke R2) of the variance and correctly classifying 94% of the cases for all
variables in the model. Individuals with CVD were 1.96 times more likely to exhibit
CKD than those without CVD. CVD, β = 0.67, t (76) = 5.79, p < .001, was seen to be a
significant coefficient in the regression model. A significant regression was found for
obesity and diabetes status and for demographic variables including age and gender.
Hypercholesterolemia and smoking status were found to non-significant factors in the
logistic regression model.

118
The regression model was tested at hs-CRP levels less than 0.09 mg/dl (first
quartile), representing baseline or low levels of hs-CRP. A significant regression was
found (F(10,66) = 38.816, p < .001), with the model explaining 58% (Nagelkerke R2) of
the variance and correctly classifying 94% of the cases for all variables in the model.
Individuals with CVD were 1.66 times more likely to exhibit CKD than those without
CVD. CVD, β = 0.50, t (75) = 2.34, p = .02, was seen to be a statistically significant
coefficient in the regression model. A significant regression was found for obesity and
diabetes status and for demographic variables including age and gender.
Hypercholesterolemia and smoking status were found to non-significant factors in the
logistic regression model.
The regression model was tested at hs-CRP levels greater than 0.51 mg/dl
(greater than third quartile), representing elevated levels of hs-CRP. A significant
regression was found (F(10,67) = 147.024, p < .001), with the model explaining 57%
(Nagelkerke R2) of the variance and correctly classifying 94% of the cases for all
variables in the model. Individuals with CVD were 2.07times more likely to exhibit
CKD than those without CVD. CVD, β = 0.72, t (76) = 5.64, p < .001, was seen to be a
significant coefficient in the regression model. A significant regression was found for
obesity and diabetes status and for demographic variables including age and gender.
Hypercholesterolemia and smoking status were found to non-significant factors in the
logistic regression model.
Comparison of the aforementioned models demonstrates that hs-CRP plays an
effect modifying role on how CVD affects CKD as hypothesized as demonstrated in
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Table 16 and Figure 15. While in the elevated hs-CRP group the odds ratio was (2.07)
much higher than 1 and statistically significant, the regular hs-CRP group had a
significant low odds ratio at 1.66. The stark contrast in the odds ratio demonstrated the
effect modifying role of hs-CRP. Additionally, different cofactors were significant in
each hs-CRP level.
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Table 17
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
Total OR (95%
CI) (N=9167)

Hcy- OR (95% CI)
(N=4609)

Hcy+ OR
(N=4558)

Model 1 (CVD)

1.59 (1.13, 2.23)*

0.47 (0.24, 0.91)*

1.76 (1.26, 2.47)*

Model 2 (CVD, obesity)

2.17 (1.51, 3.10)*

0.54 (0.28, 1.06)

1.76 (1.25, 2.49)*

Model 3 (CVD, obesity,
diabetes status)

2.02 (1.22, 3.35)*

0.64 (0.29, 1.43)

1.71 (1.11, 2.62)*

Model 4 (CVD, obesity,
diabetes status, smoking
status)

2.04 (1.22, 3.39)*

0.64 (0.27, 1.49)

1.88 (1.21, 2.90)*

Model 5 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

2.14 (1.26, 3.66)*

0.56 (0.28, 1.16)

2.46 (1.39, 4.34)*

Model 6 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia,
hypertension)

2.03 (1.19, 3.48)*

0.39 (0.11, 1.33)

2.29 (1.44, 3.64)*

Note. *p < .05 **p < .001
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Figure 16. Crude and Adjusted Odds of CKD in individuals with CVD modified by
hcy level
The regression models were tested at all homocysteine levels, normal
homocysteine levels, and elevated homocysteine levels respectively to assess for effect
modification as demonstrated in Table 17 and Figure 16. At all hcy levels, a significant
regression was found (F(10,21) = 63.036, p < .001), with the model explaining 63%
(Nagelkerke R2) of the variance and correctly classifying 94% of the cases for all variables
in the model. Individuals with CVD and higher were 2.14 times more likely to exhibit
CKD than those without CVD. CVD, β = 0.76, t (30) = 2.91, p < .05, was seen to be a
significant coefficient in the regression model. A significant regression was found for the
obesity variable as well as for demographic variables including age and gender.
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Hypercholesterolemia, diabetes status, and smoking status were found to be nonsignificant variables.
The regression model was tested at hcy levels less than 8.15 µmol/L (50 th
percentile), representing baseline or low levels of hcy. A significant regression was
found (F(8,22) = 35.982, p < .001), with the model explaining 56% (Nagelkerke R2) of the
variance and correctly classifying 97% of the cases for all variables in the model.
Individuals with CVD were 0.56 times more likely to exhibit CKD than those without
CVD. CVD, β = 0.57, t (29) = 1.63, p = 0.11, was seen to be a statistically nonsignificant coefficient in the regression model. A significant regression was found for
obesity and diabetes status and for demographic variables including age and gender.
Hypercholesterolemia and smoking status were found to non-significant factors in the
logistic regression model.
The regression model was tested at hcy levels ≥ 8.15 µmol/L (50th percentile),
representing elevated levels of hcy. A significant regression was found (F(10,21) =
42.855, p < .001), with the model explaining 64% (Nagelkerke R2) of the variance and
correctly classifying 91% of the cases for all variables in the model. Individuals with
CVD and higher were 2.46 times more likely to exhibit CKD than those without CVD.
CVD, β = 0.90, t (30) = 3.23, p = .003, was seen to be a significant coefficient in the
regression model. A significant regression was found for obesity and smoking status and
for demographic variables including age and gender. Hypercholesterolemia and diabetes
status were found to non-significant factors in the logistic regression model.
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Comparison of the aforementioned models demonstrates that homocysteine plays
an effect modifying role on how CVD affects CKD as hypothesized and as demonstrated
in Table 17 and Figure 16. While in the elevated hcy group the odds ratio was (2.46)
much higher than 1 and statistically significant, the regular hcy group had a nonsignificant low odds ratio at 0.56. The stark contrast in the odds ratio demonstrated the
effect modifying role of hcy. Additionally, different cofactors were significant in each
hcy level.
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Table 18
Age- and Sex-Adjusted CKD ORs for CVD in Multivariate Regression Modeling
controlling for different demographic and CVD risk factors.
Total OR (95%
CI) (N=2827)

Fibrinogen- OR
(95% CI)
(N=1424)

(N=1403)
Fibrinogen+

Model 1 (CVD)

1.78 (1.24, 2.57)*

1.78 (1.00, 3.16)

1.80 (1.20, 2.69)*

Model 2 (CVD, obesity)

2.59 (1.84, 3.66)*

1.98 (1.21, 3.25)*

2.17 (1.47, 4.26)*

Model 3 (CVD, obesity,
diabetes status)

2.52 (1.80, 3.52)*

1.98 (1.22, 3.23)*

2.42 (1.41, 4.14)*

Model 4 (CVD, obesity,
diabetes status, smoking
status)

2.49 (1.73, 3.58)*

2.11 (1.27-3.51)*

2.56 (1.45, 4.54)*

Model 5 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

2.87 (1.71, 4.82)*

2.35 (0.59, 9.41)

2.96 (1.58, 5.54)*

Model 6 (CVD, obesity,
diabetes status, smoking
status,
hypercholesterolemia,
hypertension)

2.78 (1.61, 4.79)*

2.35 (0.58, 9.47)

2.92 (1.52, 5.60)*

Note. *p < .05 **p < .001
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Figure 17. Crude and Adjusted Odds of CKD in individuals with CVD modified by
fibrinogen level
The regression models were tested at all fibrinogen levels, normal fibrinogen
levels, and elevated fibrinogen levels respectively to assess for effect modification as
demonstrated in Table 18 and Figure 17. At all fibrinogen levels, a significant regression
was found (F(10,6) = 16.413, p =.001), with the model explaining 52% (Nagelkerke R2)
of the variance and correctly classifying 91% of the cases for all variables in the model.
Individuals with CVD were 2.87 times more likely to exhibit CKD than those without
CVD. CVD, β = 1.05, t (15) = 4.34, p = .001, was seen to be a significant coefficient in
the regression model. A significant regression was found for obesity as well as for
demographic variables including age and gender. Hypercholesterolemia, diabetes status,
and smoking status were found to be non-significant factors in the regression equation.
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The overall regression model was tested at fibrinogen levels less than 378 mg/dL
(50th percentile), representing baseline or low levels of fibrinogen. A significant
regression was found (F(8,8) = 3.472, p < .05), with the model explaining 54%
(Nagelkerke R2) of the variance and correctly classifying 94% of the cases for all variables
in the model. Individuals with CVD were 2.35 times more likely to exhibit CKD than
those without CVD. CVD, β = 0.85, t (15) = 1.31, p = .21, was seen to be a statistically
non-significant coefficient in the regression model. A significant regression was found
for obesity as well as for demographic variables including age and gender.
Hypercholesterolemia, diabetes status, and smoking status were found to be nonsignificant factors in the regression equation.
The regression model was tested at fibrinogen levels ≥ 378 mg/dL (50th
percentile), representing elevated levels of fibrinogen. A significant regression was
found (F(8,8) = 6.722, p < .05), with the model explaining 47% (Nagelkerke R2) of the
variance and correctly classifying 86% of the cases for all variables in the model.
Individuals with CVD were 2.96 times more likely to exhibit CKD than those without
CVD. CVD, β = 1.09, t (15) = 3.70, p = .002, was seen to be a significant coefficient in
the regression model. A significant regression was found for age. Hypercholesterolemia,
diabetes status, gender, diabetes status, and smoking status were found to be nonsignificant factors in the regression equation.
Comparison of the aforementioned models demonstrates that fibrinogen plays an
effect modifying role on how CKD affects CVD as hypothesized. While in the elevated
fibrinogen group the odds ratio was (2.96) much higher than 1 and statistically
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significant, the regular fibrinogen group had a non-significant low odds ratio at 2.35. The
stark contrast in the odds ratio demonstrated the effect modifying role of fibrinogen.
Additionally, different cofactors were significant in each fibrinogen level.
When the F/T ratio was tested for effect modification, the analysis was
unsuccessful due to inadequate number of subjects as demonstrated in Table 17 and
Figure 16. At the elevated level of F/T (Ratio>11.67), there were no subjects at every
level of CVD. Therefore, comparison of odds ratio with the normal F/T ratio was
impossible. Consequently the answer to this hypothesis was not determined by the data.
Hypothesis 3
Hypothesis 3 predicted that elevated inflammatory biomarkers have an additive
effect on CRS along with CVD risk factors like obesity, hypercholesterolemia, diabetes
status, smoking status, and hypertension. The demographic variables of age and gender
were also factors that were being tested. Initially, a multiple regression analysis was
performed to determine if elevated serum hs-CRP predict cardiovascular health in
individuals 20 years and older within the U.S. population in addition to obesity,
hypercholesterolemia, diabetes status, smoking status, as well as for demographic
variables including age and gender. Then, separate multiple regression analyses were run
for homocysteine, fibrinogen, and F/T ratio levels respectively in order to study the
additive effect.
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Table 19
Regression Analysis Predicting Cardiorenal Syndrome From Elevated hs-CRP Levels of
Individuals Aged 20 Years and Older, NHANES, 1999-2010
Variables
Elevated Serum hs-CRP
Medical Variables
Obese BMI (≥30)
Presence of Diabetes
Hypercholesterolemia
Current Smoker
(Reference=Never
Smoker)
Demographic Variables
Age
Gender
(Reference=Female)

β

Adjusted OR

p-value

1.58

95%
Confidence
Interval
1.18-2.12

0.46
0.42
1.35
0.33

1.53
3.87
1.40

1.08-2.16
2.85-5.27
1.05-1.86

0.02
<0.001
0.02

0.81

2.26

1.38-3.68

0.001

0.16
-0.20

1.17
0.82

1.15-1.20
0.62-1.09

<0.001
0.171

0.003

Note. F(8,69) = 54.164, p < .001 R2 = .492 (p < .001)

As demonstrated in Table 19, the regression model was tested for hs-CRP as an
additive effect along with obesity, age, hypercholesterolemia, gender, diabetes status, and
smoking status. A significant regression was found (F(10,66) = 43.732, p < .001), with
the model explaining 52% (Nagelkerke R2) of the variance and correctly classifying 96%
of the cases for all variables in the model. Individuals with elevated hs-CRP were 1.58
times more likely to exhibit CRS than those without CRS. Elevated hs-CRP, β = 0.82, t
(75) = 2.88, p < .05, was seen to be a significant coefficient in the regression model.
Additionally, age, smoking status, obesity, cholesterol status, and diabetes status were
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found to be significant coefficients in the regression model. However, gender was found
to not be significant coefficients of the regression model.
Table 20
Regression Analysis Predicting Cardiorenal Syndrome From Elevated hcy Levels of
Individuals Aged 20 Years and Older, NHANES, 1999-2010
Variables
Elevated Serum hcy
Medical Variables
Obese BMI (≥30)
Presence of Diabetes
Hypercholesterolemia
Current Smoker
(Reference=Never
Smoker)
Demographic Variables
Age
Gender
(Reference=Female)

β

Adjusted OR

p-value

3.35

95%
Confidence
Interval
2.02-5.56

1.21
0.12
1.37
0.18

1.13
3.93
1.19

0.76-1.68
2.12-7.27
0.75-1.90

0.54
<0.001
0.44

0.32

1.37

0.71-2.66

0.34

0.16
-0.67

1.17
0.94

1.14-1.21
0.61-1.44

<0.001
0.754

<0.001

Note. F(8,23) = 40.550, p < .001 R2 = .543 (p < .001)
As demonstrated in Table 20, the regression model was tested for homocysteine
as an additive effect along with obesity, age, hypercholesterolemia, gender, diabetes
status, and smoking status. A significant regression was found (F(8,23) = 40.550, p <
.001), with the model explaining 54% (Nagelkerke R2) of the variance and correctly
classifying 97% of the cases for all variables in the model. Individuals with elevated hcy
were 3.35 times more likely to exhibit CRS than those without CRS. Elevated hcy, β =
1.21, t (30) = 4.86, p < 0.001, was seen to be a significant coefficient in the regression
model. Additionally, age and diabetes status were found to be significant coefficients in
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the regression model. However, obesity, smoking status, cholesterol status, and gender
were found to not be significant coefficients of the regression model.
Table 21
Regression Analysis Predicting Cardiorenal Syndrome From Elevated fibrinogen Levels
of Individuals Aged 20 Years and Older, NHANES, 1999-2010
Variables
Elevated Serum
fibrinogen
Medical Variables
Obese BMI (≥30)
Presence of Diabetes
Hypercholesterolemia
Current Smoker
(Reference=Never
Smoker)
Demographic Variables
Age
Gender
(Reference=Female)

β

Adjusted OR

p-value

1.58

95%
Confidence
Interval
0.05-2.12

0.36
0.30
-2.38

1.35
-10.80

0.14-13.08
-0.45-259.88

0.782
-0.132

--

--

--

--

0.28
-0.80

1.32
0.45

1.01-1.75
0.04-5.52

0.04
0.507

0.827

Note. F(5,11) = 8.593, p =0.002 R2 = .332 (p < .001)

As demonstrated in Table 21, the regression model was tested for fibrinogen as an
additive effect along with obesity, age, hypercholesterolemia, gender, diabetes status, and
smoking status. Upon running the regression including diabetes status and smoking
status was causing quasi-complete separation in the data. Therefore, fibrinogen, obesity,
age, hypercholesterolemia, and gender were the only variables included. A significant
regression was found (F(5,11) = 8.593, p = 0.002), with the model explaining 33%
(Nagelkerke R2) of the variance and correctly classifying 99% of the cases for all
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variables in the model. Individuals with elevated fibrinogen were 1.43 times more likely
to exhibit CRS than those without CRS. Elevated fibrinogen, β = 0.36, t (15) = 0.22, p =
0.83, was seen to be a non-significant coefficient in the regression model. Age was the
only variable that was significant in the model. None of the other factors were
statistically significant coefficients in the regression model.
Table 22
Regression Analysis Predicting Cardiorenal Syndrome From Elevated F/T Levels of
Individuals Aged 20 Years and Older, NHANES, 1999-2010
Variables
Elevated Serum F/T
Medical Variables
Obese BMI (≥30)
Presence of Diabetes
Hypercholesterolemia
Current Smoker
(Reference=Never
Smoker)
Demographic Variables
Age
Gender
(Reference=Female)

β

Adjusted OR

p-value

1.31

95%
Confidence
Interval
0.23-7.57

0.27
0.41
1.69
0.57

1.50
10.48
1.06

0.32-7.19
1.17-25.23
0.16-6.95

0.604
0.031
0.952

0.48

1.61

0.20-13.07

0.650

0.22
--

1.25
--

1.04-1.49
--

0.017
--

0.762

Note. F(7,58) = 13.443, p < .001 R2 = .154 (p < .001)
As demonstrated in Table 22, the regression model was tested for
ferritin/transferrin ratio as an additive effect along with obesity, age,
hypercholesterolemia, diabetes status, and smoking status. Gender was excluded because
only females had ferritin levels taken. Therefore, F/T, obesity, age,
hypercholesterolemia, diabetes status, and smoking status were the only variables
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included. A significant regression was found (F(7,58) = 13.443, p < 0.001), with the
model explaining 15% (Nagelkerke R2) of the variance and correctly classifying 99% of
the cases for all variables in the model. Individuals with elevated F/T were 1.31 times
more likely to exhibit CRS than those without CRS. Elevated F/T, β = 0.27, t (64) =
0.30, p = 0.77, was seen to be a non-significant coefficient in the regression model. Age
and diabetes status were the only variable that were significant in the model. None of the
other factors (hypercholesterolemia, smoking status, and obesity) were statistically
significant coefficients in the regression model.
Hypothesis 4
Hypothesis 4 predicted that demographic factors like race/ethnicity, family
income, or education level modify the effect of inflammatory biomarkers on CRS after
controlling for known CVD risk factors like obesity, hypercholesterolemia, diabetes
status, and smoking status. The demographic variables of age and gender were also
controlled for so that confounding factors would not influence the study results.
The effect modification of main demographic factors like race/ethnicity, family
income, and education level were systematically tested in nine stepwise logistic
regression models for hs-CRP, homocysteine, and fibrinogen respectively. The hs-CRP
was categorized by comparing less than 1 mg/L versus greater than 2 mg/L. Initially, a
multiple regression analysis was performed to determine if among the Hispanic
subpopulation, elevated serum hs-CRP predicts cardiovascular health in individuals 20
years and older within the U.S. population after controlling for obesity,
hypercholesterolemia, diabetes status, smoking status, as well as for demographic
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variables including age and gender. Then, separate multiple regression analyses were run
for hs-CRP levels in Non-Hispanic White and Non-Hispanic Black subpopulations as
well in order to assess for effect modification.
Likewise, six stepwise multiple regression models were reported, assessing for
effect modification with regards to family income and education level. Three stepwise
logistic regression models were run for the total sample, below 200% poverty level, and ≥
200% poverty level. Finally, three stepwise logistic regression models were run for
different education levels—less than high school graduate, high school graduate, and at
least some college education.
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Table 23
Age- and Sex-Adjusted hs-CRP ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by ethnicity.
Hispanic OR
(95% CI)
(N=3,146)

Non-Hispanic
White OR (95%
CI) (N=6,340)

Non-Hispanic
Black OR (95%
CI) (N=2,345)

Model 1 (hs-CRP)

3.24 (1.59, 6.57)*

2.34 (1.46, 3.74)*

Model 2 (hs-CRP,
obesity)

2.81 (1.38-5.72)*

2.01 (1.21-3.33)*

2.96 (1.824.81)**
2.86 (1.674.88)**

Model 3 (hs-CRP,
obesity, diabetes status)

3.43 (1.54-7.63)*

2.03 (1.16-3.53)*

3.02 (1.70-5.39)*

Model 4 (hs-CRP,
obesity, diabetes status,
smoking status)

3.59 (1.62-7.94)*

1.92 (1.10-3.38)

3.00 (1.71, 5.28)*

Model 5 (hs-CRP,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

4.31 (1.76-10.52)*

2.26 (1.29-3.98)*

2.88 (1.59-5.23)*

Note. *p < .05 **p < .001
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Figure 18. Effect of Race on the relationship between hs-CRP and CRS before and after
controlling for CRS risk factors
Initially, the total sample was stratified to assess for effect modification by race as
seen in Table 23 and Figure 18. The first group of regression models was calculated for
Hispanic individuals. A significant regression was found (F(10,60) = 12.922, p < .001),
with the model explaining 30% (Nagelkerke R2) of the variance and correctly classifying
98% of the cases for all variables in the model. Individuals with elevated hs-CRP were
4.31 times more likely to exhibit CRS than those without CRS. Elevated hs-CRP, β =
1.46, t (69) = 3.26, p < .05, was seen to be a non-significant coefficient in the regression
model. Additionally, age, diabetes status, and obesity were found to be the only
significant coefficients in the regression model. However, smoking status, gender, and
cholesterol status were found to not be significant coefficients of the regression model.
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The regression model was tested for Non-Hispanic Whites. A significant
regression was found (F(10,66) = 43.732, p < .001), with the model explaining 52%
(Nagelkerke R2) of the variance and correctly classifying 96% of the cases for all
variables in the model. Individuals with elevated hs-CRP were 2.26 times more likely to
exhibit CRS than those without CRS. Elevated hs-CRP, β = 0.82, t (75) = 2.88, p < .05,
was seen to be a significant coefficient in the regression model. Additionally, age,
smoking status, obesity, cholesterol status, and diabetes status were found to be
significant coefficients in the regression model. However, gender was found to not be
significant coefficients of the regression model.
The regression model was tested for Non-Hispanic Blacks. A significant
regression was found (F(10,52) = 31.408, p < .001), with the model explaining 37%
(Nagelkerke R2) of the variance and correctly classifying 95% of the cases for all
variables in the model. Individuals with elevated hs-CRP were 2.88 times more likely to
exhibit CRS than those without CRS. Elevated hs-CRP, β = 1.06, t (61) = 3.54, p <
0.001, was seen to be a significant coefficient in the regression model. Additionally, age,
smoking status, diabetes status, and cholesterol status were found to be significant
coefficients in the regression model. However, obesity and gender were found to not be
significant coefficients of the regression model.
Comparison of the aforementioned models demonstrates that ethnicity plays an
effect modifying role on how hs-CRP levels affect CRS as hypothesized. While in the
Non-Hispanic White, Non-Hispanic Black, and Hispanic populations the odds ratio of
CRS was much higher than 1 and statistically significant, the Non-Hispanic White
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population had the lowest odds ratio at 2.26 as seen in Table 23 and Figure 18. The
Hispanic population had the highest odds ratio at 4.31 when controlling for other CVD
risk factors. Additionally, different cofactors were significant in each ethnic
subpopulation.
Table 24
Age- and Sex-Adjusted hs-CRP ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by income level.
Total OR (95%
CI)
(N=20,850)

Below 200%
Poverty (95% CI)
(N=9249)

≥ 200% Poverty
(95% CI)
(N=11601)

Model 1 (hs-CRP)

2.33 (1.62-3.37)*

2.08 (1.31-3.32)*

2.23 (1.25-3.98)*

Model 2 (hs-CRP,
obesity)

2.05 (1.38-3.03)*

1.72 (1.06-2.81)*

2.08 (1.13-3.83)*

Model 3 (hs-CRP,
obesity, diabetes status)

2.18 (1.42-3.34)*

1.94 (1.11-3.41)*

2.09 (1.12-3.91)*

Model 4 (hs-CRP,
obesity, diabetes status,
smoking status)

2.08 (1.35-3.19)*

1.85 (1.05-3.25)*

2.06 (1.10-3.85)*

Model 5 (hs-CRP,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

2.17 (1.73-3.43)**

1.74 (0.88-3.42)

2.33(1.21-4.52)*

Note. *p < .05 **p < .001
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Figure 19. Effect of Income Level on the relationship between hs-CRP and CRS before
and after controlling for CRS risk factors

Initially, the overall regression model was tested to determine how elevated hsCRP played a role on the total sample as seen in Table 24 and Figure 19. A significant
regression was found (F(10,67) = 46.344, p < .001), with the model explaining 47%
(Nagelkerke R2) of the variance and correctly classifying 96% of the cases for all
variables in the model. Individuals with elevated hs-CRP were 2.17 times more likely to
exhibit CRS than those without CRS. Elevated hs-CRP, β = 0.77, t (76) = 3.36, p < .001,
was seen to be a significant coefficient in the regression model. Additionally, obesity,
age, smoking status, and cholesterol status were found to be significant coefficients of the
regression model. Gender was the only variable found to be not significant in the model.
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The total sample was stratified to assess for effect modification. The regression
model was tested at less than 200% of federal poverty levels, representing individuals in
a low socioeconomic status. A significant regression was found (F(10,66) = 25.518, p <
.001), with the model explaining 46% (Nagelkerke R2) of the variance and correctly
classifying 93% of the cases for all variables in the model. Individuals with elevated hsCRP were 1.73 times more likely to exhibit CRS than those without CRS. Elevated hsCRP, β = 0.55, t (75) = 1.63, p=0.11, was seen to be a non-significant coefficient in the
regression model. Additionally, age, obesity, cholesterol status, and diabetes status was
found to be significant coefficients in the regression model. However, smoking status
and gender were found to not be significant coefficients of the regression model.
The overall regression model was tested at ≥ 200% of federal poverty levels,
representing normal to high socioeconomic status. A significant regression was found
(F(10,67) = 29.908, p < .001), with the model explaining 48% (Nagelkerke R 2) of the
variance and correctly classifying 97% of the cases for all variables in the model.
Individuals with elevated hs-CRP were 2.33 times more likely to exhibit CRS than those
without CRS. Elevated hs-CRP, β = 0.85, t (76) = 2.55, p < .05, was seen to be a
significant coefficient in the regression model. Additionally, obesity, age, cholesterol
status, and diabetes status was found to be significant coefficients in the regression
model. However, gender and smoking status were found to not be significant coefficients
of the regression model.
Comparison of the aforementioned models demonstrates that income level does
not play an effect modifying role on how hs-CRP levels affect CRS as hypothesized.
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While in all three categories, gender was not a significant variable, when stratified by
socioeconomic status, smoking status was not significant as well as seen in Table 24 and
Figure 19. In every model in the low SES category, the odds ratio and confidence
intervals of elevated hs-CRP on CRS was lower in individuals at the high income level.
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Table 25
Age- and Sex-Adjusted CRP ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by education level.
Less than High
School Graduate
OR (95% CI)
(N=5,820)

High School
Graduate (95%
CI)
(N=4,632)

At least Some
College (95%
CI)
(N=11,129)

Model 1 (hs-CRP)

2.93 (1.79-4.79)**

2.97 (1.57-5.62)*

1.89 (0.91-3.94)

Model 2 (hs-CRP,
obesity)

2.26 (1.31-3.89)*

2.65 (1.33-5.30)*

1.89 (0.86-4.15)

Model 3 (hs-CRP,
obesity, diabetes status)

2.80 (1.52-5.15)*

2.47 (1.16-5.26)

2.03 (0.87-4.76)

Model 4 (hs-CRP,
obesity, diabetes status,
smoking status)

2.67 (1.47-4.84)*

2.48 (1.16-5.30)

1.89 (0.81-4.43)

Model 5 (hs-CRP,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

2.55 (1.25-5.19)*

3.70 (1.59-8.61)*

1.75 (0.83-3.69)

Note. *p < .05 **p < .001
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Figure 20: Effect of Education Level on the relationship between hs-CRP and CRS
before and after controlling for CRS risk factors
The total sample was stratified by education level to assess for effect modification
as seen in Table 25 and Figure 20. Initially, the overall regression model was tested to
determine how elevated hs-CRP played a role on individuals with less than a high school
education. A significant regression was found (F(10,67) = 15.899, p < .001), with the
model explaining 41% (Nagelkerke R2) of the variance and correctly classifying 92% of
the cases for all variables in the model. Individuals with elevated hs-CRP were 2.55
times more likely to exhibit CRS than those without CRS. Elevated hs-CRP, β = 0.94, t
(76) = 2.62, p < 0.05, was seen to be a non-significant coefficient in the regression model.
Out of the other variables, age, obesity, cholesterol status, and diabetes status were found
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to be the only significant coefficient in the regression model. However, smoking status
and gender were found to not be significant coefficients of the regression model.
The regression model was tested for high school graduates, representing
individuals who have graduated high school or who have at least acquired a GED. A
significant regression was found (F(10,67) = 22.730, p < .001), with the model explaining
51% (Nagelkerke R2) of the variance and correctly classifying 96% of the cases for all
variables in the model. Individuals with elevated hs-CRP were 3.70 times more likely to
exhibit CRS than those without CRS. Elevated hs-CRP, β = 1.31, t (76) = 3.08, p = .003,
was seen to be a significant coefficient in the regression model. Additionally, age,
cholesterol status, smoking status, and diabetes status were found to be significant
coefficients in the regression model. However, gender and obesity were found to not be
significant coefficients of the regression model.
Finally, the overall regression was tested for individuals with at least some
college education, representing the educated stratum of society. A significant regression
was found (F(10,67) = 26.178, p < .001), with the model explaining 47% (Nagelkerke R2)
of the variance and correctly classifying 98% of the cases for all variables in the model.
Individuals with elevated hs-CRP were 1.75 times more likely to exhibit CRS than those
without CRS. Elevated hs-CRP, β = 0.56, t (76) = 1.49, p = 0.14, was seen to be a nonsignificant coefficient in the regression model. Additionally, age, obesity, cholesterol
status, and diabetes status were found to be significant coefficients in the regression
model. However, smoking status and gender were found to not be significant coefficients
of the regression model.
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Comparison of the aforementioned models demonstrates that education level
plays an effect modifying role on how hs-CRP levels affect CRS as hypothesized. When
comparing individuals with at most a high school education with individuals with more
than a high school education, individuals with more than a high school education have an
odds ratio close to 1 as seen in Table 25 and Figure 20. Additionally, in every model
tested in the high school graduate category, the odds ratio of elevated hs-CRP on CRS
was higher in individuals with only a high school education. The covariates that were
significant were different in each model.
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Table 26
Age- and Sex-Adjusted Hcy ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by ethnicity.
Hispanic OR
(95% CI)
(N=1,944)

Non-Hispanic
White OR (95%
CI) (N=3,986)

Non-Hispanic
Black OR (95%
CI) (N=1,688)

Model 1 (Hcy)

1.06 (0.46-2.46)

3.19 (1.93, 5.28)**

2.68 (1.28-5.64)*

Model 2 (Hcy, obesity)

1.10 (0.50-2.42)

3.46 (2.01-5.95)**

2.64 (1.22-5.71)*

Model 3 (Hcy, obesity,
diabetes status)

0.44 (0.13-1.46)

4.91 (3.16-7.62)**

3.36 (1.23-9.18)*

Model 4 (Hcy, obesity,
diabetes status, smoking
status)

0.44 (0.12-1.56)

5.00 (3.07-8.16)**

3.10 (1.15-8.38)*

Model 5 (Hcy, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

0.49 (0.15-1.67)

4.15 (2.24-7.66)**

2.59 (0.91-7.39)

Note. *p < .05 **p < .001
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Figure 21: Effect of Race on the relationship between homocysteine and CRS before and
after controlling for CRS risk factors

Initially, the total sample was stratified to assess for effect modification by race as
seen in Table 26 and Figure 21. The first group of regression models was calculated for
Hispanic individuals. A significant regression was found (F(10,11) = 42.520, p < .001),
with the model explaining 18% (Nagelkerke R2) of the variance and correctly classifying
98% of the cases for all variables in the model. Individuals with elevated homocysteine
were 0.49 times more likely to exhibit CRS than those without CRS. Elevated Hcy, β = 0.71, t (20) = -1.21, p > .05, was seen to be a non-significant coefficient in the regression
model. Additionally, age and diabetes status were found to be the only significant
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coefficients in the regression model. However, obesity, smoking status, gender, and
cholesterol status were found to not be significant coefficients of the regression model.
The regression model was tested for Non-Hispanic Whites. A significant
regression was found (F(10,19) = 49.480, p < .001), with the model explaining 60%
(Nagelkerke R2) of the variance and correctly classifying 97% of the cases for all
variables in the model. Individuals with elevated homocysteine were 4.15 times more
likely to exhibit CRS than those without CRS. Elevated Hcy, β = 1.42, t (28) = 4.74, p <
.001, was seen to be a significant coefficient in the regression model. Additionally, age
and diabetes status were found to be significant coefficients in the regression model.
However, smoking status, obesity, cholesterol status, and gender were found to not be
significant coefficients of the regression model.
The regression model was tested for Non-Hispanic Blacks. A significant
regression was found (F(10,12) = 34.348, p < .001), with the model explaining 45%
(Nagelkerke R2) of the variance and correctly classifying 96% of the cases for all
variables in the model. Individuals with elevated homocysteine were 2.59 times more
likely to exhibit CRS than those without CRS. Elevated Hcy, β = 0.95, t (21) = 1.89, p =
0.07, was seen to be a non-significant coefficient in the regression model. Additionally,
age, smoking status, and cholesterol status were found to be significant coefficients in the
regression model. However, obesity, gender, and diabetes status were found to not be
significant coefficients of the regression model.
Comparison of the aforementioned models demonstrates that ethnicity play an
effect modifying role on how homocysteine levels affect CRS as hypothesized. While in
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the Non-Hispanic White and Non-Hispanic Black the odds ratio of CRS were much
higher than 1, in the Hispanic population the odds ratio was close to 1 as seen in Table 26
and Figure 21. Additionally, different cofactors were significant (i.e. age, smoking status
and cholesterol status) in the Non-Hispanic Black population than the Non-Hispanic
White and Hispanic population (i.e. age and diabetes status). In this analysis,
homocysteine did not play a significant role in the Hispanic population.
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Table 27
Age- and Sex-Adjusted Hcy ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by income level.
Total OR (95%
CI)
(N=7,567)

Below 200%
Poverty (95% CI)
(N=3212)

≥ 200% Poverty
(95% CI)
(N=4355)

Model 1 (Hcy)

2.92 (1.94-4.38)*

2.92 (1.76-4.83)**

2.80 (1.48-5.32)*

Model 2 (Hcy, obesity)

3.06 (2.00-4.70)**

3.15 (1.91-5.21)**

2.82 (1.48-5.39)*

Model 3 (Hcy, obesity,
diabetes status)

3.50 (2.40-5.10)**

4.29 (2.10-8.75)**

3.08 (1.47-6.42)*

Model 4 (Hcy, obesity,
diabetes status, smoking
status)

3.51 (2.35-5.24)**

4.27 (2.19-8.33)**

3.19 (1.45-7.03)*

Model 5 (Hcy, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

3.13 (1.89-5.18)**

3.16 (1.77-5.64)**

3.00 (1.27-7.12)*

Note. *p < .05 **p < .001
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Figure 22: Effect of Income Level on the relationship between Homocysteine and CRS
before and after controlling for CRS risk factors

Initially, the overall regression model was tested to determine how elevated
homocysteine played a role on the total sample as seen in Table 27 and Figure 22. A
significant regression was found (F(10,21) = 52.555, p < .001), with the model explaining
53% (Nagelkerke R2) of the variance and correctly classifying 97% of the cases for all
variables in the model. Individuals with elevated homocysteine were 3.13 times more
likely to exhibit CRS than those without CRS. Elevated Hcy, β = 1.14, t (30) = 4.63, p <
.001, was seen to be a significant coefficient in the regression model. Additionally, age
and diabetes status were found to be the only significant coefficients in the regression
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model. However, obesity, gender, smoking status, and cholesterol status were found to
not be significant coefficients of the regression model.
The total sample was stratified to assess for effect modification. The regression
model was tested at less than 200% of federal poverty levels, representing individuals in
a low socioeconomic status. A significant regression was found (F(10,15) = 17.752, p <
.001), with the model explaining 56% (Nagelkerke R2) of the variance and correctly
classifying 95% of the cases for all variables in the model. Individuals with elevated
homocysteine were 3.16 times more likely to exhibit CRS than those without CRS.
Elevated Hcy, β = 1.15, t (24) = 4.10, p < .001, was seen to be a significant coefficient in
the regression model. Additionally, age, obesity, cholesterol status, and diabetes status
was found to be significant coefficients in the regression model. However, smoking
status and gender were found to not be significant coefficients of the regression model.
The overall regression model was tested at ≥ 200% of federal poverty levels,
representing normal to high socioeconomic status. A significant regression was found
(F(10,21) = 31.794, p < .001), with the model explaining 52% (Nagelkerke R2) of the
variance and correctly classifying 98% of the cases for all variables in the model.
Individuals with elevated homocysteine were 3.00 times more likely to exhibit CRS than
those without CRS. Elevated Hcy, β = 1.10, t (30) = 2.60, p < .05, was seen to be a
significant coefficient in the regression model. Additionally, age and diabetes status was
found to be significant coefficients in the regression model. However, obesity, smoking
status, and cholesterol status were found to not be significant coefficients of the
regression model.
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Comparison of the aforementioned models demonstrates that income level plays
an effect modifying role on how homocysteine levels affect CRS as hypothesized. While
in the overall model and ≥ 200% of federal poverty levels only diabetes status and age
played a role in affecting CRS, in the lower socioeconomic status group only, cholesterol
status and obesity played a role as seen in Table 27 and Figure 22. Additionally, in every
model in the low SES category, the odds ratio and confidence intervals of elevated
homocysteine on CRS were higher in individuals at the low income level.
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Table 28
Age- and Sex-Adjusted Hcy ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by education level.
Less than High
School Graduate
OR (95% CI)
(N=2,117)

High School
Graduate (95%
CI)
(N=1,918)

At least Some
College (95%
CI)
(N=3,905)

Model 1 (Hcy)

2.00 (1.11-3.61)*

3.99 (1.77-9.02)*

2.87 (1.39-5.92)*

Model 2 (Hcy, obesity)

2.11 (1.16-3.84)*

4.10 (1.76-9.52)*

3.02 (1.38-6.59)*

Model 3 (Hcy, obesity,
diabetes status)

1.45 (0.64-3.31)

10.46 (1.76-62.21)* 4.31 (1.87-9.93)*

Model 4 (Hcy, obesity,
diabetes status, smoking
status)

1.53 (0.62-3.79)

9.75 (1.64-57.94)*

4.25 (1.7810.17)*

Model 5 (Hcy, obesity,
diabetes status, smoking
status,
hypercholesterolemia)

1.42 (0.62-3.23)

7.12 (1.45-35.06)*

3.83 (1.58-9.28)*

Note. *p < .05 **p < .001
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Figure 23: Effect of education level on the relationship between Homocysteine and CRS
before and after controlling for CRS risk factors
The total sample was stratified by education level to assess for effect modification
as seen in Table 28 and Figure 23. Initially, the overall regression model was tested to
determine how elevated homocysteine played a role on individuals with less than a high
school education. A significant regression was found (F(10,12) = 14.682, p < .001), with
the model explaining 55% (Nagelkerke R2) of the variance and correctly classifying 92%
of the cases for all variables in the model. Individuals with elevated homocysteine were
1.42 times more likely to exhibit CRS than those without CRS. Elevated Hcy, β = 0.35, t
(21) = 0.88, p =0.39, was seen to be a non-significant coefficient in the regression model.
Out of the other variables, age was found to be the only significant coefficient in the
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regression model. However, obesity, smoking status, diabetes status, gender, and
cholesterol status were found to not be significant coefficients of the regression model.
The regression model was tested for high school graduates, representing
individuals who have graduated high school or who have at least acquired a GED. A
significant regression was found (F(10,20) = 27.170, p < .001), with the model explaining
63% (Nagelkerke R2) of the variance and correctly classifying 97% of the cases for all
variables in the model. Individuals with elevated homocysteine were 7.12 times more
likely to exhibit CRS than those without CRS. Elevated Hcy, β = 1.96, t (29) = 2.52, p <
.05, was seen to be a significant coefficient in the regression model. Additionally, age,
obesity, and diabetes status were found to be significant coefficients in the regression
model. However, smoking status, cholesterol status, and gender were found to not be
significant coefficients of the regression model.
Finally, the overall regression was tested for individuals with at least some
college education, representing the educated stratum of society. A significant regression
was found (F(10,21) = 12.274, p < .001), with the model explaining 49% (Nagelkerke R2)
of the variance and correctly classifying 98% of the cases for all variables in the model.
Individuals with elevated homocysteine were 3.83 times more likely to exhibit CRS than
those without CRS. Elevated Hcy, β = 1.34, t (30) = 3.10, p < .05, was seen to be a
significant coefficient in the regression model. Additionally, age, obesity, and diabetes
status were found to be significant coefficients in the regression model. However,
smoking status, cholesterol status, and gender were found to not be significant
coefficients of the regression model.
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Comparison of the aforementioned models demonstrates that education level
plays an effect modifying role on how homocysteine levels affect CRS as hypothesized.
When comparing individuals who are high school graduates with individuals have at least
some college education, individuals with a high school education have a much stronger
association with CRS than those with at least some college education (OR 7.12 vs 3.83)
as seen in Table 28 and Figure 23. Additionally, in every model tested in the high school
graduate category, the odds ratio of elevated homocysteine on CRS was higher in
individuals at the low education level. Results were inconsistent in individuals with only
some high school. This may have occurred due to a smaller sample size.
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Table 29
Age- and Sex-Adjusted Fibrinogen ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by ethnicity.
Hispanic OR
(95% CI) (N=532)

Non-Hispanic
White OR (95%
CI) (N=1,280)

Non-Hispanic
Black OR (95%
CI) (N=417)

Model 1 (Fibrinogen)

0.31 (0.09-1.07)

1.53 (0.88-2.65)

3.71 (1.45-9.51)*

Model 2 (Fibrinogen,
obesity)

0.29 (0.07-1.31)

1.35 (0.65-2.78)

3.44 (1.44-8.23)*

Model 3 (Fibrinogen,
obesity, diabetes status)

0.30 (0.06-1.42)

1.37 (0.68-2.75)

3.27 (1.15-9.36)*

Model 4 (Fibrinogen,
obesity, diabetes status,
smoking status)

0.42 (0.08-2.20)

1.30 (0.65-2.62)

3.04 (1.04-8.92)*

Model 5 (Fibrinogen,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

1.81 (.005-639.8)

0.96 (0.37-2.49)

8.53 (0.89-82.19)

Note. *p < .05
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Figure 24. Effect of race on the relationship between fibrinogen and CRS before and
after controlling for CRS risk factors

Initially, the total sample was stratified to assess for effect modification by race as
seen in Table 29 and Figure 24. The first group of regression models was calculated for
Hispanic individuals. A significant regression was found (F (7, 2) = 87.533, p < .05),
with the model explaining 62% (Nagelkerke R2) of the variance and correctly classifying
98% of the cases for all variables in the model. Individuals with elevated fibrinogen were
1.81 times more likely to exhibit CRS than those without CRS. Elevated fibrinogen, β =
0.59, t (8) = 0.23, p =0.82, was seen to be a non-significant coefficient in the regression
model. Additionally, age and cholesterol status were found to be the only significant
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coefficients in the regression model. However, smoking status, gender, diabetes status,
and obesity were found to not be significant coefficients of the regression model.
The regression model was tested for Non-Hispanic Whites. A significant
regression was found (F(10,6) = 1762.953, p < .001), with the model explaining 55%
(Nagelkerke R2) of the variance and correctly classifying 93% of the cases for all
variables in the model. Individuals with elevated hs-CRP were 0.96 times more likely to
exhibit CRS than those without CRS. Elevated hs-CRP, β = -0.04, t (15) = -0.08, p =
0.94, was seen to be a non-significant coefficient in the regression model. Additionally,
age, smoking status, and cholesterol status were found to be significant coefficients in the
regression model. However, gender, diabetes status, and obesity were found to not be
significant coefficients of the regression model.
The regression model was tested for Non-Hispanic Blacks. A significant
regression was found (F(8,1) = 2421.232, p < .05), with the model explaining 58%
(Nagelkerke R2) of the variance and correctly classifying 90% of the cases for all
variables in the model. Individuals with elevated fibrinogen were 8.53 times more likely
to exhibit CRS than those without CRS. Elevated fibrinogen, β = 2.14, t (8) = 2.18, p =
0.06, was seen to be a non-significant coefficient in the regression model. Additionally,
age, obesity, and cholesterol status were found to be significant coefficients in the
regression model. However, diabetes status, smoking status, and gender were found to
not be significant coefficients of the regression model.
Comparison of the aforementioned models demonstrates that ethnicity plays an
effect modifying role on how fibrinogen levels affect CRS as hypothesized. While in the
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Non-Hispanic White and Hispanic groups, the odds of CRS in individuals with high
fibrinogen was close to 1, in the non-Hispanic Black the odds ratio of CRS was much
higher than 1 and statistically significant with most of the covariates as seen in Table 29
and Figure 24. The non-Hispanic Black population had the highest odds ratio at 8.53
when controlling for other CVD risk factors. Additionally, different cofactors were
significant in each ethnic subpopulation.
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Table 30
Age- and Sex-Adjusted Fibrinogen ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by income level.
Total OR (95%
CI)
(N=2,124)

Below 200%
Poverty (95% CI)
(N=746)

≥ 200% Poverty
(95% CI)
(N=1,378)

Model 1 (Fibrinogen)

1.50 (0.83-2.69)

1.17 (0.60-2.26)

1.56 (0.62-3.92)

Model 2 (Fibrinogen,
obesity)

1.31 (0.60-2.86)

1.02 (0.45-2.31)

1.42 (0.50-4.01)

Model 3 (Fibrinogen,
obesity, diabetes status)

1.30 (0.60-2.81)

1.02 (0.45-2.31)

1.44 (0.52-4.04)

Model 4 (Fibrinogen,
obesity, diabetes status,
smoking status)

1.29 (0.60-2.80)

1.04 (0.43-2.50)

1.49 (0.52-4.27)

Model 5 (Fibrinogen,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

1.50 (0.58-3.91)

1.96 (0.60-6.42)

1.16(0.29-4.59)

Note. *p < .05 **p < .001
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Figure 25: Effect of income level on the relationship between Fibrinogen and CRS before
and after controlling for CRS risk factors.
Initially, the overall regression model was tested to determine how elevated
fibrinogen played a role on the total sample as seen in Table 30 and Figure 25. A
significant regression was found (F(10,6) = 62.232, p < .001), with the model explaining
50% (Nagelkerke R2) of the variance and correctly classifying 93% of the cases for all
variables in the model. Individuals with elevated fibrinogen were 1.50 times more likely
to exhibit CRS than those without CRS. Elevated fibrinogen, β = 0.41, t (15) = 0.90, p
=0.38, was seen to be a non-significant coefficient in the regression model. Additionally,
age, smoking status, and cholesterol status were found to be significant coefficients of the
regression model. Gender and obesity were the only variables found to be not significant
in the model.

163
The total sample was stratified to assess for effect modification. The regression
model was tested at less than 200% of federal poverty levels, representing individuals in
a low socioeconomic status. A significant regression was found (F(10,5) = 7.455, p <
.05), with the model explaining 47% (Nagelkerke R2) of the variance and correctly
classifying 85% of the cases for all variables in the model. Individuals with elevated
fibrinogen were 1.96 times more likely to exhibit CRS than those without CRS. Elevated
fibrinogen, β = 0.68, t (14) = 1.22, p=0.24, was seen to be a non-significant coefficient in
the regression model. Additionally, age was found to be significant coefficients in the
regression model. However, smoking status, obesity, cholesterol status, diabetes status,
and gender were found to not be significant coefficients of the regression model.
The overall regression model was tested at ≥ 200% of federal poverty levels,
representing normal to high socioeconomic status. A significant regression was found
(F(10,6) = 1264.317, p < .001), with the model explaining 54% (Nagelkerke R 2) of the
variance and correctly classifying 94% of the cases for all variables in the model.
Individuals with elevated fibrinogen were 1.16 times more likely to exhibit CRS than
those without CRS. Elevated fibrinogen, β = 0.15, t (15) = 0.23, p = .82, was seen to be a
non-significant coefficient in the regression model. Additionally, age and cholesterol
status were found to be significant coefficients of the regression model. However,
obesity, gender, smoking status, and diabetes status was not found to be significant
coefficients in the regression model.
Comparison of the aforementioned models demonstrates that income level does
not play an effect modifying role on how fibrinogen levels affect CRS as hypothesized.
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While in all three categories, gender was not a significant variable, when stratified by
socioeconomic status, smoking status was not significant as well as seen in Table 30 and
Figure 25. In every model in the low SES category, the odds ratio and confidence
intervals of elevated fibrinogen on CRS was no different in individuals at any income
level. Different variables were significant in each regression model.
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Table 31
Age- and Sex-Adjusted Fibrinogen ORs for CRS in Multivariate Regression Modeling
controlling for different CRS risk factors stratified by income level.
Less than High
School Graduate
OR (95% CI)
(N=343)

High School
Graduate (95%
CI)
(N=510)

At least Some
College (95%
CI)
(N=1,102)

Model 1 (Fibrinogen)

2.16 (0.67-6.94)

1.84 (0.57-5.93)

1.35 (0.67-2.72)

Model 2 (Fibrinogen,
obesity)

1.74 (0.44-6.83)

1.43 (0.34-5.95)

1.33 (0.61-2.89)

Model 3 (Fibrinogen,
obesity, diabetes status)

1.62 (0.39-6.72)

1.63 (0.37-7.10)

1.33 (0.60-2.95)

Model 4 (Fibrinogen,
obesity, diabetes status,
smoking status)

1.85 (0.47-7.25)

1.53 (0.36-6.51)

1.36 (0.60-3.11)

Model 5 (Fibrinogen,
obesity, diabetes status,
smoking status,
hypercholesterolemia)

3.84 (0.51-29.04)

2.07 (0.43-10.01)

0.71 (0.19-2.58)
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Figure 26: Effect of Education Level on the relationship between Fibrinogen and CRS
before and after controlling for CRS risk factors
The total sample was stratified by education level to assess for effect modification
as seen in Table 31 and Figure 26. Initially, the overall regression model was tested to
determine how elevated fibrinogen played a role on individuals with less than a high
school education. A significant regression was found (F(10,6) = 2144.229, p < .001),
with the model explaining 49% (Nagelkerke R2) of the variance and correctly classifying
79% of the cases for all variables in the model. Individuals with elevated fibrinogen were
3.84 times more likely to exhibit CRS than those without CRS. Elevated fibrinogen, β =
1.35, t (15) = 1.42, p = 0.18, was seen to be a non-significant coefficient in the regression
model. Out of the other variables, age and cholesterol status were found to be the only
significant coefficient in the regression model. However, smoking status, obesity,
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diabetes status, and gender were found to not be significant coefficients of the regression
model.
The regression model was tested for high school graduates, representing
individuals who have graduated high school or who have at least acquired a GED. A
significant regression was found (F(10,6) = 89.109, p < .001), with the model explaining
59% (Nagelkerke R2) of the variance and correctly classifying 94% of the cases for all
variables in the model. Individuals with elevated fibrinogen were 2.07 times more likely
to exhibit CRS than those without CRS. Elevated fibrinogen, β = 0.73, t (15) = 0.98, p =
0.34, was seen to be a non-significant coefficient in the regression model. Additionally,
age and cholesterol status were found to be significant coefficients in the regression
model. However, gender, smoking status, diabetes status, and obesity were found to not
be significant coefficients of the regression model.
Finally, the overall regression was tested for individuals with at least some
college education, representing the educated stratum of society. A significant regression
was found (F(9,7) = 399.130, p < .001), with the model explaining 53% (Nagelkerke R2)
of the variance and correctly classifying 95% of the cases for all variables in the model.
Individuals with elevated fibrinogen were 0.71 times more likely to exhibit CRS than
those without CRS. Elevated fibrinogen, β = -0.35, t (15) = -0.57, p = 0.58, was seen to
be a non-significant coefficient in the regression model. Additionally, age and obesity
were found to be significant coefficients in the regression model. However, smoking
status, cholesterol status, diabetes status, and gender were found to not be significant
coefficients of the regression model.
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Comparison of the aforementioned models demonstrates that education level
plays an effect modifying role on how fibrinogen levels affect CRS as hypothesized.
When comparing individuals with at most a high school education with individuals with
more than a high school education, individuals with more than a high school education
have an odds ratio close to 1 as seen in Table 31 and Figure 26. Additionally, in every
model tested in the high school graduate category, the odds ratio of elevated fibrinogen
on CRS was higher in individuals with only a high school education. The covariates that
were significant were different in each model.
Summary of Results
In summary, when tested for additive effect of each inflammatory marker (hsCRP, homocysteine, fibrinogen, and F/T Ratio) on CRS after controlling for known risk
factors, there was a significant effect found for hs-CRP, homocysteine, and fibrinogen.
However, for F/T ratio there was a non-significant additive effect, when controlling for
other risk factors. Additionally, there was a significant modifying effect by hs-CRP,
homocysteine, and fibrinogen in the context of Type 4 and Type 2 CRS even after
controlling known CVD and CKD risk factors. However, due to the lack of adequate
subjects, the modifying effect of F/T ratio could not be tested. Finally, in the context of
demographic factors, race modified the effect of inflammatory markers on CRS. Income
modified the effect of inflammatory markers on CRS, except in the context of hs-CRP
and fibrinogen. Education level also modified the effect of inflammatory markers on
CRS. However, due to the lack of adequate subjects, the modifying effect of F/T ratio
could not be tested.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Through the analysis of NHANES data, 1999-2010, the theory was evaluated that
if elevated levels of biomarkers in the context of the development of cardiovascular
disease leads to the subsequent development of chronic kidney disease or vice versa
among a multi-ethnic high risk population group. Through analysis of the same
NHANES data sets, the theory was also evaluated if education level, income level, and
race modify the relationship between inflammatory biomarkers and CRS. CRS has been
shown to be present in relationship with heart failure and other chronic conditions. For
instance, as many as one-third of individuals who have acute decompensated heart failure
have been shown to have type 1 CRS (Ronco et al., 2010). From a pathophysiological
perspective, diabetes, obesity, hypertension, smoking status, elevated serum cholesterol
levels, and even elevated inflammatory markers have been shown to have a close
interrelationship with cardiovascular disease and chronic kidney disease individually
(Levitan et al., 2009; Liu et al., 2012; Nguyen et al., 2009). However, not much research
has been done in studying how to prevent CRS (Lekawanvijit et al., 2012).
Understanding the pathophysiology of specific cardiovascular disease (i.e. CHF) and
renal disease like can lead to identifying critical biomarkers that could signal clinically
aberrant manifestations before they occur (Xue, Chan, Sakariya, & Maisel, 2010).
Individuals in the U.S. who have a history of diabetes, obesity, have elevated serum
cholesterol levels, and have a positive smoking status also have an increased risk for
cardiovascular disease. The results from this study concluded that elevated serum
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inflammatory marker levels independently and additively predict CRS in individuals in
the United States. Positive social change is instrumental for the implementation of
revised policies and protocols, creation of novel funding mechanisms, and development
of specific intervention programs aimed at educating about CRS and preventing rapid
progression of CRS in individuals, ages 20 years and older in the U.S. population.
Interpretation of Findings
According to the literature, diabetes, hypertension, obesity, and increased serum
cholesterol were all shown to increase the risk of cardiovascular disease and cardiorenal
syndrome in U.S. individuals, aged 20 years and older (Levitan et al., 2009; Liu et al.,
2012). In all individuals, inflammatory biomarkers were also shown to increase the risk
of cardiovascular disease. The literature also provided evidence that obesity and
hypertension cause elevated serum biomarkers like hs-CRP and homocysteine levels. In
the current study, data from NHANES, 1999-2010, showed that hs-CRP levels,
fibrinogen, and homocysteine have an additive effect on CRS and independently modifies
the effect in in the U.S. population. Additionally, demographic factors modify the effect
of hs-CRP, fibrinogen and hcy on CRS in the U.S. population except for income level on
hs-CRP. More data was necessary in order to study the effect of F/T ratio.
Population-Specific CRS Research Findings
Data was available from NHANES, 1999-2010, on 1,548 individuals with CRS,
aged 20-85 years. The majority of the population was non-Hispanic White women, with a
mean age 72.8 years. There were proportional numbers of non-Hispanic blacks and
Hispanics to non-Hispanic Whites. There were also proportional numbers of individuals
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aged 20-34 years and 66-85 years, when compared to those aged 35-65 years. The
category of multiracial and other races were lacking in the study population. Nearly 40%
of all study participants had some college education or were college graduates.
Overall, serum hs-CRP and cholesterol levels were elevated for the majority of
the study population. Overweight/obesity and hypertension were both highly prevalent in
the study population. The incidence of cardiovascular disease was quite low because,
according to self-reported data, very few individuals reported having physician-diagnosed
heart attack, coronary heart disease, congestive heart failure, and angina. Concurrently,
very few individuals had GFR less than 60, as calculated through the Cockcroft-Gaullt
equation from measured creatinine. Thus, the incidence of CKD was quite low and CRS
was even lower.
Hypothesis 1
Hypothesis 1 predicted that elevated inflammatory biomarker levels modify the
effect of CKD on cardiovascular health in the U.S. population after controlling for
obesity, hypercholesterolemia, diabetes status, and smoking status. Demographic
variables including age and gender were also controlled for to prevent potential
confounders. Twelve sets of separate multiple regression analyses were performed. For
hs-CRP, hcy, and fibrinogen the null hypothesis was rejected in lieu of the alternative
hypothesis that the elevated inflammatory biomarkers do modify the effect of CKD on
CVD controlling for CVD and CKD risk factors. Due to the lack of adequate subjects,
the modifying effect of F/T ratio could not be tested, and the null hypothesis could not be
rejected.
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The first set of multiple regression analyses set were performed to determine if
elevated serum hs-CRP levels after controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status modify the effect of CVD on CKD in a multiethnic population aged 20 years and older within the U.S. population. Results showed
that elevated serum hs-CRP levels modifies the effect of CVD for predicting stage 3
CKD and higher in individuals aged 20 years and older in the U.S. population. Obesity,
hypercholesterolemia, diabetes status, and smoking status were significant in the
regression models. In addition, demographic variables (i.e., age and gender) had an
additive effect along with elevated serum hs-CRP levels in predicting cardiovascular
disease in individuals aged 20 years and older in the U.S. population.
The second set of multiple regression analyses set were performed to determine if
elevated serum homocysteine levels after controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status modify the effect of
CVD on CKD in a multi-ethnic population aged 20 years and older within the U.S.
population. Results showed that elevated serum hcy levels modifies the effect of CVD for
predicting stage 3 CKD and higher in individuals aged 20 years and older in the U.S.
population. Obesity, hypercholesterolemia, diabetes status, and smoking status were
significant in the regression models. In addition, demographic variables (i.e., age and
gender) had an additive effect along with elevated serum hcy levels in predicting
cardiovascular disease in individuals aged 20 years and older in the U.S. population.
The third set of multiple regression analyses set were performed to determine if
elevated serum fibrinogen levels after controlling for obesity, age, hypercholesterolemia,
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gender, diabetes status, and smoking status modify the effect of CVD on CKD in a multiethnic population aged 20 years and older within the U.S. population. Results showed
that elevated serum fibrinogen levels modifies the effect of CVD for predicting stage 3
CKD and higher in individuals aged 20 years and older in the U.S. population. Obesity,
hypercholesterolemia, diabetes status, and smoking status were significant in the
regression models. In addition, demographic variables (i.e., age and gender) had an
additive effect along with elevated serum fibrinogen levels in predicting cardiovascular
disease in individuals aged 20 years and older in the U.S. population.
Hypothesis 2
Hypothesis 2 predicted elevated inflammatory biomarkers (hcy, F/T, fibrinogen,
and hs-CRP) modify the effect of CVD on CKD after controlling for CVD and CKD risk
factors like obesity, age, hypercholesterolemia, gender, diabetes status, and smoking
status. For this analysis, four sets of multiple regression analyses were performed. For
hs-CRP, hcy, and fibrinogen the null hypothesis was rejected in lieu of the alternative
hypothesis that the elevated inflammatory biomarkers do modify the effect of CVD on
CKD controlling for CVD and CKD risk factors. There was not enough data to
adequately complete the analysis to assess the modifying effect of F/T ratio, and the null
hypothesis could not be rejected.
The first set of multiple regression analyses set were performed to determine if
elevated serum hs-CRP levels controlling for obesity, age, hypercholesterolemia, gender,
diabetes status, and smoking status modify the effect of CKD on CVD in a multi-ethnic
population aged 20 years and older within the U.S. population. Results showed that
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elevated serum hs-CRP levels modifies the effect of CKD for predicting cardiovascular
health in individuals aged 20 years and older in the U.S. population. Obesity,
hypercholesterolemia, diabetes status, and smoking status were differentially significant
in the regression models. In addition, demographic variables (i.e., age and gender) had an
additive effect along with elevated serum hs-CRP levels in predicting cardiovascular
disease in individuals aged 20 years and older in the U.S. population.
The second set of multiple regression analyses set were performed to determine if
elevated serum homocysteine levels controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status modify the effect of CKD on CVD in a multiethnic population aged 20 years and older within the U.S. population. Results showed
that elevated serum hcy levels modifies the effect of CKD for predicting cardiovascular
health in individuals aged 20 years and older in the U.S. population. Obesity,
hypercholesterolemia, diabetes status, and smoking status were differentially significant
in the regression models. In addition, demographic variables (i.e., age and gender) had an
additive effect along with elevated serum hcy levels in predicting cardiovascular disease
in individuals aged 20 years and older in the U.S. population.
The third set of multiple regression analyses set were performed to determine if
elevated serum fibrinogen levels controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status modify the effect of CKD on CVD in a multiethnic population aged 20 years and older within the U.S. population. Results showed
that elevated serum fibrinogen levels modifies the effect of CKD for predicting
cardiovascular health in individuals aged 20 years and older in the U.S. population.

175
Obesity, hypercholesterolemia, diabetes status, and smoking status were differentially
significant in the regression models. In addition, demographic variables (i.e., age and
gender) had an additive effect along with elevated serum fibrinogen levels in predicting
cardiovascular disease in individuals aged 20 years and older in the U.S. population.
Hypothesis 3
The third set of multiple regression analyses were performed to determine if
elevated serum elevated inflammatory biomarkers (hcy, F/T, fibrinogen, and hs-CRP)
have an additive effect on CRS along with CVD risk factors like obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. For all of the
inflammatory biomarkers, the null hypothesis was rejected in lieu of the alternative
hypothesis that elevated specific inflammatory biomarkers act as additive risk factors and
increase the susceptibility of CRS along with known CVD risk factors.
Results showed that elevated serum ethnicity levels along with the additive effect
of obesity, cholesterol status, smoking status, diabetes status predict cardiorenal
syndrome in individuals aged 20 years and older in the U.S. population. While gender
was non-significant, the demographic variable of age had an additive effect along with
elevated serum hs-CRP levels in predicting CRS in individuals aged 20 years and older in
the U.S. population.
Furthermore, results showed that elevated serum hcy levels when controlling for
obesity, cholesterol status, smoking status, diabetes status predict cardiorenal syndrome
in individuals aged 20 years and older in the U.S. population. Obesity, cholesterol status,
smoking status, and diabetes status were non-significant predictors for CRS. While
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gender was non-significant, the demographic variable of age had an additive effect along
with elevated serum hcy levels in predicting CRS in individuals aged 20 years and older
in the U.S. population.
Results showed that elevated serum fibrinogen levels along with the additive
effect of obesity, cholesterol status, smoking status, diabetes status predict cardiorenal
syndrome in individuals aged 20 years and older in the U.S. population. Obesity,
cholesterol status, smoking status, and diabetes status were non-significant predictors for
CRS. While gender was non-significant, the demographic variable of age had an additive
effect along with elevated serum fibronogen levels in predicting CRS in individuals aged
20 years and older in the U.S. population. While gender was non-significant, the
demographic variable of age had an additive effect along with elevated serum fibrinogen
levels in predicting CRS in individuals aged 20 years and older in the U.S. population.
Finally, results showed that elevated serum F/T ratio levels along with the
additive effect of obesity, cholesterol status, smoking status, diabetes status nonsignificantly predict cardiorenal syndrome in individuals aged 20 years and older in the
U.S. population. Diabetes was the only medical variable that was significant in this
model. Individuals with elevated F/T ratio had a 31% higher chance of having CRS than
those without elevated CRS. While gender was not considered because only females
were in this sample, the demographic variable of age had an additive effect in predicting
CRS in individuals aged 20 years and older in the U.S. population.
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Hypothesis 4
The fourth set of multiple regression analyses were performed to determine if
sociodemographic (race/ethnicity, family income, expressed relative to the poverty
threshold, or education level) indicators play a modifying role between the relationship of
inflammatory markers and CRS after controlling for known CRS risk factors like obesity,
age, hypercholesterolemia, gender, diabetes status, and smoking status. In the context of
race, the null hypothesis was rejected in lieu of the alternative hypothesis that race plays a
modifying role between the relationship of inflammatory markers and CRS. However,
for income, only one inflammatory the null hypothesis was rejected only in the context of
one biomarker, hcy. The null hypothesis was rejected in lieu of the alternative hypothesis
that income played a modifying role between the relationship of hcy and CRS . For hsCRP and fibrinogen, the null hypothesis was not rejected since income failed to play a
modifying role between the relationship of hs-CRP and fibrinogen and CRS. Finally, due
to the lack of adequate subjects, the modifying effect of demographic factors could not be
tested between F/T ratio and cardiorenal syndrome.
The first set of multiple regression analyses set were performed to determine if
ethnicity modify the effect of hs-CRP on CRS in a multi-ethnic population aged 20 years
and older within the U.S. population controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status. Results showed that ethnicity modifies the
effect of hs-CRP for predicting cardiorenal syndrome in individuals aged 20 years and
older in the U.S. population. While in the Non-Hispanic White, Non-Hispanic Black, and
Hispanic populations the odds ratio of CRS was much higher than 1 and statistically
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significant, the Non-Hispanic White population had the lowest odds ratio at 2.26. The
Hispanic population had the highest odds ratio at 4.31 when controlling for other CVD
risk factors. Obesity, hypercholesterolemia, diabetes status, and smoking status were
differentially significant in the regression models. In addition, demographic variables
(i.e., age and gender) had an additive effect along with elevated serum hs-CRP levels in
predicting cardiovascular disease in individuals aged 20 years and older in the U.S.
population.
The second set of multiple regression analyses set were performed to determine if
income level modify the effect of hs-CRP on CRS in a multi-ethnic population aged 20
years and older within the U.S. population controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that
income level does not modify the effect of hs-CRP for predicting cardiorenal syndrome
in individuals aged 20 years and older in the U.S. population. In every model in the low
SES category, the odds ratio and confidence intervals of elevated hs-CRP on CRS was
lower in individuals at the high income level. Obesity, hypercholesterolemia, diabetes
status, and smoking status were differentially significant in the regression models. In
addition, demographic variables (i.e., age and gender) had an additive effect along with
elevated serum hs-CRP levels in predicting cardiovascular disease in individuals aged 20
years and older in the U.S. population.
The third set of multiple regression analyses set were performed to determine if
education level modify the effect of hs-CRP on CRS in a multi-ethnic population aged 20
years and older within the U.S. population controlling for obesity, age,
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hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that
education level modifies the effect of hs-CRP for predicting cardiorenal syndrome in
individuals aged 20 years and older in the U.S. population. In every model in the low
SES category, the odds ratio and confidence intervals of elevated hs-CRP on CRS was
lower in individuals at the high education level. When comparing individuals with at
most a high school education with individuals with more than a high school education,
individuals with more than a high school education have an odds ratio close to 1.
Additionally, in every model tested in the high school graduate category, the odds ratio of
elevated hs-CRP on CRS was higher in individuals with only a high school education.
Obesity, hypercholesterolemia, diabetes status, and smoking status were differentially
significant in the regression models. In addition, demographic variables (i.e., age and
gender) had an additive effect along with elevated serum hs-CRP levels in predicting
cardiovascular disease in individuals aged 20 years and older in the U.S. population.
The fourth set of multiple regression analyses set were performed to determine if
ethnicity modify the effect of hcy on CRS in a multi-ethnic population aged 20 years and
older within the U.S. population controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status. Results showed that ethnicity modifies the
effect of hcy for predicting cardiorenal syndrome in individuals aged 20 years and older
in the U.S. population. While in the Non-Hispanic White and Non-Hispanic Black the
odds ratio of CRS were much higher than 1, in the Hispanic population the odds ratio was
close to 1. Obesity, hypercholesterolemia, diabetes status, and smoking status were
differentially significant in the regression models. In addition, demographic variables
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(i.e., age and gender) had an additive effect along with elevated serum hcy levels in
predicting cardiovascular disease in individuals aged 20 years and older in the U.S.
population.
The fifth set of multiple regression analyses set were performed to determine if
income level modify the effect of hcy on CRS in a multi-ethnic population aged 20 years
and older within the U.S. population controlling for obesity, age, hypercholesterolemia,
gender, diabetes status, and smoking status. Results showed that income level does
modify the effect of hcy for predicting cardiorenal syndrome in individuals aged 20 years
and older in the U.S. population. While in the overall model and ≥ 200% of federal
poverty levels only diabetes status and age played a role in affecting CRS, in the lower
socioeconomic status group only, cholesterol status and obesity played a role.
Additionally, in every model in the low SES category, the odds ratio and confidence
intervals of elevated homocysteine on CRS were higher in individuals at the low income
level. Obesity, hypercholesterolemia, diabetes status, and smoking status were
differentially significant in the regression models. In addition, demographic variables
(i.e., age and gender) had an additive effect along with elevated serum hcy levels in
predicting cardiovascular disease in individuals aged 20 years and older in the U.S.
population.
The sixth set of multiple regression analyses set were performed to determine if
education level modify the effect of hcy on CRS in a multi-ethnic population aged 20
years and older within the U.S. population controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that

181
education level modifies the effect of hcy for predicting cardiorenal syndrome in
individuals aged 20 years and older in the U.S. population When comparing individuals
who are high school graduates with individuals have at least some college education,
individuals with a high school education have a much stronger association with CRS than
those with at least some college education (OR 7.12 vs 3.83). Additionally, in every
model tested in the high school graduate category, the odds ratio of elevated
homocysteine on CRS was higher in individuals at the low education level. Results were
inconsistent in individuals with only some high school. This may have occurred due to a
smaller sample size. Obesity, hypercholesterolemia, diabetes status, and smoking status
were differentially significant in the regression models. In addition, demographic
variables (i.e., age and gender) had an additive effect along with elevated serum hs-CRP
levels in predicting cardiovascular disease in individuals aged 20 years and older in the
U.S. population.
The seventh set of multiple regression analyses set were performed to determine if
ethnicity modify the effect of fibrinogen on CRS in a multi-ethnic population aged 20
years and older within the U.S. population controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that
ethnicity modifies the effect of fibrinogen for predicting cardiorenal syndrome in
individuals aged 20 years and older in the U.S. population. While in the Non-Hispanic
White and Hispanic groups, the odds of CRS in individuals with high fibrinogen was
close to 1, in the non-Hispanic Black the odds ratio of CRS was much higher than 1 and
statistically significant with most of the covariates. The non-Hispanic Black population
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had the highest odds ratio at 8.53 when controlling for other CVD risk factors. Obesity,
hypercholesterolemia, diabetes status, and smoking status were differentially significant
in the regression models. In addition, demographic variables (i.e., age and gender) had an
additive effect along with elevated serum fibrinogen levels in predicting cardiovascular
disease in individuals aged 20 years and older in the U.S. population.
The eighth set of multiple regression analyses set were performed to determine if
income level modify the effect of fibrinogen on CRS in a multi-ethnic population aged 20
years and older within the U.S. population controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that
income level does not modify the effect of fibrinogen for predicting cardiorenal
syndrome in individuals aged 20 years and older in the U.S. population. In every model
in the low SES category, the odds ratio and confidence intervals of elevated fibrinogen on
CRS was no different in individuals at any income level. Obesity, hypercholesterolemia,
diabetes status, and smoking status were differentially significant in the regression
models. In addition, demographic variables (i.e., age and gender) had an additive effect
along with elevated serum fibrinogen levels in predicting cardiovascular disease in
individuals aged 20 years and older in the U.S. population.
The ninth set of multiple regression analyses set were performed to determine if
education level modify the effect of fibrinogen on CRS in a multi-ethnic population aged
20 years and older within the U.S. population controlling for obesity, age,
hypercholesterolemia, gender, diabetes status, and smoking status. Results showed that
education level modifies the effect of fibrinogen for predicting cardiorenal syndrome in
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individuals aged 20 years and older in the U.S. population. When comparing individuals
with at only a high school education with individuals with more than a high school
education, individuals with more than a high school education have an odds ratio close to
1. Additionally, in every model tested in the high school graduate category, the odds
ratio of elevated fibrinogen on CRS was higher in individuals with only a high school
education. Obesity, hypercholesterolemia, diabetes status, and smoking status were
differentially significant in the regression models. In addition, demographic variables
(i.e., age and gender) had an additive effect along with elevated serum fibrinogen levels
in predicting cardiovascular disease in individuals aged 20 years and older in the U.S.
population.
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Summation of Findings

Figure 27. Inflammatory biomarkers involved in effect modification of Type 2 CRS and
Type 4 CRS.
Overall, when tested for additive effect of each inflammatory marker (hs-CRP,
homocysteine, fibrinogen, and F/T Ratio) on CRS after controlling for known risk
factors, there was a significant effect found for hs-CRP, homocysteine, and fibrinogen.
However, for F/T ratio there was a non-significant additive effect, when controlling for
other risk factors. Additionally, there was a significant modifying effect by hs-CRP,
homocysteine, and fibrinogen in the context of Type 4 and Type 2 CRS even after
controlling known CVD and CKD risk factors as shown by the highlighted biomarkers in
Figure 27. However, due to the lack of adequate subjects, the modifying effect of F/T
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ratio could not be tested, which is denoted by ferritin/transferrin written in red. Finally,
in the context of demographic factors, race modified the effect of inflammatory markers
on CRS. Income modified the effect of inflammatory markers on CRS, except in the
context of hs-CRP and fibrinogen. Education level also modified the effect of
inflammatory markers on CRS. However, due to the lack of adequate subjects, the
modifying effect of F/T ratio could not be tested.
Implications for Social Change
The results of the current study suggest both direct and indirect sources of
positive social change. On a direct level, the findings from this study provide evidence of
a direct link between tangible and identifiable biomarkers and CRS. This can lead to
dissemination of information to promote discussion in conferences and medical
communities in order to increase awareness. On an indirect level, findings from this
study can lead to positive social change to control cardiorenal syndrome in individuals,
aged 20 years and older, in the United States: implementing new policies and procedures
aimed at health and nutrition awareness, creating new funding mechanisms, and
developing intervention programs aimed at controlling CRS.
The finding from this study will aid in creating positive social change by
providing evidence that will be useful for developing and implementing new policies for
control of cardiovascular disease and cardiorenal syndrome. While the Cardiorenal
Society of America has teamed up with the National Kidney Foundation to disseminate
information about CRS, more information needs to reach physicians and the public about
the unique challenges surrounding CRS and the nutritional changes that are necessary.
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More funding is necessary in order educate public health practitioners about the
deleterious effects of inflammation. New policies and procedures aimed at health and
nutrition awareness provided additional federal and state funding for intervention
programs aimed at combating obesity, which both helped reduce elevated serum
inflammatory markers and cholesterol levels. Implementation of intervention programs
will allow improvement of quality of life and prevention of cardiorenal syndrome.
Monitoring C-reactive protein and other inflammatory markers is another change
in clinical practice that can save money and lives in the future. Additionally, making this
a national goal like through Healthy People 2020, can let patients and health care
providers realize the importance of inflammation. Obesity has clearly been shown to be
associated with inflammation. With this being a common risk factor for many different
conditions, it is also important to study this connection in the context of CRS. While
Healthy People 2020 has cardiovascular related goals, there are no goals specifically
related to inflammation. The challenge is to make a case strong enough to convince
public policy makers to invest money into doing research and implement public health
initiatives in this area.
Recommendations for Action
The study findings reiterate how imperative it is to increase awareness and
promote healthy living by controlling and preventing chronic kidney disease,
cardiovascular disease, and cardiorenal syndrome. Because the link between
inflammation and CRS has been established, now the next step is to empower patients
through knowledge of cardiorenal disease likelihood in order to achieve greater health
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equity in populations with greater barriers to access. As demonstrated by Mogford,
Gould, and Devoght (2011), by motivating, engaging, and empowering individuals on
specific health topics like the importance of inflammation in disease progression,
improvements can be made in physical health in high risk groups. Through this
dissertation, the assertion may be made for a greater awareness of the role of
inflammation in disease progression which may help both health practitioners and
patients alike. In this paradigm shift, the crux of medical practice needs to shift from
treating each individual organ to treating the body as a whole (Wallace & Wallace, 2004).
In cardiovascular disease, health practitioners are beginning to recognize the dire need to
track inflammatory markers. For instance, Kaptoge et al. (2012) found from a metaanalysis of 52 studies that if inflammatory biomarkers like fibrinogen and hs-CRP are
measured in those deemed to have intermediate risk of cardiovascular disease, then a
considerable amount of subsequent cardiovascular events can be decreased. Similarly,
the importance of inflammatory markers in the development of subsequent renal disease
needs to be emphasized among patients and become a national priority (Stenvinkel,
2010).
The implications from this study are multifold. The findings from this study will
not only impact individuals who have CRS, but also bring a general awareness about the
importance of monitoring inflammatory markers in CKD and even CVD. Dieticians and
nutritionists can utilize this information to educate individuals about following an antiinflammatory diet which leads to optimal health. Nutrition labels can go as far as to
indicate the dietary inflammatory index of specific food to indicate to consumers directly
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which food causes an increase in inflammation and which do not. For implementation of
these policies, major governmental agencies like the Food and Drug Administration need
to be convinced of the importance on proper anti-inflammatory nutrition in the context of
cardiovascular disease and cardiorenal syndrome. Additionally, taking certain vitamins
and dietary supplements could aid in decreasing inflammation and preventing the
progression and development of CRS. By providing knowledge to healthcare providers
and patients, they will be empowered to make positive changes in their life. Prevention
of disease will lead to lower health care related expenditures and propagation of positive
social change from health care workers to patients.
Limitations and Recommendations for Further Study
There were multiple limitations in this study that will need to be adequately
addressed. There is insufficient preexisting information concerning the association of
inflammatory markers and CRS. Another related limitation was the inability to
extrapolate association data to represent causation data. In order to overcome this lack of
preexisting information, a methodical approach was employed where theoretical
frameworks and conceptual models were utilized to better understand the association. By
applying existing models to better understand the relationship, the etiology of CRS was
better elucidated, making prevention a possible option. With the framework established
in this study future studies can be performing by following a cohort longitudinally similar
to the Framingham cohort and studying if increased inflammatory markers lead to CRS
and CRS exacerbation. This will also help establish causation.
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Another limitation was the presence of potentially large false positive rates in this
study due to multiple hypothesis testing. Even though according to Rothman (1990), no
adjustments are needed in multiple hypothesis testing and Cohen (1994) demonstrates that
corrections increase Type II error rate, there is controversy surrounding testing of multiple
hypotheses. In order to assess for underlying patterns and effect modification, correction was
not used for this study. However, for future studies a feasible Type 1 error correction method
like Bonferroni correction can be utilized in order to specifically measure the effect of a single
biomarker in the context of several covariates. This method on the conservative end also has
its drawbacks due to comparison of an omnibus alternative hypothesis against the backdrop of
a generic and universal null hypothesis (Glickman, Rao, & Schultz, 2014). Another
alternative calculation approach available through statistical packages is the Benjamin and
Hochberg method for calculating the false discovery rate (Hu, Zhao, & Zhou, 2010).
This addresses the presence of Type 1 error more effectively.
The third limitation is that when using previously collected survey data, there were
limitations as to what types of questions and how they were asked. When using
previously collected data, the problem of the increased statistical error may occur because
of the lack of ability to check for complete accuracy of the data presented. Because the
NHANES survey had gone through numerous iterations in the past four decades,
researchers had made sure to include as many questions as are appropriate for
researchers to analyze data for stakeholders. Additionally, due to the inability to check
accuracy of data, there may be an increase in statistical error. As mentioned
previously, because of the reputation for validity in collection and recording of the
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data, this potential error is minimal. Any possible errors can also be mitigated by
using overlapping information from so that data can be cross-checked. In future studies
more use of overlapping data can overcome the potential for bias.
The effect modification method utilized in this study could be a source of
potential limitations. Even though there are multiple ways to approach effect
modification, in this study the stratified regression approach was utilized (Van Ness &
Allore, 2003). While this approach reduces the effect of multicollinearilty and there is
no test for statistical significance, the interpretation of this method is intuitive and thus
widely used. For future studies, in order to overcome this shortcoming techniques like
centering can be utilized. This allows for better generalization to the population.
Additionally, other approaches like the analytic approach, interaction term approach,
specified levels approach, nesting approach, and the centered interaction term
approach can be utilized in future studies in order to assess for effect modification.
Another potential limitation is the reliance on self-reported information, which
may lead to bias. Again, in order to address this limitation, objective, examination
information was used. In order to make the dataset more robust, instead of utilizing
self-reported data, future studies can be conducted with medical personnel collecting
the data. However, this approach would compromise the national representativeness
of the study.
While the NHANES dataset is compatible with specific programs, all functions
are not available without the knowledge or access to specific programs. Consequently,
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another limitation is that rudimentary knowledge in weighting methods and analysis in
specific statistical software is necessary for the proper use of the data.
Finally, a limitation that is an aspect of many cross-sectional studies is that the
biomarker levels are a reflection of one moment in time and could be as a result of a
spurious factor like infection. In order to control for these factors a large,
representative population was utilized for this study. For future studies, inflammatory
biomarker information needs to be collected at several periods of time in order to
reflect the trend. This type of data is only possible with the establishment of a registry
or surveillance type of data collection method.
Summary
In summary hs-CRP, homocysteine, and fibrinogen had a modifying effect
on Type 4 (chronic reno-cardiac etiology) and Type 2 CRS (chronic cardio-renal
etiology) and a significant additive effect on CRS even after controlling known CVD and
CKD risk factors. Secondarily, different demographic factors modify the effect of
inflammatory biomarkers on CRS differentially. While F/T ratio had a non-significant
additive effect, due to the lack of adequate subjects, the modifying effect of F/T ratio
could not be tested. This knowledge has major implications for social change in that
health care professionals and patients must give as much attention to traditional CVD risk
factors as they do to inflammatory risk factors. Future longitudinal studies need to be
done to assess the causative effect of inflammatory biomarkers.
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